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A B S T R A C T
Background
Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle, producing
bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for
the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the
commonly used LABAs licensed for use in asthmamanagement (formoterol and salmeterol) require twice-daily administration, whereas
VI is a once-daily therapy.
Fluticasone furoate (FF) is an inhaled corticosteroid (ICS), and ICS therapy is recommended by the BTS asthma guidelines. ICSs,
the mainstay of asthma treatment, lead to a reduction in both airway inflammation and airway hyper-responsiveness. Regular use
leads to improvement in symptoms and lung function. ICSs are currently recommended as ’preventer’ therapy for patients who use a
’reliever’ medication (e.g. short-acting beta2 agonist (SABA), salbutamol) three or more times per week. Most of the commonly used
ICS treatments are twice-daily medications, although two once-daily products are currently licensed (ciclesonide and mometasone).
At the present time, only one once-daily ICS/LABA combination (FF/VI) is available, and several other combination inhalers are
recommended for twice-daily administration.
Objectives
To compare effects of VI and FF in combination versus placebo, or versus other ICSs and/or LABAs, on acute exacerbations and on
health-related quality of life (HRQoL) in adults and children with chronic asthma.
Search methods
We searched theCochrane AirwaysGroupRegister of trials, clinical trial registries, manufacturers’ websites and reference lists of included
studies up to June 2016.
Selection criteria
We included randomised controlled trials (RCTs) of adults and children with a diagnosis of asthma. Included studies compared VI
and FF combined versus placebo, or versus other ICSs and/or LABAs. Our primary outcomes were health-related quality of life, severe
asthma exacerbation, as defined by hospital admissions or treatment with a course of oral corticosteroids, and serious adverse events.
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Data collection and analysis
Two review authors independently extracted data and analysed outcomes using a fixed-effect model. We used standard Cochrane
methods.
Main results
We identified 14 studies that met our inclusion criteria, with a total of 6641 randomised participants, of whom 5638 completed the
study. All studies lasted between two and 78 weeks and showed good methodological quality overall.
We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo;
VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500
mcg twice-daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily; VI/FF 100/25 mcg vs FP/
SAL 250/25 mcg twice-daily; FF/VI 100/25 vs FP/SAL500/50) and three for which the dose of VI and FF was 200/25 mcg (VI/FF
200/25 mcg vs placebo; VI/FF 200/25 mcg vs FP 500 mcg; VI/FF 200/25 mcg vs same dose of FF).
We found very few opportunities to combine results from the 14 included studies in meta-analyses. We tabulated the data for our pre-
specified primary outcomes. In particular, we found insufficient information to assess whether once-daily VI/FF was better or worse
than twice-daily FP/SAL in terms of efficacy or safety.
Only one of the 14 studies looked at health-related quality of life when comparing VI and FF 100/25 mcg versus placebo and
identified a significant advantage of VI/FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence interval (CI) 0.14 to 0.46; 329
participants); we recognised this as moderate-quality evidence. Only two studies compared VI/FF 100/25 mcg versus placebo with
respect to exacerbations; both studies reported no exacerbations in either treatment arm. Five studies (VI/FF 100/25 mcg vs placebo)
sought information on serious adverse events; all five studies reported no serious adverse events in the VI/FF 100/25 mcg or placebo
arms. We found no comparison relevant to our primary outcomes for VI/FF at a higher dose (200/25 mcg) versus placebo.
The small number of studies contributing to each comparison precludes the opportunity to draw robust conclusions for clinical practice.
These studies were not of sufficient duration to allow conclusions about long-term side effects.
Authors’ conclusions
Some evidence suggests clear advantages for VI/FF, in combination, compared with placebo, particularly for forced expiratory volume
in one second (FEV1) and peak expiratory flow; however, the variety of questions addressed in the included studies did not allow review
authors to draw firm conclusions. Information was insufficient for assessment of whether once-daily VI/FF was better or worse than
twice-daily FP/SAL in terms of efficacy or safety. It is clear that more research is required to reduce the uncertainties that surround
interpretation of these studies. It will be necessary for these findings to be replicated in other work before more robust conclusions are
revealed. Only five of the 13 included studies provided data on health-related quality of life, and only six recorded asthma exacerbations.
Only one study focused on paediatric patients, so no conclusions can be drawn for the paediatric population. More research is needed,
particularly in the primary outcome areas selected for this review, so that we can draw firmer conclusions in the next update of this
review.
P L A I N L A N G U A G E S U M M A R Y
Vilanterol and fluticasone furoate for chronic asthma in adults and children
Review question
We considered in this review whether the combination of vilanterol (VI) and fluticasone furoate (FF) is better than placebo for people
with asthma. We also compared VI and FF with other inhaled steroids and long-acting beta2-agonist medications.
Background
Asthma is an inflammatory lung condition whereby the pathway through the airways may become very restricted. By the year 2025, it is
estimated that 400 million people will have this condition. Asthma can very seriously affect people’s quality of life, and the combination
of VI and FF may help to reduce difficulties related to the impact on everyday life of breathlessness and other associated symptoms.
Study characteristics
2Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We included 14 studies in this review, involving a total of 6641 participants. All studies lasted between two and 78 weeks. All people
included in these studies had received a diagnosis of asthma. Trials included both men and women, and one study included children
and young people.
All studies looked at VI and FF versus another medication or placebo. In all studies, the VI/FF combination was taken through a dry
powder inhaler.
Key results
We found that participants who received a combination of FF and VI therapy had improved lung function compared with those given
placebo, but evidence was insufficient to permit any other conclusions because researchers attempted to answer too many different
questions. Evidence was lacking on whether the combination of VI and FF therapy once-daily is better or worse than a twice-daily
alternative. More studies are needed, so that we can gain a better understanding of the evidence overall.
Quality of the evidence
Overall, the evidence presented in this review is taken from well-designed studies at low risk of bias in terms of decisions on who
received which treatment, blinding and how to report outcomes for participants who did not finish the study. However, because we
were not able to combine results for many of our outcomes of interest, or because the outcome was rare, we judged the quality of the
evidence overall to be low to moderate.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
VI and FF compared with placebo for asthma
Patient or population: people with asthma
Settings: community
Intervention: VI and FF
Comparison: placebo




Quality of the evidence
(GRADE)
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MD 0.17 L, 95% CI 0.09 to 0.
26
Signif icant dif f erence in
favour of VI/ FF 100/ 25
mcg vs placebo with re-
spect to mean change
in trough FEV1 (pre-bron-
chodilator and pre-dose)
f rom baseline to week 12 in
1 trial (Bleecker 2012) (N =
609 part icipants, 515 com-
pleted study) (MD 0.17 L,
95% CI 0.09 to 0.26), and
a sim ilar ef fect was found
in a small cross-over trial
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advantage in favour of VI/
FF 100/ 25 mcg vs placebo
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2012a) produced a sim i-
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morning (MD 44.0 L/ m in,
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MD 17.90, 95% CI 11.95 to
23.85
Only 1 trial (Bleecker
2012) (N = 609 part icipants,
515 completed study) made
VI/ FF vs placebo com-
parison with respect to
asthma symptoms, indicat-
ing a clear advantage for VI/
FF 100/ 25 mcg
Moderatea
Adverse events Not est imable Several trials reported a
range of adverse events for
which overall aggregat ion
was not possible. These are
tabulated in Table 8
Moderated
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
AM: morning; CI: conf idence interval; FEV1: f orced expirator volume in one second; FF: f lut icasone furoate; GRADE: Grades of Recommendation, Assessment, Development























































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
aPoint deducted to ref lect that these data were derived f rom only one trial
bInvest igators reported no events in either arm of these trials
cPoint deducted to ref lect that data contribut ing to the main result (MD 0.17 L, 95% CI 0.09 to 0.26) were obtained f rom only
one trial
























































































B A C K G R O U N D
Description of the condition
Asthma, a chronic respiratory disease, may be well controlled at
times, but periods of marked deterioration in symptoms and lung
function (referred to as an exacerbation) may abruptly occur. Cur-
rently, the number of people with asthma is estimated at 300 mil-
lion, and forecasts suggest that by 2025, the total will be closer to
400 million (WHO 2007). Between 2001 and 2009, the num-
ber of people with asthma increased from 20 million to 25 mil-
lion in the United States, where prevalence rates are slightly lower
among adults (8%) than children (10%) (CDC 2012; CDCP
2011). Considerable differences in asthma prevalence have been
noted among different ethnic groups. Between 2008 and 2010,US
rates were as follows: multiple-race 14.1%, Alaskan Native 9.4%,
American Indian 9.4%, black 11.2%, white 7.7% and Asian 5.2%
(CDCP 2011). The prevalence of wheezing symptoms in children
varies geographically, with the UK having the highest recorded
prevalence of current wheezing at 32.3%, and Ethiopia the lowest
at 1.7% (Patel 2008).
Asthma is associated with impaired quality of life (Clayton 2005),
and the condition presents financial implications (Wu 2007). Each
year, asthma exacerbations impact approximately 10 million peo-
ple in the USA (Krishnan 2006). Other countries report similarly
high incidence rates; in the UK,more than 65,000 hospital admis-
sions for asthma occurred in the period from 2005 to 2006 (NHS
2011). Well-recognised factors can be addressed to prevent hos-
pital admissions in children with acute asthma (Ordonez 1998).
In recent years, evidence-based clinical guidelines have emerged,
at both national (e.g. BTS/SIGN 2014; NIH 2007) and inter-
national (e.g. GINA 2015) levels, to provide guidance for the
management of asthma. Asthma is a consequence of airways in-
flammation, but with appropriate clinical management, health-
related quality of life can be maintained for considerable periods
(WHO 2011). Mortality specifically associated with both asthma
and asthma morbidity is a major health concern (Braman 2006).
Description of the intervention
Asthma is a chronic inflammatory disorder of the airways that
is characterised by reversible airways obstruction. A combina-
tion of inhaled corticosteroid (ICS) and long-acting beta2-agonist
(LABA) is recommended for patients at step three of the British
Thoracic Society guidelines, that is, patients not controlled by
ICS alone. Evidence suggests that addition of a LABA to ICS
alone can lead to improved lung function, improved symptoms,
reduced use of rescue medications and reduced asthma exacerba-
tions among patients with uncontrolled symptoms (BTS/SIGN
2014). Although generally less effective, the combination of ICS
and a leukotriene antagonist (LTRA) is a valid alternative to ICS
combined with LABA (Montuschi 2008; Montuschi 2010).
Inhaled corticosteroids are fundamental in the treatment of
asthma, and fluticasone furoate (FF) belongs to this class of drugs.
Inhaled corticosteroidswork by reducing inflammation and airway
hyper-responsiveness (Barnes 1998), thus improving symptoms of
asthma and lung function (Montuschi 2011). Most available ICS’
are administered twice-daily, and studies have shown that once-
daily use is less effective and leads to an increase in the requirement
for rescue medication (BTS/SIGN 2014; Weiner 1995).
Vilanterol (VI) is a new drug that belongs to the LABA class. It
has a rapid onset of action in experimental models and a 24-hour
duration of bronchodilating effects in patients with asthma (Fuso
2013). Long-acting beta2-agonist therapy added to ICS treatment
in asthmahas been shown to improve lung function, reduce asthma
symptoms and decrease exacerbation rates (Remington 2005).
Available LABAs licensed for the treatment of patients with asthma
require twice-daily administration. Indacaterol and olodaterol are
approved for chronic obstructive pulmonary disease (COPD) and
require once-daily administration.
At the present time, several combination inhalers containing both
ICS and LABA are available for the treatment of adults with
asthma. However, all of these involve twice-daily dosing, which is
less convenient for patients and leads to reduced adherence with
long-term therapy. Clinicians anticipate that providing a once-
daily combination inhaler would lead to increased adherence with
treatment long-term among people with asthma.
Investigators have provided few data on once-daily combination
treatments other than VI and FF for asthma. A 12-week ran-
domised controlled double-blind study of 531 children aged six
to 15 years showed that taking a single inhaler containing budes-
onide and formoterol once-daily maintained pulmonary function,
but taking the same inhaler twice-daily resulted in improved pul-
monary function, fewer discontinuations for worsening asthma
and less need for daytime rescue medication (Eid 2010). Once-
daily budesonide/formoterol has shown improved asthma control
when compared with once-daily budesonide alone (at a four times
higher dose) in children four to 11 years of age (Bisgaard 2006).
How the intervention might work
Inhaled corticosteroids serve as the cornerstone of asthma treat-
ment and are initiated when patients require use of short-acting
‘reliever’ medications on a regular basis. As well as the benefits
mentioned previously, patients who are compliant with ICS ther-
apy demonstrate a reduction in asthma exacerbations and in mor-
tality related to asthma (Powell 2003). It is well recognised that
poor adherence is a major issue among patients with poorly con-
trolled symptoms (BTS/SIGN 2014). One of the issues that may
contribute to this is the twice-daily dosing regimen of most ICS’.
Fluticasone furoate is a relatively new long-acting ICS. It remains
active for at least 24 hours after administration. Early studies have
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shown improvement in lung function tests and a favourable safety
and tolerability profile (Bleecker 2011; Woodcock 2011).
In recent years, investigators have provided increasing evidence
for the addition of LABAs to ICS therapy for the treatment of
patients with asthma, and the benefit appears to consist of more
than bronchodilatation alone. The action of corticosteroids is me-
diated by cytoplasmic glucocorticoid receptors (GRs); after bind-
ing with corticosteroids, GRs translocate to the nucleus, where
they are able to regulate gene expression (Montuschi 2011). Long-
acting beta2-agonists have also been shown to induce GR nuclear
translocation, although not as effectively as glucocorticoids. Study
of sputum epithelial cells and macrophages of people with asthma
has shown that the LABA, salmeterol, given in combination with
fluticasone propionate (FP), was more effective than low-dose FP
alone in enhancing GR nuclear translocation (Usmani 2005).
Interleukin-8 (IL-8) is a chemokine that has been implicated in
the abnormal airway inflammation seen in patients with asthma;
studies have shown that study participants with clinically stable
asthma have higher levels of IL-8 in bronchoalveolar lavage sam-
ples than normal healthy control participants (Nocker 1996). A
study looking at IL-8 production from neutrophils stimulated by
cigarette smoke reported that salmeterol and FP additively sup-
pressed IL-8 release from neutrophils when compared with either
agent alone. This effect is not seen in all human cell types and
appears to be cell-specific. The mechanism of action is not yet
clear, but researchers have suggested that increased translocation
of GRs to the nucleus may be involved (Mortaz 2008).
For patients whose condition is uncontrolled by regular ICS ther-
apy, current British Thoracic Society (BTS) guidelines recom-
mend the addition of a LABA, such as salmeterol or formoterol
(BTS/SIGN 2014). Both of these medications have a twice-daily
dosing regimen that affects adherence and, therefore, asthma con-
trol. Long-acting beta2-agonists are of benefit because of their
bronchodilation effect, and VI is a new selective beta2-agonist
within this class (Cazzola 2011). It has been shown that VI is well
tolerated with no significant adverse effects (Kempsford 2013),
and that it leads to an increase in symptom-free periods and a
reduction in the use of rescue medication (Lotvall 2012).
In summary, limited studies suggest that effective once-daily ICS
and LABA therapy would allow a once-daily dosing regimen (e.g.
Kuna 2006), leading to the possibility of increased adherence and
improved asthma control in adults and in children.
Why it is important to do this review
Published randomised trials have examined use of VI and FF in
combination. This review aims to establish whether VI combined
with FF may play a positive role in the management of chronic
asthma among children and adults. This is important to deter-
mine, as a VI/FF combination would consist of a once-daily med-
ication. This dosing regimen may lead to increased medication
adherence, improved health-related quality of life (HRQoL) and
reduced asthma exacerbations and symptoms.
O B J E C T I V E S
To compare effects of VI and FF in combination versus placebo,
or versus other ICSs and/or LABAs, on acute exacerbations and
on HRQoL in adults and children with chronic asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full
text, those published as abstract only and unpublished data.
Types of participants
We included studies involving adults and children with a diag-
nosis of asthma. We excluded participants with the following co-
morbidities: co-existing chronic disease such as smoking-related
COPD, congenital heart disease and diseases such as cystic fibrosis
and chronic renal failure.We also excluded people who are current
smokers and pregnant women.
Types of interventions
We planned to include studies comparing the following interven-
tions.
• VI and FF versus placebo.
• VI and FF versus ICS and required short-acting beta2-
agonist (SABA).
• VI and FF versus other combination inhalers.
• VI and FF versus ICS and LABA in separate inhalers.
We also planned to include the following co-interventions, pro-
vided they were not part of the randomised treatment: bron-
chodilators, systemic steroids, leukotriene antagonists, oral amino-
phylline and macrolide antibiotics.
Types of outcome measures
Primary outcomes
• Health-related quality of life.
• Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroids (OCS)
• Serious adverse event*.
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Secondary outcomes
• Measures of lung function: forced expiratory flow in one
second (FEV1), peak expiratory flow (PEF).
• Asthma symptoms.
• Adverse events/side effects.
A study report describing one or more of the outcomes listed here
was not an inclusion criterion for the review.
*Defined as any adverse event or adverse reaction that results in
death, is life-threatening, requires hospitalisation or prolongation
of existing hospitalisation or results in persistent or significant
disability or incapacity.
Search methods for identification of studies
Electronic searches
We identified studies by searching the Cochrane Airways Group
Specialised Register (CAGR), which is maintained by the In-
formation Specialist for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases, including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, Embase, the Cumulative Index
toNursing andAlliedHealth Literature (CINAHL), theAllied and
Complementary Medicine Database (AMED) and PsycINFO,
and by handsearching of respiratory journals andmeeting abstracts
(please see Appendix 1 for further details). We searched all records
in the CAGR using the search strategy presented in Appendix 2.
We also conducted a search of
ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
searched all databases from their inception to 24 June 2016, and
we imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information.
We searched on 24 June 2015 for errata or retractions
from included studies published in full text on PubMed (
www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (LB, NW) independently screened the titles
and abstracts of all studies identified for possible inclusion as a
result of the search and coded them as ’retrieve’ (eligible or po-
tentially eligible/unclear) or ’do not retrieve’. We retrieved full-
text study reports/publications, and two review authors (LB, NW)
independently screened the full text, identified studies for inclu-
sion and identified and recorded reasons for exclusion of ineligible
studies. We planned to resolve disagreements through discussion
or, if required, by consultation with a third review author (CP);
however, this was not necessary.We identified and excluded dupli-
cates and collated multiple reports of the same study, so that each
study rather than each report was the unit of interest in the review.
We recorded the selection process in sufficient detail to complete a
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow diagram (Figure 1) and entered data regard-
ing all studies into the Characteristics of included studies table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a data collection form that had been piloted on at least
one study in the review to record study characteristics and outcome
data. Two review authors (CP, SJM) extracted study characteristics
from reports of included studies. We extracted the following study
characteristics.
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
settings, withdrawals and date of study.
• Participants: number (N), mean age, age range, gender,
severity of condition, diagnostic criteria, baseline lung function,
smoking history, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected and time points reported.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (CP, SJM) independently extracted outcome
data from the included studies. We noted in the Characteristics of
included studies table if outcome data were not reported in a use-
able way. We planned to resolve disagreements by consensus or by
consultation with a third review author (NW); however, this was
not necessary. One review author (KD) transferred data into the
ReviewManager (ReviewManager 2014) file.We double-checked
that data were entered correctly by comparing data presented in
the systematic review with those provided in study reports. A sec-
ond review author (SJM) spot-checked study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (CP, SJM) independently assessed risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to resolve disagreements by discussion or by consultation with
another review author (KD); however, this was not necessary. We
assessed risk of bias according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear, and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for a
patient-reported pain scale).When information on risk of bias was
related to unpublished data or to correspondence with a trialist,
we noted this in the ’Risk of bias’ table.
When considering each treatment effect,we took into account the
risk of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We planned to analyse dichotomous data as odds ratios (ORs) and
continuous data as mean differences (MDs) or standardised mean
differences (SMDs), and to present them with 95% confidence
intervals (CIs). We entered data presented as a scale with a consis-
tent direction of effect.
We undertook meta-analyses only when data were available, and
when it was meaningful to do so (i.e. when treatments, partici-
pants and the underlying clinical question were similar enough for
pooling to make sense).
We will narratively describe skewed data reported as medians and
interquartile ranges if reported for future updates of this review.
When a single trial reported multiple trial arms, we included only
the relevant arms.
Unit of analysis issues
We identified cross-over trials and sought data for a paired analysis
from the trial report or study authors to appropriately include data
in the review using the inverse variance method. However, this was
unsuccessful, and we provided the data in additional tables. We
identified no cluster-randomised trials, but future versions of this
review will analyse data at the level of the individual while allowing
for clustering in the data by using the intracluster correlation co-
efficient. If this is not reported in the trial, we will impute it from
similar studies.
Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
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data when possible (e.g. when a study is identified as abstract
only) when uncertainties arise during completion of the study. In
practice for this review, we had to do this with only one of the
study authors.
Assessment of heterogeneity
We visually assessed statistical heterogeneity between studies by
inspecting forest plots and using the Chi2 test (P value < 0.1 was
considered significant owing to the low power of the test). We cal-
culated the I2 statistic, which describes the percentage of variabil-
ity in effect estimates that is due to heterogeneity rather than to
sampling error (chance). Values of I2 range from 0 to 100, with 0
representing no heterogeneity and 100 representing considerable
heterogeneity.
For this review:
• 0% to 40%: Heterogeneity might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: shows considerable heterogeneity.
Assessment of reporting biases
If we cannot pool more than 10 studies for a future update of this
review, we will create and examine a funnel plot to explore possible
small-study biases and publication bias.
Data synthesis
We used a fixed-effect model and performed a sensitivity analysis
with a random-effects model when heterogeneity was substantial.
Wewill combine data on outcomes at sixmonths and at 12months
in future versions of this review if sufficient data become available.
We will describe other time points when data become available.
’Summary of findings’ table
We created a ’Summary of findings’ table by using the following
outcomes.
• Health-related quality of life.
• Asthma exacerbation as defined by hospital admission or
treatment with a course of OCS.
• Serious adverse events.
• Adverse events/side effects.
We used the five GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation Working Group) considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of a body of
evidence as it relates to studies that contribute data to the meta-
analyses for pre-specified outcomes. We followed themethods and
recommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011) and used GRADEpro software. We justified all decisions to
downgrade or upgrade the quality of studies by using footnotes;
we included comments to aid the reader’s understanding of the
review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
• Age (nought to five years, six to 16 years, 16 plus years).
We planned to use the following outcomes in subgroup analyses.
• Health-related quality of life.
• Asthma symptoms.
We planned to use the formal test for subgroup interactions in
ReviewManager (ReviewManager 2014), but sufficient data were
not available.
Sensitivity analysis
We planned to carry out the following sensitivity analyses, but
sufficient data were not available.
• Excluding studies with an overall high risk of bias.
• Excluding cross-over trials and cluster-randomised trials.
• Using a random-effects model.
R E S U L T S
Description of studies
Results of the search
We identified 29 records through electronic searches conducted
in October 2013, and we identified 15 similar records in October
2014, together with eight additional records in October 2015 and
an additional nine in June 2016, yielding a total of 59 records
obtained from electronic searches. Additional searches from trial
registries provided 20 additional records (Figure 1).
Thirty-eight records (representing 14 studies) met our criteria
for inclusion; we have described these in the Characteristics of
included studies table.
We excluded 29 records (representing 20 studies) and listed our
reasons for exclusion in the Characteristics of excluded studies
table.
We identified 12 ongoing studies and provided details of these
studies in the Characteristics of ongoing studies table.
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Included studies
In all, 14 studies met our criteria for inclusion, with a total of 6641
randomised participants, of whom 5638 completed the study (
Characteristics of included studies). Eight of these studies included
both adolescents and adults (12 years of age and older): Allen 2013;
Bateman 2014; Bernstein 2014; Bleecker 2012; Busse 2013; Lin
2013; NCT01134042; Woodcock 2013. Five studies recruited
only adult participants (18 years of age and older): Hojo 2015;
Kempsford 2012; Lee 2014; Oliver 2012; Oliver 2013, and one
study recruited only paediatric participants (between five and 11
years of age): NCT01453023.
We noted considerable variation in the range of comparisons pre-
sented in the eight studies that included both adolescents and
adults (12 years of age and older).
• One compared FF/VI 100/25 mcg versus FF/VI 200/25
mcg versus placebo versus prednisolone (Allen 2013).
• One compared FF/VI 100/25 mcg versus FF 100 mcg
(Bateman 2014).
• One compared FF/VI 100/25 mcg versus FF/VI 200/25
mcg and versus FF 100 mcg (Bernstein 2014).
• One compared FF/VI 100/25 mcg versus FF 100 mcg and
versus placebo (Bleecker 2012).
• One compared FF/VI 100/25 mcg versus FF/VI 200/25
mcg and versus FP 500 mcg (Busse 2013).
• One compared FF/VI 200/25 mcg versus FP 500 mcg (Lin
2013).
• One compared FF 200 mcg versus FF/VI 200/25 mcg and
versus FP 500 mcg (NCT01134042).
• One compared FF/VI 100/25 mcg versus FP/salmeterol
(SAL) 250/50 mcg (Woodcock 2013).
We observed similar variation in the range of comparisons pre-
sented in the five studies that included only adults.
• One compared FF/VI 100/25 versus FP/SAL500/50 (Hojo
2015).
• One compared FF/VI 100/25 mcg AM versus FF/VI 100/
25 mcg PM and versus placebo (Kempsford 2012).
• One compared FF 100 mcg versus FF/VI 100/25 mcg and
versus placebo (Oliver 2012).
• One compared FF 100 mcg versus FF/VI 100/25 mcg and
versus umeclidinium (Lee 2014).
• One compared FF/VI 100/25 mcg versus FF 100 mcg and
versus placebo versus VI 25 mcg (Oliver 2013).
The study that included only children presented the following
comparison.
• FF/VI 100/25 mcg versus FF 100 mcg (NCT01453023).
We have provided additional detailed information on the included
studies in theCharacteristics of included studies table and in Table
1.
Excluded studies
We excluded 20 studies for the following reasons: Participants
in the study did not have a diagnosis of asthma (N = 9, 45%);
the ICS used in the study was not FF (N = 3, 15%); pooled
analysis included data from the clinical trials (N = 2, 10%); study
was withdrawn before participants were enrolled (N = 1, 5%); VI
and FF were not used together in the intervention arm (N = 1,
5%); focus of trial was on VI and FP, not on VI and FF (N = 1,
5%) and evaluation of dry powder inhaler (DPI) (N = 1, 5%);
trial compared budesonide/formoterol maintenance and reliever
therapy versus FF/VI (N = 1, 5%); and study evaluated exhaled
nitric oxide time profile as a biomarker of airway Inflammation
(N = 1, 5%) (Characteristics of excluded studies).
Risk of bias in included studies
Allocation
We judged 12 of the included studies to be at low risk with respect
to selection bias. We considered risk of selection bias in the two
remaining studies (Bleecker 2012; Hojo 2015) to be unclear (
Figure 2; Figure 3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Blinding
For blinding, we judged 12 of the included studies to be at low
risk. For Kempsford 2012 and Hojo 2015, we judged the risk to
be unclear (Figure 2; Figure 3).
Incomplete outcome data
For attrition bias, we judged 12 of the included studies to have
low risk. We considered risk of selection bias in the two remaining
studies (Hojo 2015; Kempsford 2012) to be unclear (Figure 2;
Figure 3).
Selective reporting
For reporting bias, we judged 13 studies to be at low risk of bias;
for Hojo 2015, we judged this risk to be unclear (Figure 2; Figure
3).
Effects of interventions
See: Summary of findings for the main comparison Vilanterol
and fluticasone furoate compared with placebo for asthma
VI and FF 100/25 mcg versus placebo
Primary outcomes
Health-related quality of life
See Table 2.
Bleecker 2012 provided data on the change in quality of life (as
measured by the Asthma Quality of Life Questionnaire (AQLQ)
at 12 weeks), indicating a significant difference in favour of VI and
FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence
interval (CI) 0.14 to 0.46; Analysis 1.1). The minimal important
difference on this scale is 0.5 unit.
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
See Table 3.
No exacerbations were reported in the VI and FF 100/25 mcg or
placebo arms in the two short-term trials (Allen 2013; Kempsford
2012) pooled in Analysis 1.2.
Serious adverse events
See Table 4.
No serious adverse events were observed in the VI and FF 100/
25 mcg or placebo arms in the five studies (Allen 2013; Bleecker
2012; Kempsford 2012; Oliver 2012; Oliver 2013) aggregated in
Analysis 1.3. These studies were of short duration; the longest
(Bleecker 2012) had a treatment period of 12 weeks.
Secondary outcomes
Measures of lung function: forced expiratory flow in one
second (FEV1), peak expiratory flow (PEF)
See Table 5; Table 6.
Data contributed by Bleecker 2012 on FEV1 (litres) indicated a
significant difference in favour of VI and FF 100/25 mcg (MD
0.17, 95% CI 0.09 to 0.26; Analysis 1.4). A similar effect was
reported for peak expiratory flow rate (PEFR) AM L/min (MD
28.20, 95% CI 21.67 to 34.73; Analysis 1.5) and PEFR AM L/
min (MD 28.20, 95% CI 21.67 to 34.73; Analysis 1.6).
Asthma symptoms
See Table 7.
Bleecker 2012 reported a significant difference in favour of VI and
FF 100/25 mcg with respect to change in asthma symptoms as
measured by the Asthma Control Test (ACT) (MD 1.90, 95% CI
1.22 to 2.58; Analysis 1.7).
VI and FF 100/25 mcg versus same dose of FF
Primary outcomes
Health-related quality of life
Bleecker 2012 provided data on the change in quality of life (as
measured by the AQLQ at 12 weeks) that indicated no statistically
reliable difference between the two arms of this trial (MD 0.15,
95% CI -0.00 to 0.30; Analysis 2.1).
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Two studies provided data on exacerbations (Bateman 2014;
Bleecker 2012). The difference between the two arms was not sig-
nificant (odds ratio (OR) 1.38, 95% CI 0.86 to 2.22; Analysis
2.2).
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Serious adverse events
No serious adverse events were observed in either of the two arms
in three of the five included studies (NCT01453023; Oliver 2012;
Oliver 2013) combined in Analysis 2.3. The difference between
the two arms was not significant (OR 1.61, 95%CI 0.42 to 6.17).
Secondary outcomes
Measures of lung function: FEV1, PEF
The trough FEV1 at 12 weeks was significant in favour of VI and
FF 100/25 mcg in a single study (Bernstein 2014) (MD 0.08L,
95% CI 0.02 to 0.14; Analysis 2.4).
Researchers reported a significant difference in favour of VI and
FF 100/25 mcg for PEFR AM (change from baseline at 12 weeks)
(MD 20.29, 95% CI 15.72 to 24.85; Analysis 2.5) and for PEFR
PM(change frombaseline at 12weeks) (MD18.52, 95%CI 14.03
to 23.01; Analysis 2.6).
Data from a three-period crossover study (Lee 2014), which are
reported in a format that cannot be aggregated in lung function
analyses, also show a significant difference in favour of VI and FF
100/25 mcg of a similar magnitude for trough FEV1 and PEFR
AM and PM.
Asthma symptoms
One study (Bleecker 2012) contributed data to this outcome, re-
porting no significant differences between the two arms with re-
spect to change in asthma symptoms as measured by ACT (MD
0.60, 95% CI -0.04 to 1.24; Analysis 2.7). The minimal impor-
tant difference on this scale is 0.5 unit.
VI and FF 100/25 mcg versus same dose of VI
For this comparison, data on only one outcome were available for
analysis: serious adverse events. Investigators observed no serious
adverse events in either of the two arms of a single short-term trial
(Oliver 2013; Analysis 3.1).
VI and FF 100/25 mcg versus FP 500 mcg twice-daily
Primary outcomes
For this comparison, data were available for analysis on only two
outcomes: exacerbations and serious adverse events.
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Only one study of 52 weeks’ duration contributed data to this
analysis (Busse 2013). Researchers reported no significant differ-
ences between VI and FF 100/25 mcg versus FP 500 mcg twice-
daily for this outcome (OR 0.49, 95% CI 0.10 to 2.47; Analysis
4.1).
Serious adverse events
Only Busse 2013 contributed data to this analysis. Investigators
observed significantly fewer serious adverse events in the VI and
FF 100/25 mcg arm (OR 0.20, 95% CI 0.05 to 0.80; Analysis
4.2).
VI and FF 100/25 mcg versus FP/SAL 250/50 mcg
twice-daily
Primary outcomes
Health-related quality of life
One study (Woodcock 2013) of 24 weeks’ duration considered
change in quality of life (as measured by the AQLQ at 12 weeks).
Investigators reported no significant differences between VI and
FF 100/25mcg versus FP/SAL250/50mcg twice-daily (MD0.09,
95% CI -0.03 to 0.21; Analysis 5.1).
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Researchers reported no significant differences between the two
arms in terms of exacerbations (OR 0.50, 95% CI 0.05 to 5.52;
Analysis 5.2).
Serious adverse events
Study authors described no significant difference between the two
arms for serious adverse events (OR 0.80, 95% CI 0.21 to 2.99;
Analysis 5.3).
Secondary outcomes
Measures of lung function: FEV1, PEF
Woodcock 2013 reported no significant differences between the
two arms for FEV1 (MD -0.02, 95% CI -0.07 to 0.03; Analysis
5.4).
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Asthma symptoms
Study authors also described no significant differences between
the two arms in terms of asthma symptoms (MD 0.24, 95% CI -
0.20 to 0.68; Analysis 5.5).
VI and FF 100/25 mcg versus FP/SAL 250/25 mcg
twice-daily
Primary outcomes
For this comparison, data on only two outcomes were available
for analysis: exacerbations and serious adverse events.
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Only two studies provided data for this outcome: one short-term
trial (Allen 2013) and one of 52 weeks’ duration (Busse 2013).
Investigators reported no significant differences between the two
arms (OR 2.02, 95% CI 0.50 to 8.19; Analysis 6.1).
Serious adverse events
Allen 2013 and Busse 2013 also contributed data for serious ad-
verse events, noting no significant differences between the two
arms (OR 0.33, 95% CI 0.03 to 3.18; Analysis 6.2).
VI and FF 200/25 mcg versus placebo
For this comparison, data on four outcomes were available for
analysis: exacerbations, serious adverse events, FEV1 and symp-
toms.
Primary outcomes
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Only one short-term trial contributed data to this outcome (Allen
2013), indicating no exacerbations in either arm.
Serious adverse events
Study authors also described no adverse events in either arm (Allen
2013).
Secondary outcomes
Measures of lung function: FEV1, PEF
Only one study (24 weeks’ duration; NCT01134042) provided
data for this outcome (FEV1 in litres), noting a significant advan-
tage for VI and FF 200/25 mcg (MD 0.21, 95% CI 0.13 to 0.29;
Analysis 7.3).
Asthma symptoms
NCT01134042 described a similar significant advantage related
to change in asthma symptoms for VI and FF 200/25 mcg (MD
0.90, 95% CI 0.12 to 1.68; Analysis 7.4).
VI and FF 200/25 mcg versus FP/SAL 500/50 mcg
Primary outcomes
The four week cross-over trial addressing this comparison did not
include the review’s primary outcomes (Hojo 2015).
Secondary outcomes
Measures of lung function: FEV1, PEF
Hojo 2015 reported an improvement in AM PEF in the VI/FF
200/25 mcg condition. However, investigators provided no infor-
mation on this outcome in relation to the FP/SAL 500/50 mcg
condition.
Asthma symptoms
Only Hojo 2015 looked at this comparison, noting no significant
improvement on the ACT with either treatment.
VI and FF 200/25 mcg versus FP 500 mcg
Primary outcomes
Health-related quality of life
Two studies (Lin 2013; NCT01134042) of 12 and 24 weeks’
duration, respectively, looked at change in quality of life at 12
weeks (MD 0.05, 95% CI -0.08 to 0.17; Analysis 8.1) and at 24
weeks (MD 0.03, 95% CI -0.15 to 0.21; Analysis 8.2). Neither
analysis indicated a significant difference between the two arms.
19Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
Busse 2013 (52 weeks’ duration) and Lin 2013 provided data for
this outcome, noting no significant differences between the two
arms (OR 0.70, 95% CI 0.22 to 2.20; Analysis 8.4).
Serious adverse events
Busse 2013, Lin 2013 and NCT01134042 contributed data, in-
dicating no significant differences between the two arms for this
outcome (OR 0.61, 95% CI 0.25 to 1.49; Analysis 8.5).
Secondary outcomes
Measures of lung function: FEV1, PEF
Only one study (Lin 2013) provided data on PEF, reporting a
significant advantage in favour of VI and FF 200/25 mcg (MD
28.60, 95% CI 20.23 to 36.97; Analysis 8.6). NCT01134042
provided additional data specifically for AM and PM PEFR. With
respect to both the former (MD 33.00, 95% CI 24.84 to 41.16;
Analysis 8.7) and the latter (MD 26.20, 95% CI 18.04 to 34.36;
Analysis 8.8), a significant advantage favoured VI and FF 200/25
mcg.
Asthma symptoms
Lin 2013 reported the proportion of symptom-free days as a per-
centage for this comparison (MD 4.80, 95% CI -2.84 to 12.44;
Analysis 8.9), revealing no significant differences for VI and FF
200/25 mcg versus FP 500 mcg in this analysis. However, for
change in asthma symptoms, NCT01134042 provided an indi-
cation of significance in favour of VI and FF 200/25 mcg (MD
0.80, 95% CI 0.01 to 1.59; Analysis 8.10), based on the ACT,
which has a minimal important difference of 0.5 unit.
VI and FF 200/25 mcg versus same dose of FF
Primary outcomes
Health-related quality of life
One study (NCT01134042) considered change in health-related
quality of life at 12 weeks (MD 0.08, 95% CI -0.08 to 0.24;
Analysis 9.1) and at 24 weeks (MD 0.05, 95% CI -0.14 to 0.24;
Analysis 9.2). Both cases reported no significant differences be-
tween VI and FF 200/25 mcg versus the same dose of FF for this
outcome.
Severe asthma exacerbation as defined by hospital admission
or treatment with a course of oral corticosteroid
No data were available for inclusion in our analyses for this out-
come.
Serious adverse events
NCT01134042 provided data showing no significant differences
between VI and FF 200/25 mcg versus the same dose of FF for
this outcome (OR 6.06, 95% CI 0.72 to 50.84; Analysis 9.3).
Secondary outcomes
Measures of lung function: FEV1, PEF
NCT01134042 contributed data showing a significant advantage
in favour of VI and FF 200/25 mcg for FEV1 (litres) (MD 0.19,
95% CI 0.10 to 0.28; Analysis 9.4), PEFR AM (MD 33.60, 95%
CI 25.41 to 41.79; Analysis 9.5) and PEFR PM (MD 30.70, 95%
CI 22.51 to 38.89; Analysis 9.6).
Asthma symptoms
Data from NCT01134042 revealed no significant differences be-
tween VI and FF 200/25 mcg versus the same dose of FF for this
outcome (MD 0.30, 95% CI -0.50 to 1.10; Analysis 9.7).
D I S C U S S I O N
Summary of main results
We found very few opportunities to combine results from the 14
included studies into meta-analyses. We tabulated the data for
our pre-specified primary outcomes: health-related quality of life
(Table 2), exacerbations (Table 3) and serious adverse events (Table
4). We included nine comparisons in this review, six for which the
dose of vilanterol (VI) and fluticasone furoate (FF) was 100/25
mcg (VI and FF 100/25 mcg vs placebo; VI and FF 100/25 mcg
vs same dose of FF; VI and FF 100/25 mcg vs same dose of VI; VI
and FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice-
daily; VI and FF 100/25 mcg vs FP/salmeterol (SAL) 250/50 mcg
twice-daily; VI and FF 100/25 mcg vs FP/SAL 250/25 mcg twice-
daily) and three for which the dose of VI and FF was 200/25 mcg
(VI and FF 200/25 mcg vs placebo; VI and FF 200/25 mcg vs
FP 500 mcg; VI and FF 200/25 mcg vs same dose of FF). In this
review, we focused on our pre-specified primary outcomes: health-
related quality of life, severe asthma exacerbation as defined by
hospital admission, treatment with a course of oral corticosteroid
and serious adverse events.
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In the comparison betweenVI and FF 100/25 mcg versus placebo,
only one study (Bleecker 2012) provided data on health-related
quality of life, showing a significant difference in favour of VI
and FF 100/25 mcg (mean difference (MD) 0.30, 95% confi-
dence interval (CI) 0.14 to 0.46; Analysis 1.1) when using the
Asthma Quality of Life Questionnaire (AQLQ) with a minimally
important difference of 0.5 unit. The two studies contributing
data (Allen 2013; Kempsford 2012) reported no exacerbations in
the VI and FF 100/25 mcg or placebo arms, and the five aggre-
gated studies (Allen 2013; Bleecker 2012; Kempsford 2012;Oliver
2012; Oliver 2013) described no serious adverse events in the VI
and FF 100/25 mcg or placebo arms.When viewed together, these
data provide some evidence of benefit; however, in light of the
small number of studies contributing to this impression and their
mostly very short duration, it should be noted that this does not
constitute strong evidence for efficacy nor for safety.
The second comparison (VI and FF 100/25 mcg vs same dose of
FF) indicated no statistically reliable difference for health-related
quality of life between the two arms of the single contributing
study (Bleecker 2012;MD0.15, 95%CI -0.00 to 0.30). Only two
studies provided data on exacerbations (Bateman 2014; Bleecker
2012), noting that the difference between the two armswas not sig-
nificant (odds ratio (OR) 1.38, 95% CI 0.86 to 2.22). Researchers
noted no serious adverse events in either of the two arms in three
of the five included studies (NCT01453023; Oliver 2012; Oliver
2013), and no significant differences between the two conditions
for this outcome (OR 1.61, 95% CI 0.42 to 6.17). The small
number of studies contributing data to this comparison precludes
opportunities for drawing robust conclusions for this comparison
as well.
In terms of our comparison betweenVI and FF 100/25 mcg versus
same dose of VI, data were available for analysis on only one of
our pre-specified primary outcomes: serious adverse events; no
serious adverse events were observed in either of the two arms of
the aggregated study (Oliver 2013).
For the comparison betweenVI and FF 100/25 mcg versus FP 500
mcg twice-daily, data were available for analysis for only two out-
comes: exacerbations and serious adverse events. Only one study
contributed data with respect to the former (Busse 2013), report-
ing no significant differences between the two interventions (OR
0.49, 95% CI 0.10 to 2.4). With regard to serious adverse events
only, Busse 2013 contributed data, revealing significantly fewer se-
rious adverse events in the VI and FF 100/25 mcg arm (OR 0.20,
95% CI 0.05 to 0.80). Again, the small number of contributing
studies precludes the opportunity for reaching any robust conclu-
sions.
Researchers also compared VI and FF 100/25 mcg versus FP/SAL
250/50 mcg twice-daily. In terms of health-related quality of life,
which was considered by only one study (Woodcock 2013), data
show no significant differences between the two arms (MD 0.09,
95% CI -0.03 to 0.21) and no significant differences between the
two arms in terms of exacerbations (OR 0.50, 95% CI 0.05 to
5.52), or between the two arms for serious adverse events (OR
0.80, 95% CI 0.21 to 2.99).
Finally, in terms of comparisons including VI and FF at 100/25
mcg, we considered VI and FF 100/25 mcg versus FP/SAL 250/
25 mcg twice-daily. Data on only two outcomes were available for
analysis: exacerbations and serious adverse events.
For exacerbations, only two studies (Allen 2013; Busse 2013) pro-
vided data, revealing no significant differences between the two
arms (OR 2.02, 95% CI 0.50 to 8.19). These studies also con-
tributed data on serious adverse events, showing no significant dif-
ferences between the two arms (OR 0.33, 95% CI 0.03 to 3.18).
In summary, with respect to VI and FF at 100/25 mcg, it is not
possible to draw strong conclusions in relation to our pre-specified
primary outcomes.
Investigators also considered VI and FF at the higher dose of
200/25 mcg. For the comparison VI and FF 200/25 mcg versus
placebo, data on only two of our primary outcomes were available
for analysis: exacerbations and serious adverse events. Only one
study contributed data on these two outcomes (Allen 2013), not-
ing no exacerbations in either arm and no adverse events in either
arm.
Study authors also comparedVI and FF 200/25mcg versus FP 500
mcg. Two studies (Lin 2013; NCT01134042) looked at change
in quality of life at 12 weeks (MD 0.05, 95% CI -0.08 to 0.17)
and at 24 weeks (MD 0.03, 95% CI -0.15 to 0.21; Analysis 8.2);
neither analysis indicated a significant difference between the two
arms. Busse 2013 and Lin 2013 provided data on exacerbations,
showing no significant differences between the two arms (OR
0.70, 95% CI 0.22 to 2.20). Three studies (Busse 2013; Lin
2013;NCT01134042) contributed data on serious adverse events,
showing no significant differences between the two arms for this
outcome (OR 0.61, 95% CI 0.25 to 1.49).
In addition, study authors described the comparison between VI
and FF 200/25 mcg versus same dose of FF. NCT01134042 con-
sidered change in health-related quality of life at 12 weeks (MD
0.08, 95% CI -0.08 to 0.24) and at 24 weeks (MD 0.05, 95% CI
-0.14 to 0.24), with neither analysis indicating a significant dif-
ference between the two interventions. No data were available for
inclusion in our analyses on exacerbations. With regard to serious
adverse events, NCT01134042 provided data, revealing no signif-
icant differences between the two interventions for this outcome
(OR 6.06, 95% CI 0.72 to 50.84).
In summary, the evidence gathered in relation to our primary
outcomes for VI and FF at 100/25 mcg and at 200/25 mcg is too
inconclusive to provide the basis of robust conclusions.
Overall completeness and applicability of
evidence
At the present time, inhaled corticosteroid (ICS) and long-acting
beta2-agonist (LABA) combination inhalers are recommended at
step 3 of the British Thoracic Society (BTS) guidelines for asthma
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management in children and adults. This means that patients tak-
ing a low dose of ICS should have their treatment ’stepped up’ to
include a LABA in addition to continued ICS only if their asthma
is not well controlled. This treatment pathway has a clear evidence
base. The question is whether the combination of VI and FF could
be also be used at this stage. Owing to the wide range of com-
parisons and the short duration of most trials, applicability of the
evidence is very limited.
From the limited number of available studies, some evidence has
supported the use of VI/FF, particularly with regard to forced ex-
piratory volume in one second (FEV1) and peak expiratory flow
(PEF) (Bleecker 2012; Kempsford 2012; NCT01134042); how-
ever, additional studies are required to support its role. Research
has suggested that the combination may improve health-related
quality of life compared with placebo (Bleecker 2012), but longer-
term placebo-controlled studies are required to support this find-
ing. The evidence reviewed reveals no significant short-term in-
crease in asthma exacerbations (Allen 2013; Kempsford 2012) nor
in serious adverse events (Allen 2013; Bleecker 2012; Kempsford
2012; Oliver 2012; Oliver 2013) in the VI/FF group. Evidence is
presently insufficient for comparison of VI/FF versus alternative
twice-daily combination therapy inhalers.
Studies have excluded participants with an episode of life-threaten-
ing asthma, so potentially, these trials may have excluded a group
of participants with more severe disease.
Most studies included adult and adolescent participants, and only
one study enrolled only paediatric participants (NCT01453023).
Confirmation of benefit for paediatric patients is important - par-
ticularly as a once-daily dosing regimen may improve adherence
in the paediatric population. Large variability in study duration
and in the severity of asthma heterogeneity makes it difficult to
examine safety and side effects.
Quality of the evidence
In our judgement, 12 of the 14 studies had low risk of selection
bias; in Bleecker 2012 and Hojo 2015, the risk was considered to
be unclear. We also judged performance bias and detection bias
based on blinding processes to be low in 12 of the 14 studies; in
Kempsford 2012 andHojo 2015, we judged this risk to be unclear.
We evaluated attrition bias to be similarly low in 12 of the 14
studies; we judged the risk to be unclear in Kempsford 2012 and
Hojo 2015. In our judgement, risk of reporting bias was low in
13 studies, and we judged Hojo 2015 as having unclear risk in
this respect. In summary, we believe the quality of the evidence
with respect to risk of bias was generally uniform across the various
categories assessed (Figure 3).
The small number of included studies precluded formal assess-
ment of publication bias using funnel plots. However, we designed
our search strategy, which extended to conference abstracts and
ongoing studies, with the goal of identifying unpublished studies.
Potential biases in the review process
Potential for publication bias can be seen in this review in that
unpublished trials may not have been included. These studies may
have had positive or negative outcomes that would have affected
described treatment benefits. We undertook a thorough and sys-
tematic search of databases, and to the best of our knowledge, we
assessed all relevant studies for inclusion in this review. Two review
authors independently evaluated all studies that met the inclusion
criteria to reduce potential selection bias. Assessment of each study
was consistent in relation to the inclusion criteria.
Agreements and disagreements with other
studies or reviews
We found the main body of evidence for use of VI and FF in the
randomised controlled trials (RCTs) represented in this review.We
are not aware of any other systematic review on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence from 14 studies involving 6641 participants in-
cluded in this review suggests that the combination of FF and VI
may provide safe and effective therapy in the short term compared
with placebo. Evidence suggests some improvement in health-re-
lated quality of life, FEV1 and peak expiratory flow rate (PEFR).
However, the limited number of studies combined with the va-
riety of endpoints and the short duration of most trials indicates
that firm conclusions cannot be drawn. In particular, information
was insufficient for assessment of whether once-daily VI/FF was
better or worse than twice-daily FP/SAL in terms of efficacy or
safety. Additional studies, which would allow meta-analyses to be
undertaken, are required before robust conclusions can be drawn.
Very limited evidence is available for its use in paediatric patients,
so additional studies in this area are required before conclusions
can be drawn for this population.
Implications for research
The 14 studies included in this review are of high quality. How-
ever, the diverse nature of the questions addressed in these studies
presents a considerable challenge in summarising an overview of
the data. It is clear that more research is required to reduce un-
certainties arising in the interpretation of currently available ev-
idence. These findings may need to be replicated before robust
conclusions can be drawn. Given the short duration of many stud-
ies, investigators have not addressed the adrenal axis and cortisol
suppression, and we could not comment on concerns around in-
creased asthma deaths associated with other LABAs. These may
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be important areas for further study. Only five studies provided
data on health-related quality of life, and only six recorded asthma
exacerbations. Only one study enrolled paediatric participants, so
presently we can draw no conclusions for the paediatric popula-
tion. Additional data, particularly related to the primary outcomes
of this review, derived from longer-term trials comparing current
standard combination therapy would be especially helpful. Data
on comparison of VI/FF versus twice-daily LABA/ICS are sparse,
and this topic should be the focus of future research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2013
Methods Randomised double-blind multi-centre trial
Participants Total sample
N = 185 participants, 177 completed study
FF/VI 100/25 mcg, n = 56 (54 completed study)
FF/VI 200/25 mcg, n = 56 (55 completed study)
Placebo, n = 58 (55 completed study)
Prednisolone, n = 15 (13 completed study)
Age
FF/VI 100/25 mcg, mean 34.4 (SD 15.63)
FF/VI 200/25 mcg, mean 34.0 (SD 13.74)
Placebo, mean 36.1 (SD 15.42)
Prednisolone, mean 37.5 (SD 14.19)
Males
FF/VI 100/25 mcg, 25 (45%)
FF/VI 200/25 mcg, 33 (59%)
Placebo, 31 (53%)
Prednisolone, 9 (60%)
Baseline FEV1 (% predicted)
FF/VI 100/25 mcg, mean 79.9 (SD 12.58)
FF/VI 200/25 mcg, mean 77.5 (SD 13.22)
Placebo, mean 77.0 (SD 11.88)
Prednisolone, mean 78.6 (SD 13.17)
Inclusion criteria
• Outpatient with ability to comply with study requirements and complete two 24-
hour clinic visits
• Clinical diagnosis of asthma for ≥ 12 weeks
• Reversibility FEV1 ≥ 12% and ≥ 200 mL
• FEV1 ≥ 50% of predicted
Exclusion criteria
• History of life-threatening asthma
• Respiratory infection or oral candidiasis
• Asthma exacerbation
• Uncontrolled disease or clinical abnormality
• Allergies to study drugs, study drugs’ excipients, medications related to study
drugs
• Taking another investigational medication or prohibited medication
Interventions Arm 1: FF/VI dose 100/25 mcg inhalation powder once-daily for 6 weeks’ treatment +
1 oral placebo capsule each day on the last 7 days of the study
Arm 2: FF/VI 200/25 mcg inhalation powder once-daily for 6 weeks’ treatment + 1 oral
placebo capsule each day on the last 7 days of the study
Arm 3: placebo inhalation powder once-daily for 6 weeks’ treatment + 1 oral placebo
capsule each day on the last 7 days of the study
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Allen 2013 (Continued)
Arm4:placebo inhalationpowder once-daily for 6weeks’ treatment +1oral prednisolone
10 mg capsule each day on the last 7 days of the study
Outcomes Primary outcome
• Ratio from baseline of serum cortisol weighted mean (0-24 hours) at day -1/1
(baseline) and day 42
Secondary outcomes
• Ratio from baseline of serum cortisol area under concentration-time curve (AUC)
(0-24 hours) at day -1/1 (baseline) and day 42
• Ratio from baseline of serum cortisol trough (0-24 hours) at day -1/1 (baseline)
and day 42
• Ratio from baseline of 0 to 24 hours urinary free cortisol excretion at day -1/1
(baseline) and day 42
• Plasma FF and VI PK concentration
• AUC(0-t) and AUC(0-24) for FF at day 42
• Cmax for FF at day 42
• Tmax and Tlast of FF at day 42
• AUC(0-t) for VI at day 42
• Cmax for VI at day 42
• Tmax and Tlast of VI at day 42
• Number of participants with any AE or SAE during treatment period
• Change from baseline in basophil, eosinophil, lymphocyte, monocyte and
segmented neutrophil values at day 42/early withdrawal
• Change from baseline in eosinophil, total neutrophil, platelet and white blood cell
(WBC) count values at day 42/early withdrawal
• Change from baseline in haemoglobin values at day 42/early withdrawal
• Change from baseline in haematocrit values at day 42/early withdrawal
• Change from baseline in ALT, ALP, AST, CK and GGT values at day 42/early
withdrawal
• Change from baseline in albumin and total protein values at day 42/early
withdrawal
• Change from baseline in direct bilirubin, indirect bilirubin, total bilirubin and
creatinine values at day 42/early withdrawal
• Change from baseline in chloride, CO2 content/bicarbonate, glucose, potassium,
sodium, and urea/BUN values at day 42/early withdrawal
• Change from baseline in SBP and DBP at days 14, 28 and 42, and maximum
post baseline
• Change from baseline in pulse rate at days 14, 28 and 42, and maximum post
baseline
Notes Data collected from 17 locations in Germany (6), Poland (7) and USA (4)
Funded by GlaxoSmithKline
Study duration: 6 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated
computerised system (RandAll, Glaxo-
SmithKline, Stevenage, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
(GlaxoSmithKline)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Placebo inhalers and cap-
sules were identical in appearance to active
treatments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind. Placebo inhalers and cap-
sules were identical in appearance to active
treatments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of the 8 withdrawals included in
NCT01086410 report
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Bateman 2014
Methods Randomised double-blind parallel-group trial
Participants Total sample
N = 2020 participants, 1748 completed study
FF/VI 100/25, n = 1009 (885 completed study)
FF 100, n = 1011 (863 completed study)
Age
FF/VI 100/25, mean 41.1 (SD 17.10)
FF 100, mean 42.3 (SD 16.82)
Males
FF/VI 100/25, 348 (34%)
FF 100, 321 (32%)
Baseline FEV1 (% predicted)
FF/VI 100/25, mean 24.4 (SD 12.71)
FF 100, mean 24.3 (SD 12.10)
Inclusion criteria
• Clinical diagnosis of asthma
• Reversibility FEV1 ≥ 12% and ≥ 200 mL and greater approximately 10 to 40
minutes following 2 to 4 inhalations of albuterol
• FEV1 50% to 90% of predicted
• Currently using ICS therapy
• History of ≥ 1 asthma exacerbations requiring treatment with oral/systemic
corticosteroids or emergency department visit or in-patient hospitalisation in previous
year
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Exclusion criteria
• History of life-threatening asthma in previous 5 years (requiring intubation and/
or associated with hypercapnia, hypoxic seizure or respiratory arrest)
• Respiratory infection or oral candidiasis
• Uncontrolled disease or clinical abnormality
• Allergies
• Taking another investigational medication or prohibited medication
Interventions Arm 1: FF/VI dose 100/25 mcg inhalation powder inhaled orally once-daily in the
evening
Arm 2: FF dose 100 mcg inhalation powder inhaled orally once-daily in the evening
Outcomes Primary outcome
• Number of participants with ≥ 1 SAE
Secondary outcomes
• Number of SAEs
• Change from baseline in evening pre-dose trough FEV1 at week 36
Notes Data collected from 182 locations in Argentina (9), Australia (6), Germany (28), Japan
(14), Mexico (6), Philippines (5), Poland (15), Romania (6), Russian Federation (16),
Ukraine (13) and USA (64)
Funded by GlaxoSmithKline
Study duration: variable (≥ 24 to 78 weeks)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated
computerised system (RandAll, Glaxo-
SmithKline, Stevenage, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
(GlaxoSmithKline)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on 271 participants failing to
complete study included in trial report
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Bateman 2014 (Continued)
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Bernstein 2014
Methods Randomised double-blind parallel-group multi-centre study
Participants Total sample
N = 2019 screened, N = 1039 randomised, 956 completed study
FF/VI 100/25, n = 346 (314 completed study)
FF 100, n = 347 (296 completed study)
FF/VI 200/25, n = 346 (321 completed study)
Age
FF/VI 100/25, mean 45.9 (SD 16.14)
FF 100, mean 44.7 (SD 15.89)
FF/VI 200/25, mean 46.6 (SD 14.72)
Males
FF/VI 100/25, 141 (40.75%)
FF 100, 148 (42.65%)
FF/VI 200/25, 122 (35.26%)
Baseline FEV1 (% predicted)
Not reported
Inclusion criteria
• > 12 years of age
• FEV1 40% to 80% of predicted
• Reversibility FEV1 ≥ 12% and ≥ 200 mL and greater approximately 10 to 40
minutes following 4 inhalations of salbutamol/albuterol
• Received ICS for > 12 weeks before study
Exclusion criteria
• History of life-threatening asthma within past 5 years
• Unresolved upper or lower respiratory tract, sinus or middle ear infection in past
4 weeks that led to a change in asthma management
• Asthma exacerbation requiring oral corticosteroids in 12 weeks before visit 1, or
exacerbation resulting in overnight hospitalisation and additional asthma treatment in
6 months before visit 1
• Evidence of atelectasis (segmental or larger), bronchopulmonary dysplasia,
chronic obstructive pulmonary disease or concurrent respiratory disease
• Any clinically significant, uncontrolled condition or disease state
• Chronic stable hepatitis B or C if screening alanine transaminase (ALT) is > 2 >
upper limit of normal (ULN)
• Chronic co-infection with hepatitis B and hepatitis C
• Clinical visual evidence of candidiasis
• Use of any investigational drug within 30 days before visit 1, or within 5 half-lives
(t½), whichever is longer of the 2
• Allergies or adverse reactions to drug or milk protein: any adverse reaction to any
beta2-agonist, sympathomimetic drug or intranasal, inhaled or systemic corticosteroid
therapy
• Taking another investigational medication or prohibited medication
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Bernstein 2014 (Continued)
• Current smoker or smoking history of 10 pack-years or used inhaled tobacco
products within the past 3 months
• Shift workers
Interventions Randomised 1:1:1
Arm 1: FF/VI dose 100/25 mcg inhalation powder inhaled orally once-daily in the
evening
Arm 2: FF 100 mcg inhalation powder inhaled orally once-daily in the evening
Arm 3: FF/VI dose 200/25 mcg inhalation powder inhaled orally once-daily in the
evening
Outcomes Primary endpoint
Weighted mean (WM) serial FEV1 0 to 24 hours post dose at week 12
Secondary endpoints
• Change from baseline in trough FEV1
• Change from baseline in % rescue-free 24-hour periods
• Change from baseline in % symptom-free 24-hour periods
• Change from baseline in morning and evening PEF
Adverse events were assessed throughout the study
Notes Data collected from 137 locations in Argentina (13), Chile (7), Germany (12), Mexico
(4), Netherlands (7), Poland (8), Romania (13), Russian Federation (19), Sweden (5),
Ukraine (12) and USA (37)
Funded by GlaxoSmithKline
Study duration: 12 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised through a
validated computerised system (RandAll
Version 2.5, GlaxoSmithKline)
Allocation concealment (selection bias) Low risk TheRegistration andMedicationOrdering
System was used to register and randomise
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on 108 participants fail-
ing to complete study included in
NCT01686633 report
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Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Bleecker 2012
Methods Randomised double-blind placebo-controlled parallel-group multi-centre trial
Participants Total sample
N = 609 participants, 515 completed study
FF/VI 100/25, n = 201 (179 completed study)
FF 100, n = 205 (185 completed study)
Placebo, n = 203 (151 completed study)
Age
FF/VI 100/25, mean 40.7 (SD 16.38)
FF 100, mean 40.4 (SD 16.78)
Placebo, mean 38.1 (SD 16.49)
Males
FF/VI 100/25, 85 (42%)
FF 100, 79 (39%)
Placebo, 92 (45%)
Baseline FEV1 (% predicted)
Not reported
Inclusion criteria
• Outpatients 12 years of age or older
• Male and female; female participants of childbearing potential must be willing to
use birth control
• Pre-bronchodilator FEV1 40% to 90% of predicted normal
• Reversibility FEV1 ≥ 12% and ≥ 200 mL
• Current asthma therapy includes ICS use for ≥ 12 weeks before first visit
Exclusion criteria
• History of life-threatening asthma during past 10 years
• Respiratory infection or oral candidiasis
• Asthma exacerbation requiring OCS or overnight hospitalisation with additional
asthma treatment
• Uncontrolled disease or clinical abnormality
• Allergies to study drugs or to excipients
• Taking another investigational or prohibited medication
• Night shift workers
• Current smokers or participants with a smoking history of 10 or more pack-years
Interventions Arm 1: FF/VI dose 100/25 mcg inhalation powder inhaled orally once-daily for 12
weeks
Arm 2: FF dose 100 mcg inhalation powder inhaled orally once-daily for 12 weeks
Arm 3: Placebo inhalation powder inhaled orally once-daily for 12 weeks
Outcomes Primary outcomes
• Mean change from baseline in clinic visit trough (pre-bronchodilator and pre-
dose) FEV1 at week 12
• Change from baseline in weighted mean serial FEV1 over 0 to 24 hours post dose
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• Mean change from baseline in % of rescue-free 24-hour periods during 12-week
treatment period
• Change from baseline in % of symptom-free 24-hour periods during 12-week
treatment period
• Change from baseline in total AQLQ (+12) score at week 12/early withdrawal
• Number of participants who withdrew owing to lack of efficacy
• Serial FEV1 over 0 to 1 hour post dose at randomisation
• Clinic visit 12-hour post-dose FEV1 at week 12
• Weighted mean serial FEV1 over 0 to 24 hours post dose at baseline
• Weighted mean serial FEV1 over 0 to 4 hours post dose at baseline and at week 12
• Number of participants with bronchodilator effect
• Mean change from baseline in daily AM PEF averaged over 12-week treatment
period
• Mean change from baseline in daily PM PEF averaged over 12-week treatment
period
• Change from baseline in ACT score at week 12
• Number of participants with indicated global assessment of change responses at
week 4, week 8 and week 12/early withdrawal
• Number of indicated unscheduled asthma-related healthcare visits during
treatment period
• Number of participants who used the inhaler correctly or incorrectly at baseline,
week 2 and week 4
• Number of participants with indicated reason for incorrect inhaler use who
required additional instruction indicated number of times at baseline, week 2 and week
4
Notes Data collected from 12 sites in Poland (1), Ukraine (10) and USA (1)
Funded by GlaxoSmithKline
Study duration: 12 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details not reported
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double -blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double -blind
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Bleecker 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of 94 participants withdrawn from
the study are included in NCT01165138
report
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Busse 2013
Methods Randomised double-blind double-dummy parallel-group multi-centre trial
Participants Total sample
N = 503 participants, 393 completed study
FF/VI 100/25, n = 201 (161 completed study)
FF/VI 200/25, n = 202 (161 completed study)
FP 500 mcg twice-daily, n = 100 (71 completed study)
Age
FF/VI 100/25, mean 39.7 (SD 15.85)
FF/VI 200/25, mean 38.5 (SD 15.64)
FP 500 mcg twice-daily, 38.6 (SD 15.97)
Males
FF/VI 100/25, 71 (35%)
FF/VI 200/25, 78 (39%)
FP 500 mcg twice-daily, 38 (38%)
Baseline FEV1 (% predicted)
FF/VI 100/25, mean 74.2 (SD 13.48)
FF/VI 200/25, mean 74.1 (SD 14.13)
FP 500 mcg twice-daily, mean 75.2 (SD 12.46)
Inclusion criteria
• Clinical diagnosis of asthma
• Reversibility FEV1 ≥ 12% and ≥ 200 mL and greater approximately 10 to 40
minutes following 2 to 4 inhalations of albuterol
• FEV1 ≥ 50% of predicted
• Currently using moderate- to high-dose ICS therapy
Exclusion criteria
• History of life-threatening asthma
• Respiratory infection or oral candidiasis
• Asthma exacerbation
• Uncontrolled disease or clinical abnormality
• Allergies
• Taking another investigational or prohibited medication
Interventions Arm 1: FF/VI 100/25 mcg once-daily
Arm 2: FF/VI 200/25 mcg once-daily
Arm 3: FP 500 mcg twice-daily
Outcomes Primary outcome measures
• Number of participants with any AE or SAE during treatment period
• Number of participants with severe asthma exacerbations during treatment period
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• Change from baseline in albumin and total protein at week 12, week 28 and week
52/early withdrawal
• Change from baseline in ALP, ALT, AST, CK and GGT at week 12, week 28 and
week 52/early withdrawal
• Change from baseline in direct bilirubin, indirect bilirubin, total bilirubin and
creatinine at week 12, week 28 and week 52/early withdrawal
• Change from baseline in chloride, CO2 content/bicarbonate, glucose, potassium,
sodium and urea/BUN at week 12, week 28 and week 52/early withdrawal
• Change from baseline in % of basophils, eosinophils, haematocrit, lymphocytes,
monocytes and segmented neutrophils in the blood at week 12, week 28 and week 52/
early withdrawal
• Change from baseline in eosinophil count, total ANC, platelet count and WBC
count at week 12, week 28 and week 52/early withdrawal
• Change from baseline in haematocrit at week 12, week 28 and week 52/early
withdrawal
• Change from baseline in haemoglobin at week 12, week 28 and week 52/early
withdrawal
• Number of participants with indicated shift from baseline to high, normal or no
change, and with low post-baseline values for urinary cortisol excretion
• Ratio of 24-hour urinary cortisol excretion at week 12 to baseline, week 28 to
baseline and week 52 to baseline
• Number of participants with evidence of oral candidiasis during treatment period
• Maximum change from baseline in SBP and minimum change from baseline in
DBP
• Maximum change from baseline in pulse rate
• Number of participants with indicated change from baseline in LOCS III
posterior subcapsular opacity (P) at week 28 and week 52
• Number of participants with indicated change from baseline in IOP at week 28
and week 52
• Change from baseline in horizontal cup-to-disc ratio at week 28 and week 52
• Number of participants with indicated change from baseline in LOCS III cortical
opacity (C) at week 28 and week 52
• Change from baseline in LOCS III nuclear color (NC) at week 28 and week 52
• Change from baseline in LOCS III nuclear opalescence (NO) at week 28 and
week 52
• Change from baseline in LogMAR visual acuity at week 28 and week 52
• Maximum change from baseline in QTcB and QTcF
• Mean 24-hour Holter heart rate for participants with 16 or more hours of
recorded data
• Maximum 24-hour Holter heart rate for participants with 16 or more hours of
recorded data
Notes Data collected from 46 sites in Germany (15), Thailand (4), Ukraine (9) and USA (18)
Funded by GlaxoSmithKline
Study duration: 52 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated
computerised system (RandAll, Glaxo-
SmithKline, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via an au-
tomated telephone-based registration and
medication ordering system (Registra-
tion and Medication Ordering System
(RAMOS))
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of 110participantswithdrawn from
the study are provided in the ClinicalTrials.
gov NCT01018186 report
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Hojo 2015
Methods Randomised cross-over trial
Participants Total sample: 32 adults
Age: participants over 20 years of age with severe asthma. Mean age, 62.2 years (SD 13.
3)
Baseline: % FEV1 mean, 70 (SD 11.9%); ACT mean, 20.3 (SD 2.79)
ppb at time of entry to trial suggested relatively poor asthma control status
Interventions Sequence 1: FF/VI 100/25 once-daily vs FP/salmeterol 500/50 twice-daily
Sequence 2: FP/salmeterol 500/50 twice-daily vs FF/VI 100/25 once-daily
Participants randomised to receive 4 weeks of treatment followed by 4-week washout
period, then second 4 weeks of treatment with the remaining intervention
Outcomes Fractional exhaled nitric oxide (FeNO) measured by NIOX-MINO
Asthma control test
Morning PEF
Respiratory resistance/reactance measured by Forced Oscillation Technique Mostgraph-
01
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Notes Reported as conference abstract. Minimal information available
Study duration: Each treatment period ran for 4 weeks with a 4-week washout period
between treatment periods
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details not reported
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details not reported
Selective reporting (reporting bias) Unclear risk Details not reported
Kempsford 2012
Methods Randomised double-blind cross-over trial
Participants Total sample
N = 26 participants
Age: mean, 38.1 (SD 11.30)
Males: 18 (69%)
Baseline FEV1 (% predicted): not reported
Inclusion criteria
• Participants with documented history of persistent asthma, with exclusion of
other significant pulmonary disease
• Male or female between 18 and 70 years of age inclusive
• A female participant is eligible to participate if she is of non-childbearing
potential. Females on HRT and whose menopausal status is in doubt will be required
to use a contraception method if they wish to continue their HRT during the study.
Otherwise, they must discontinue HRT to allow confirmation of post-menopausal
status before study enrolment. Childbearing potential and agrees to use one of the
protocol contraception methods
• All participants must be using ICS, with or without SABA, for ≥ 12 weeks before
screening
• Participants with screening pre-bronchodilator FEV1 ≥ 60% of predicted
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• During screening visit, participants must demonstrate the presence of reversible
airway disease
• All participants must be able to replace all their current asthma treatments with
albuterol/salbutamol aerosol inhaler at screening for use as needed for run-in period
and throughout the duration of the study. Participants must be able to withhold
albuterol/salbutamol for ≥ 6 hours before study visits
• Participants who are current non-smokers, who have not used any inhaled
tobacco products in the 12-month period preceding the screening visit
• Body weight ≥ 50 kg and BMI within the range of 19.0 to 29.9 kg/m2 (inclusive)
• No evidence of significant abnormality on the 12-lead ECG performed at
screening
• AST and ALT < 2 × ULN; alkaline phosphatase and bilirubin ≤ 1.5 × ULN
(isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct
bilirubin is < 35%
• Capable of giving written informed consent
• Able to satisfactorily use novel DPI
Exclusion criteria
• History of life-threatening asthma within past 5 years
• Culture-documented or suspected bacterial or viral infection that was not resolved
within 4 weeks of screening and led to a change in asthma management or, in the
opinion of the investigator, is expected to affect participant’s asthma status or ability to
participate in the study
• Any asthma exacerbation requiring OCS within 12 weeks of screening or
resulting in overnight hospitalisation with additional treatment for asthma within 6
months before screening
• Participant with any clinically significant, uncontrolled condition or disease state
that, in the opinion of the investigator, would put the safety of the patient at risk
through study participation




• Participant has participated in a clinical trial and has received an investigational
product within 30 days before first dosing day in the current study
• Exposure to ≥ 4 new chemical entities within 12 months before first dosing day
• Any adverse reaction including immediate or delayed hypersensitivity to any
beta2-agonist, sympathomimetic drug or intranasal, inhaled or systemic corticosteroid
therapy
• History of severe milk protein allergy
• History of drug or other allergy that, in the opinion of the investigator or the
GSK medical monitor, contraindicates participation
• Use of prescription or non-prescription drugs within 7 days (or 14 days if the
drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before first
dose of study medication, unless in the opinion of the Investigator and the GSK
medical monitor, the medication will not interfere with study procedures or
compromise participant safety
• Participants who have taken high doses of an ICS within 8 weeks of screening
visit or OCS within 12 weeks of screening visit
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• Participants who have changed their ICS treatment within the past 4 weeks before
screening or can be expected to do so during the study
• History of regular alcohol consumption within 6 months of the study
• Positive test for hepatitis B or hepatitis C within 3 months of screening
• Positive breath carbon monoxide (CO) test
• Positive pre-study drug/alcohol screen
• Positive test for HIV antibody
• When participation in the study would result in donation of blood or blood
products in excess of 500 mL within a 56-day period
• No participant is permitted to perform night shift work for 1 week before
screening until completion of study treatment periods
• Unwillingness or inability to follow procedures outlined in the protocol
Interventions Sequence 1: placebo, FF/VI 100/25 mcg AM, FF/VI 100/25 mcg PM
Sequence 2: placebo, FF/VI 100/25 mcg PM, FF/VI 100/25 mcg AM
Sequence 3: FF/VI 100/25 mcg AM, FF/VI 100/25 mcg PM, placebo
Sequence 4: FF/VI 100/25 mcg AM, placebo, FF/VI 100/25 mcg PM
Sequence 5: FF/VI 100/25 mcg PM, placebo, FF/VI 100/25 mcg AM
Sequence 6: FF/VI 100/25 mcg PM, FF/VI 100/25 mcg AM, placebo
Participants received all treatments once a day in the evening from a DPI for 14 days.
Each 14-day treatment period was followed by a 14 to 21-day washout period
Outcomes Primary outcome
• Weighted mean FEV1 over 0 to 24 hours post dose on day 14
Secondary outcomes
• Pre-treatment PEF (AM and PM) at days 1 to 12
• AM and PM pre-treatment trough FEV1 at day 14
• Number of participants with any AE or SAE
Notes Data collected from 1 site in New Zealand
Funded by GlaxoSmithKline
Study duration: Each treatment period ran for 14 days, with a 14 to 21-day washout
period between treatment periods
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gener-
ated by GSK
Quantitative sciences using validated inter-
nal software
Allocation concealment (selection bias) Low risk Investigator or designee received medi-
cation assignment information and ran-
domised participants using sequentially
numbered containers
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details of the 2 withdrawals are included in
the trial report
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Lee 2014
Methods Randomised double-blind 3-period cross-over incomplete block study
Participants Total sample
706 screened, N = 421 participants, 323 completed study
Age







• > 18 years of age
• Diagnosis of asthma for > 6 months
• Pre-bronchodilator FEV1 40% to 80% of predicted
• Demonstrated reversibility by ≥ 12% and ≥ 200 mL of FEV1 within 40 minutes
following albuterol
• Need for regular controller therapy for minimum of 8 weeks
• Stable dose of ICS for > 4 weeks
Exclusion criteria
• History of life-threatening asthma
• Respiratory infection not resolved
• Asthma exacerbation
• Concurrent respiratory disease
• Current smoker
• Uncontrolled disease
• Positive hepatitis B surface antigen or positive hepatitis C antibody and/or HIV
• Visual clinical evidence of oropharyngeal candidiasis
• Drug or milk protein allergies
• Concomitant medications affecting course of asthma
• Use of any other investigational medication within 30 days or 5 drug half-lives
(whichever is longer)
• Previous use of GSK573719
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• Any disease preventing use of anticholinergics
• Any condition that impairs compliance with study protocol, including visit
schedule and completion of daily diaries
• Any participant with a history of alcohol or substance abuse
Interventions Arm 1: FF 100 mcg once daily for 14 days
Arm 2: FF/VI 100/25 mcg once daily for 14 days
Arm 3: FF/UMEC 100/variable dose (15.6, 31.25, 62.5, 125, 250 mcg) once daily for
14 days
Outcomes Primary outcome measure
• Change from baseline in trough FEV1
Secondary outcome measures
• Mean change from baseline in daily AM/PM PEF
• Mean change from baseline in rescue albuterol use
Notes 32 centres - Argentina (6), Chile (7), Russia (11), Thailand (4) and USA (4)
Funded by GlaxoSmithKline
Study duration: Each treatment period ran for 14 days with a 12 to 14-day washout
period between treatment periods
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk In a 3-period cross-over study, participants
were randomised to a sequence of 3 of 7
treatments using SAS-generated codes in
a validated computerised system (RandAll
Version 2.5, GlaxoSmithKline)
Allocation concealment (selection bias) Low risk TheRegistration andMedicationOrdering
System was used to register and randomise
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding in all 3 conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding in all 3 conditions
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on 98 participants who failed
to complete the study included in the trial
report
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
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Methods Randomised double-blind double-dummy parallel-group trial
Participants Total sample
N = 309 participants, 255 completed study
FF/VI 200/25, n = 155 (136 completed study)
FP 500, n = 154 (119 completed study)
Age
FF/VI 200/25, mean 46.9 (SD 12.93)
FP 500, n = 48.8 (SD 13.41)
Males
FF/VI 100/25. 59 (38%)
FP 500. n = 64 (42%)
Baseline FEV1 (% predicted)
FF/VI 100/25, mean 67.51 (SD 13.249)
FP 500, n = 67.55 (SD 13.432)
Inclusion criteria
• Informed consent: All participants must be able and willing to give written
informed consent to take part in the study
• Type of participant: outpatients, of Asian ancestry, 12 years of age or older at visit
1 (or 18 years of age or older if local regulations or regulatory status of the study
medication permits enrolment of adults only) with a diagnosis of asthma as defined by
the Global Initiative for Asthma (GINA, 2009) ≥ 12 weeks before visit 1
• Gender: male or eligible female, defined as non-childbearing potential or
childbearing potential and using an acceptable method of birth control consistently
and correctly
• Severity of disease: best FEV1 40% to 90% of predicted normal value at visit 1
screening visit. Predicted values will be based upon NHANES III using the Asian
adjustment
• Reversibility of disease: demonstrated ≥ 12% and ≥ 200 mL reversibility of FEV1
within 10 to 40 minutes following 2 to 4 inhalations of albuterol/salbutamol inhalation
aerosol (or 1 nebulised treatment with albuterol/salbutamol solution) at screening visit
• Current antiasthma therapy: All participants must be using an ICS, with or
without LABA, for ≥ 12 weeks before visit 1
• SABA: All participants must be able to replace their current SABA with albuterol/
salbutamol inhaler at visit 1 for use as needed for the duration of the study. Participants
must be able to withhold albuterol/salbutamol for ≥ 4 hours before study visits
Exclusion criteria
• History of life-threatening asthma: defined for this protocol as an asthma episode
that required intubation and/or was associated with hypercapnia, respiratory arrest or
hypoxic seizures within the past 10 years
• Respiratory infection: culture-documented or suspected bacterial or viral infection
of upper or lower respiratory tract, sinus or middle ear that is not resolved within 4
weeks of visit 1 and led to a change in asthma management or, in the opinion of the
investigator, is expected to affect participant’s asthma status or ability to participate in
the study
• Asthma exacerbation: any asthma exacerbation requiring OCS within 12 weeks of
visit 1 or resulting in overnight hospitalisation with additional treatment for asthma
within 6 months before visit 1
• Concurrent respiratory disease: Participant must not have current evidence of
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pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary
dysplasia, chronic bronchitis, emphysema, COPD or other respiratory abnormalities
other than asthma
• Other concurrent diseases/abnormalities: Participant must not have a clinically
significant, uncontrolled condition or disease state that, in the opinion of the
investigator, would put the safety of the patient at risk through study participation, or
would confound interpretation of efficacy results if the condition/disease was
exacerbated during the study
• Oropharyngeal examination: Participant will not be eligible for the run-in if he/
she has clinical visual evidence of candidiasis at visit 1
• Allergies: drug allergy: any adverse reaction including immediate or delayed
hypersensitivity to any beta2-agonist, sympathomimetic drug or intranasal, inhaled or
systemic corticosteroid therapy. Known or suspected sensitivity to constituents of the
new powder inhaler; milk protein allergy: history of severe milk protein allergy
• Concomitant medications: use of protocol-defined prohibited medications within
prohibited time intervals before screening (visit 1) or during the study
• Tobacco use: current smoker or smoking history of 10 pack-years (e.g. 20
cigarettes/d for 10 years). Participant may not have used inhaled tobacco products
within the past 3 months (i.e. cigarettes, cigars, smokeless or pipe tobacco)
• Affiliation with investigator’s site: Participant will not be eligible for this study if
he/she is an immediate family member of the participating investigator, subinvestigator
or study co-ordinator, or is an employee of the participating investigator
• Previous participation: Participant may not have been randomised previously to
treatment in another phase III FF/VI combination product study
• Compliance: Participant will not be eligible if he/she or his/her parent or legal
guardian has any infirmity, disability, disease or geographical location that seems likely
(in the opinion of the Investigator) to impair compliance with any aspect of this study
protocol, including visit schedule and completion of daily diaries
Interventions • Arm 1: FF/VI 200/25 mcg once-daily
• Arm 2: FP 500 mcg twice-daily
Outcomes Primary outcome
• Mean change from baseline in daily PM PEF averaged over 12-week treatment
period
Secondary outcomes
• Mean change from baseline in daily AM PEF averaged over 12-week treatment
period
• Mean change from baseline in % of rescue-free 24-hour periods during 12-week
treatment period
• Mean change from baseline in % of symptom-free 24-hour periods during 12-
week treatment period
• Change from baseline in total AQLQ score at week 12
Notes Data collected from 24 sites in China (12), Republic of Korea (10) and Philippines (2)
Funded by GlaxoSmithKline
Study duration: 12 weeks
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated
computerised system (RandAll, Glaxo-
SmithKline, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via an au-
tomated telephone-based registration and
medication ordering system (Registra-
tion and Medication Ordering System
(RAMOS))
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of attrition bias included in trial re-
port. Three participants (1 FF/VI; 2 FP)
reported a total of 5 serious adverse events
and were withdrawn from the study
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
NCT01134042
Methods Randomised double-blind parallel-group multi-centre trial
Participants Total sample
N = 586 participants, 476 completed study
FF 200 mcg once-daily, n = 198 (146 completed study)
FF/VI 200/25 mcg once-daily, n = 197 (169 completed study)
FP 500 mcg twice-daily, n = 195 (161 completed study)
Age
FF 200 mcg once-daily, mean 44.6 years (SD 14.33)
FF/VI 200/25 mcg once-daily, mean 46.6 (SD 15.05)
FP 500 mcg twice-daily, mean 47.3 (SD 14.06 )
Males
FF 200 mcg once-daily, 81 (42%)
FF/VI 200/25 mcg once-daily, 81 (42%)
FP 500 mcg twice-daily, 79 (41%)
Baseline FEV1 (% predicted)
FF 200 mcg once-daily, mean 66.66 (SD 12.388)
FF/VI 200/25 mcg once-daily, mean 66.59 (SD 12.614)
48Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01134042 (Continued)
FP 500 mcg twice-daily, mean 67.57 (SD 12.185)
Inclusion criteria
• Outpatient ≥ 12 years of age
• Both genders; females of childbearing potential must be willing to use birth
control method
• Pre-bronchodilator FEV1 40% to 90% of predicted
• Reversibility FEV1 ≥ 12% and ≥ 200 mL
• Current asthma therapy that includes an ICS for ≥ 12 weeks before first visit
Exclusion criteria
• History of life-threatening asthma
• Respiratory infection or oral candidiasis
• Asthma exacerbation within 12 weeks
• Concurrent respiratory disease or other disease that would confound study
participation or affect participant safety
• Allergies to study drugs, study drug excipients, medications related to study drugs
• Taking another investigational medication or medication prohibited for use
during this study
Interventions Arm 1: FF 200 mcg once-daily
Arm 2: FF/VI 200/25 mcg once-daily
Arm 3: FP 500 mcg twice-daily
Outcomes Primary outcomes
• Change from baseline in clinic visit trough (pre-bronchodilator and pre-dose)
FEV1 at the end of the 24-week treatment period
• Change from baseline in weighted mean serial FEV1 over 0 to 24 hours post dose
at week 24
Secondary outcomes
• Change from baseline in percentage of rescue-free and symptom-free 24-hour
periods at the end of the 24-week treatment period
• Change from baseline in total AQLQ (+12) score at week 12 and at week 24/early
withdrawal
• Clinic visit 12-hour post-dose FEV1 at week 24
• Change from baseline in weighted mean serial FEV1 over 0 to 4 hours post dose
at week 24
• Mean change from baseline in daily trough AM and PM PEF averaged over first
12 weeks and 24 weeks of 24-week treatment period
• Number of participants who withdrew owing to lack of efficacy during 24-week
treatment period
• Change from baseline in ACT scores at week 12 and at week 24
• Number of participants with indicated global assessment of change questionnaire
responses at weeks 4, 12 and 24
• Number of indicated unscheduled asthma-related healthcare visits during
treatment period
Notes Data collected from 71 sites in Germany (10), Japan (12), Poland (8), Romania (7),
Russian Federation (11) and USA (23)
Funded by GlaxoSmithKline
Study duration: 24 weeks
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated,
computerised system (RandAll, Glaxo-
SmithKline, Stevenage, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
(GlaxoSmithKline)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on 110 participants not com-
pleting the study is reported at http://clin-
icaltrials.gov/show/NCT01134042
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
NCT01453023
Methods Randomised double-blind cross-over trial
Participants Total sample
N = 26 participants, 23 completed study
Age: mean 8.1 years (SD 1.97)
Males: 15 (58%)
Asthma severity, no. (%)
Mild (well controlled with GINA step 2 low-dose ICS), 21 (84%)
Moderate (well controlled with GINA step 3 medium-dose ICS), 4 (16%)
Inclusion criteria
• Healthy as determined by a study physician on the basis of medical history,
physical examination, laboratory testing and electrocardiogram (ECG), with no
significant medical condition apart from asthma, eczema or rhinitis. Participant with a
clinical abnormality or laboratory parameters outside the reference range for this study
may be included if the investigator and the GSK medical monitor agree that the finding
is not likely to introduce additional risk factors nor interfere with study procedures
• Male and pre-menarcheal female participants 5 to less than 12 years of age on last
planned treatment day are eligible for this study. A pre-menarcheal female is defined as
any female who has not begun menses and is considered Tanner stage 2 or less
50Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01453023 (Continued)
• Diagnosis of asthma ≥ 6 months before screening
• Stable asthma therapy (FP, total daily dose ≤ 400 mcg or equivalent) and SABA
inhaler for ≥ 4 weeks before screening
• Participants must be controlled on existing asthma treatment at screening, which
will be continued during run-in, washout and run-out periods (but not during active
treatment periods). Control is defined as Childhood ACT score > 19 and PEF > 75%
predicted
• Participants must demonstrate an ability to accept and effectively use a
demonstration inhaler from demonstration kits provided
• Participants must weigh ≥ 20 kg
• Participant and parent/guardian are able to understand and comply with protocol
requirements, instructions and protocol stated restrictions. Parent or guardian must
have the ability to read, write and record diary information collected throughout the
study. Parent or guardian must have the ability to manage study drug administration
and PEF assessments
• One or more parents/guardians have signed and dated the written informed
consent before admission to the study. This will be accompanied by informed assent
from the participant for children 7 to 11 years of age
Exclusion criteria
• Participants with a history of life-threatening asthma, an asthma exacerbation
requiring systemic corticosteroids or emergency room attendance (within 3 months) or
hospitalisation (within 6 months) before screening
• Participants with any medical condition or circumstance making the volunteer
unsuitable for participation in the study
• Culture-documented or suspected bacterial or viral infection of the upper or
lower respiratory tract, sinus or middle ear, not resolved within 4 weeks of screening
and leading to a change in asthma management, or, in the opinion of the investigator,
is likely to affect participants’ asthma status or ability to participate in the study
• Clinical visual evidence of oral candidiasis at screening
• Participants currently receiving (or received within 4 weeks of screening) asthma
therapies including theophyllines, long-acting inhaled beta-agonists or oral beta-
agonists, or who have changed their asthma medication within 4 weeks of screening
• Significant abnormality of rate, interval, conduction or rhythm in the 12-lead
ECG, as determined by the investigator, in conjunction with age and gender of the
child and assessment provided by the remote analysis service
• QTcF > 450 milliseconds or ECG not suitable for QT measurement (e.g. poorly
defined termination of the T wave)
• Aspartarte aminotransferase, alanine aminotransferase, alkaline phosphatase and
bilirubin > 1.5 times ULN (isolated bilirubin > 1.5 times ULN is acceptable if
bilirubin is fractionated and direct bilirubin is less than 35%)
• Known or suspected sensitivity to any constituents of the novel DPI (i.e. lactose
or magnesium stearate) (e.g. history of severe milk protein allergy)
• Any adverse reaction including immediate or delayed hypersensitivity to any
beta2-agonist, sympathomimetic drug or intranasal, inhaled or systemic corticosteroid
therapy
• Use of prescription or non-prescription drugs, including vitamins and herbal and
dietary supplements (including St John’s Wort) within 7 days or 5 half-lives (whichever
is longer) before first dose of study medication, unless in the opinion of the investigator
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and the GSK medical monitor the medication will not interfere with study procedures
nor compromise participant safety
• Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or
pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days before first
dose of study medication
• Individual has participated in a clinical trial and has received an investigational
product within 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer)
• Exposure to more than 4 new chemical entities within 12 months before first
dosing day
• When participation in the study would result in donation of blood or blood
products in excess of the lesser of 50 mL or 3 mL per kilogram within a 56-day period
• Parent/guardian has a history of psychiatric disease, intellectual deficiency,
substance abuse or other condition (e.g. inability to read, comprehend and write) that
will limit the validity of consent to participate in this study
• Unwillingness or inability of participant or parent/guardian to follow procedures
outlined in the protocol
• Participant who is mentally or legally incapacitated
• Children who are wards of the state or government
• Participant will not be eligible for this study if he/she is an immediate family
member of the participating investigator, sub-investigator or study co-ordinator, or is
an employee of the participating investigator
Interventions Sequence 1: FF 100 mcg/VI 25 mcg in period 1 and FF 100 mcg in period 2
Sequence 2: FF 100 mcg in period 1 and FF 100 mcg/VI 25 mcg in period 2
With a washout period ≥ 7 days
Outcomes Primary outcomes
• Number of participants with AE or SAE during treatment period
• Basophil, eosinophil, lymphocyte, monocyte, total neutrophil, platelet and white
blood cell count values at day 14 of treatment period
• Haemoglobin and MCHC values at day 14 of treatment period
• Reticulocyte and RBC values at day 14 of treatment period
• Haematocrit values at day 14 of treatment period
• MCV value at day 14 of treatment period
• MCH values at day 14 of treatment period
• ALT, ALP, AST and GGT values at day 14 of treatment period
• Albumin and total protein values at day 14 of treatment period
• Calcium chloride, CO2 content/bicarbonate, glucose, potassium, sodium and
urea/BUN values at day 14 of treatment period
• Total bilirubin, direct bilirubin, creatinine and uric acid values at day 14 of
treatment period
• PEF at days 1 and 14 of treatment period
• Change from baseline in SBP and DBP at days 1 and 14 of treatment period
• Change from baseline in heart rate at days 1 and 14 of treatment period
• Maximum QTcF at days 1 and 14 of treatment period
Secondary outcomes
• AUC(0-t) and AUC(0-4) of FF on day 14 of treatment period
• Cmax of FF at day 14 of treatment period
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• Tmax and Tlast of FF at day 14 of treatment period
• AUC(0-t) and AUC(0-4) of VI at day 14 of treatment period
• Cmax of VI at day 14 of treatment period
• Tmax and Tlast of VI at day 1 of treatment period
• Blood glucose and potassium values at day 14 of treatment period
• Serum cortisol weighted mean (0 to 12 hours) at day 14 of treatment period
• Average oropharyngeal cross-sectional area at days 1 and 14 of treatment period
• Distance of assessment at days 1 and 14 of treatment period
• Oropharyngeal volume at days 1 and 14 of treatment period
• Average flow rate and PIFR at days 1 and 14 of treatment period
• Inhalation time at days 1 and 14 of treatment period
• Inhaled volume at days 1 and 14 of treatment period
• Peak pressure drop at days 1 and 14 of treatment period
• TED at day 14 of treatment period
• Ex-throat dose (ETD) and ETD < 2 microns at day 14 of treatment period
Notes Data collected from 1 site in California, USA
Funded by GlaxoSmithKline
Study duration: 2 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a vali-
dated computerised system (RandAll,Glax-
oSmithKline, Stevenage, UK)
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
(GlaxoSmithKline)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on the 3 participants not com-
pleting the study is provided at http://
clinicaltrials.gov/show/NCT01453023
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
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Methods Randomised double-blind cross-over trial
Participants Total sample
N = 52 participants, 50 completed
Age: mean, 35.4 (SD 8.63)
Males: 34 years (65%)
Pre-bronchodilator FEV1% predicted: mean, 89.71 (SD 8.848)
Inclusion criteria
• BMI within the range 18.5 to 35.0 kg/m2
• Females of non-childbearing potential
• Documented history of bronchial asthma, first diagnosed ≥ 6 months before
screening visit and currently treated only with intermittent SABA therapy by inhalation
• Pre-bronchodilator FEV1 > 70% of predicted at screening
• Participants who are current non-smokers
• Methacholine challenge PC20 < 8 mg/mL at screening
• Screening allergen challenge demonstrates that participant experiences an early
asthmatic response
Exclusion criteria
• Current or chronic history of liver disease, or known hepatic or biliary
abnormalities
• Participant hypertensive at screening
• Respiratory tract infection and/or exacerbation of asthma within 4 weeks before
first dose of study medication
• History of life-threatening asthma
• Symptomatic with hay fever at screening or predicted to have symptomatic hay
fever
• Unable to abstain from short-acting beta-agonists
• Unable to abstain from antihistamines
• Unable to abstain from other medications, including NSAIDs, antidepressant
drugs and antiasthma, anti-rhinitis or hay fever medication
• Participant has participated in a study with a new molecular entity during previous
3 months or has participated in 4 or more clinical studies in previous 12 months
• Undergoing allergen desensitisation therapy
Interventions Sequence 1: placebo, FF 100 mcg, FF/VI 100/25 mcg
Sequence 2: placebo, FF/VI 100/25 mcg, FF 100 mcg
Sequence 3: FF 100 mcg, FF/VI 100/25 mcg, placebo
Sequence 4: FF 100 mcg, placebo, FF/VI 100/25 mcg
Sequence 5: FF/VI 100/25 mcg, placebo, FF 100 mcg
Sequence 6: FF/VI 100/25 mcg, FF 100 mcg, placebo
Following the run-in period, participants were randomised to 1 of 6 treatment sequences
of placebo, FF 100 mcg once-daily and FF/VI 100/25 mcg once-daily. The 3 treatment
periods were separated by a washout period of ≥ 21 days (from day 28 dose) and
maximum of 35 days
Outcomes Primary outcome
• Weighted mean change from baseline in FEV1 from 0 to 2 hours, following 22 to
23-hour post-treatment allergen challenge on day 29 of each treatment period
Secondary outcomes
• Maximum % decrease from baseline in FEV1 from 0 to 2 hours, following 22 to
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23-hour post-treatment allergen challenge on day 29 of each treatment period
• Minimum FEV1 absolute change from baseline from 0 to 2 hours, following 22
to 23-hour post-treatment allergen challenge on day 29 of each treatment period
• Number of participants with treatment-emergent AEs
Notes Data collected from 4 sites in Germany (1), New Zealand (1) and UK (2)
Funded by GlaxoSmithKline
Study duration: 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by RandAll (GlaxoSmithK-
line validated internal randomisation soft-
ware) to 1 of 6 treatment sequences, each
comprising 3 treatment periods
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
(GlaxoSmithKline)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of attrition bias included in trial re-
port. Two participants withdrew: 1 with-
drew consent and 1 experienced an SAE
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Oliver 2013
Methods Randomised double -blind cross-over trial
Participants Total sample
N = 27 participants
Age: mean, 30.8 years (SD 7.46)
Males: 19 (70%)
Pre-bronchodilator FEV1: mean % pred, 92.3 (range 71.3 to 119.8)
Inclusion criteria
• BMI within the range 18.5 to 35.0 kg/m2
• Females of non-childbearing potential
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• Documented history of bronchial asthma, first diagnosed ≥ 6 months before
screening visit and currently treated only with intermittent SABA therapy by inhalation
• Pre-bronchodilator FEV1 > 70% of predicted at screening
• Participants who are current non-smokers
• Methacholine challenge PC20 < 8 mg/mL at screening
• Screening allergen challenge demonstrates that participant experiences an early
asthmatic response
Exclusion criteria
• Current or chronic history of liver disease, or known hepatic or biliary
abnormalities
• Participant hypertensive at screening
• Respiratory tract infection and/or exacerbation of asthma within 4 weeks before
first dose of study medication
• History of life-threatening asthma
• Symptomatic with hay fever at screening or predicted to have symptomatic hay
fever
• Unable to abstain from short-acting beta-agonists
• Unable to abstain from antihistamines
• Unable to abstain from other medications, including NSAIDs, antidepressant
drugs and antiasthma, antirhinitis or hay fever medication
• Participant has participated in a study with a new molecular entity during previous
3 months or has participated in 4 or more clinical studies in previous 12 months
• Undergoing allergen desensitisation therapy
Interventions Sequence 1: VI 25 mcg, placebo, FF 100 mcg, FF/VI 100/25 mcg
Sequence 2: FF/VI 100/25 mcg, FF 100 mcg, placebo, VI 25 mcg
Sequence 3: placebo, FF/VI 100/25 mcg, VI 25 mcg, FF 100 mcg
Sequence 4: FF 100 mcg, VI 25 mcg, FF/VI 100/25 mcg, placebo
Participants meeting all inclusion criteria and no exclusion criteria during screening visit,
conducted 14 to 42 days before first dose of study medication, entered a 14-day run-in
period. Participants were then randomised to 4 treatment periods, each lasting 21 days
and all separated by a nominal washout period of 21 to 35 days
Outcomes Primary outcomes
• LAR: absolute change from baseline in minimum FEV1 between 4 and 10 hours
following 1-hour post-treatment allergen challenge on day 21 of each treatment period
• LAR: absolute change from saline in weighted mean FEV1 between 4 and 10
hours following 1-hour post-treatment allergen challenge on day 21 of each treatment
period
• EAR: absolute change from baseline in minimum FEV1 between 0 and 2 hours
following 1-hour post-treatment allergen challenge on day 21 of each treatment period
• EAR: absolute change from baseline in weighted mean FEV1 between 0 and 2
hours following 1-hour post-treatment allergen challenge on day 21 of each treatment
period
Secondary outcomes
• Maximum % change from baseline in FEV1 between 0 and 2 hours following 1-
hour post-treatment allergen challenge on day 21 of each treatment period
• PC20 on day 22 of each treatment period
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Notes Data collected from 4 sites in Australia (1), New Zealand (1) and Sweden (2)
Funded by GlaxoSmithKline
Study duration: Each treatment period ran for 21 days with a 21 to 35-day washout
period between treatment periods
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation schedule based on a
Williams square generated by the sponsor
through validated internal software (Ran-
dAll, GlaxoSmithKline, London, UK)
Allocation concealment (selection bias) Low risk Automated telephone-based interactive
voice response system - RAMOS (Glaxo-
SmithKline, London,UK) -was used by in-
vestigators to register participants and ob-
tain randomised treatment assignments in
a blinded manner
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details of attrition bias included in trial re-
port. Twenty-seven participants were ran-
domised, and 26 completed the study. One
participant withdrew consent, and 4 proto-
col deviations were noted during period 1.
Data for those participants were excluded
from the analysis of relevant study periods
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Woodcock 2013
Methods Randomised double-blind double-dummy parallel-group multi-centre trial
Participants Total sample
N = 806 participants, 715 completed study
FF/VI 100/25 mcg, n = 403 (358 completed study)
FP/SAL 250/50 mcg twice-daily, n = 403 (357 completed study)
Age
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FF/VI 100/25 mcg, mean 43.8 years (SD 15.86)
FP/SAL 250/50 mcg twice-daily, mean 41.9 years (SD 16.90)
Males
FF/VI 100/25 mcg 159 (44%)
FP/SAL 250/50 mcg twice-daily 158 (44%)
Baseline FEV1 (L)
FF/VI 100/25 mcg, mean 2.013 (SD 0.653)
FP/SAL 250/50 mcg twice-daily, mean 2.043 (SD 0.6378)
Inclusion criteria
• Clinical diagnosis of asthma
• Reversibility ≥ 12% and ≥ 200 mL within 10 to 40 minutes following 2 to 4
inhalations of albuterol
• FEV1 40% to 85% of predicted normal
• Currently using ICS therapy
Exclusion criteria
• History of life-threatening asthma within previous 5 years (requiring intubation
and/or associated with hypercapnia, respiratory arrest or hypoxic seizures)
• Respiratory infection or oral candidiasis
• Asthma exacerbation requiring OCS, or overnight hospitalisation requiring
additional asthma treatment
• Uncontrolled disease or clinical abnormality
• Allergies
• Taking another investigational medication or prohibited medication
• Night shift workers
• Current smokers or participants with smoking history of ≥ 10 pack-years
Interventions Arm 1: FF/VI 100/25 mcg once-daily
Arm 2: FP/SAL 250/50 mcg twice-daily
Outcomes Primary outcome
• Change from baseline in weighted mean 24-hour serial FEV1 at day 168/week 24
Secondary outcomes
• Serial FEV1 (0-24 hours)
• Number of participants with indicated time to onset of bronchodilator effect at
day 1
• Change from baseline in weighted mean serial FEV1 over 0 to 4 hours post first
dose (at randomisation)
• Change from baseline in weighted mean serial FEV1 over 0 to 4 hours at day 168
• Number of participants obtaining ≥ 12% and ≥ 200 mL increase from baseline
in FEV1
• Change from baseline in trough FEV1 at day 168
• Baseline FEV1 by completion status
• Change from baseline in ACT scores at day 168
• Number of healthcare contacts related to asthma or to treatment of asthma from
baseline to day 168
• Change from baseline in AQLQ total score for participants ≥ 12 years of age
(AQLQ + 12)
• Percentage of participants with “no problems” in EQ-5D descriptive system
dimensions at day 168/week 24
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• Change from baseline in EQ-5D VAS score at day 168
Notes Data collected from 63 sites in Argentina (10), Chile (7), Republic of Korea (7), Nether-
lands (8), Phillipines (6) and US (25)
Funded by GlaxoSmithKline
Study duration: 24 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation schedule was gen-
erated by the sponsor through a validated
computerised system (RandAll, Glaxo-
SmithKline)
Allocation concealment (selection bias) Low risk Participants were randomised via the Reg-
istration and Medication Ordering System
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double-blind
’Neither the patients nor the investigator
knew which study medication the patient
was receiving’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double-blind
’Neither the patients nor the investigator
knew which study medication the patient
was receiving’
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% completed the study. Details of par-
ticipant withdrawal included in trial report





ANC: absolute neutrophil count
AQLQ: asthma quality of life questionnaire
AST: aspartate aminotransferase
AUC: area under the curve
BMI: body mass index
BUN: blood urea nitrogen
CK: creatine kinase
Cmax: maximum serum concentration
CO: carbon monoxide
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CO2: carbon dioxide
COPD: chronic obstructive pulmonary disease
DBP: diastolic blood pressure
DPI: dry powder inhaler
EAR: early asthmatic response
ECG: electrocardiogram
EQ-5D: EuroQuality of Life 5D questionnaire
ETD: ex-throat dose
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume in one second
FF: fluticasone furoate
FP: fluticasone propionate
GGT: gamma glutamyl transferase
HIV: human immunodeficiency virus




LOCS III: Lens Opacities Classification System, Version III
LogMAR: logarithm of the minimum angle of resolution
MCH: mean corpuscular haemoglobin
MCHC: mean corpuscular haemoglobin concentration
MCV: mean corpuscular volume
NHANES: National Health and Nutrition Examination Survey
NIOX-MINO: first point-of-care medical device for measuring fractional exhaled nitric oxide
NSAIDs: non-steroidal anti-inflammatory drugs
OCS: oral corticosteroid
OM: evening
PC20: provocative concentration of methacholine estimated to result in a 20% reduction in FEV1
PEF: peak expiratory flow
PEFR: peak expiatory flow rate
PIRF: peak inspiratory flow rate
PK: pharmacokinetics
ppb: parts per billion
QTcB: QT interval using Bazett’s correction
QTcF: QT interval using Fridericia’s correction
RAMOS: Registration and Medication Ordering System
RBC: red blood cell
SABA: short-acting beta2-agonist
SAE: serious adverse event
SAL: salmeterol
SAS: Statistical Analysis System (a software suite developed by SAS Institute)
SBP: systolic blood pressure
SD: standard deviation
TED: total emitted dose
Tlast: time of the last point with quantifiable concentration
Tmax: time to Cmax
ULN: upper limit of normal
UMEC: umeclidinium bromide
VAS: visual analogue scale
VI: vilanterol
WBC: white blood cell count
WM: weighted mean
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Calverley 2014 Study focuses on chronic obstructive pulmonary disease participants with community-acquired pneumonia
Gross 2013 Pooled analysis of data from clinical trials
Gross 2015 Pooled analysis of data from clinical trials
Hozawa 2016 Comparison includes budesonide/formoterol maintenance and reliever therapy vs fluticasone furoate/vi-
lanterol. Therefore, the comparison is not a direct evaluation of budesonide/formoterol maintenance vs
fluticasone furoate/vilanterol
Ishiura 2015 Participants have a diagnosis of asthma /chronic obstructive pulmonary disease overlap syndrome, rather
than asthma per se. COPD is included in the review’s exclusion criteria
Kempsford 2011 Participants did not have a diagnosis of asthma (healthy participants)
Kempsford 2011a Participants did not have a diagnosis of asthma (healthy participants)
Kempsford 2012a Participants did not have a diagnosis of asthma (healthy participants)
Nakahara 2013 Report of 3 safety, pharmacokinetics and pharmacodynamics studies with healthy participants
NCT00603746 VI and FF are not used together in the intervention arm
NCT01181895 Inhaled steroid used in the trial was not specifically FF
NCT01213849 Dose proportionality study comparing 3 doses of FF/VI without an additional comparison arm in healthy
participants
NCT01435902 Study was withdrawn before participants were enrolled
NCT01485445 Participants did not have a diagnosis of asthma (healthy participants)
NCT01573767 Trial focuses on VI and FP, not on VI and FF
NCT01711463 Participants did not have a diagnosis of asthma (healthy participants)
NCT02712047 2016 Study evaluating exhaled nitric oxide time profile as a biomarker of airway inflammation
Oliver 2014 Inhaled steroid used in the trial was not specifically FF
Sterling 2012 Inhaled steroid used in the trial was not specifically FF
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Woepse 2013 Evaluation of DPI among participants with asthma and COPD
COPD: chronic obstructive pulmonary disease




Characteristics of ongoing studies [ordered by study ID]
NCT01498679
Trial name or title A randomised, double-blind, placebo-controlled, parallel group, multi-centre study to evaluate the efficacy
and safety of FF/VI inhalation powder delivered once-daily for 12 weeks in the treatment of asthma in
adolescent and adult participants of Asian ancestry currently treated with low to mid-strength ICS or low-
strength combination therapy
Methods Randomised double-blind placebo-controlled parallel-group multi-centre study
Participants Participants of Asian ancestry with asthma. 12 years of age or older
Inclusion criteria
• Informed consent: All participants must be able and willing to give written informed consent to take
part in the study
• Type of participants: outpatients, of Asian ancestry, 12 years of age or older at visit 1 (or ≥ 18 years of
age or older if local regulations or the regulatory status of study medication permit enrolment of adults
only), with a diagnosis of asthma as defined by the Global Initiative for Asthma (GINA 2009) ≥ 12 weeks
before visit 1
• Gender: male or eligible female, defined as non-childbearing potential or childbearing potential using a
protocol-defined acceptable method of birth control consistently and correctly. Female participants should
not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study
participation. A serum pregnancy test is required for females of childbearing potential at initial screening
visit (visit 1) and at visit 5 or early withdrawal
• Severity of disease: best FEV1 40% to 90% of predicted normal value at visit 1, screening visit.
Predicted values will be based upon NHANES III using adjustment for Asians (Hankinson 2010)
• Reversibility of disease: demonstrated ≥ 12% and ≥ 200 mL reversibility of FEV1 within 10 to 40
minutes following 2 to 4 inhalations of albuterol/salbutamol inhalation aerosol (or 1 nebulised treatment
with albuterol/salbutamol solution) at screening visit
• Current antiasthma therapy: All participants must be using an ICS, with or without LABA, for ≥ 12
weeks before visit 1, in accordance with protocol-defined acceptable dose ranges
• SABA: All participants must be able to replace their current SABA with albuterol/salbutamol inhaler at
visit 1 for use as needed for the duration of the study. Participants must be able to withhold albuterol/
salbutamol for ≥ 4 hours before study visits
Exclusion criteria
• History of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 10
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years
• Respiratory infection: culture-documented or suspected bacterial or viral infection of the upper or
lower respiratory tract, sinus or middle ear that was not resolved within 4 weeks of visit 1 and led to a
change in asthma management or, in the opinion of the investigator, was expected to affect participant
asthma status or ability of participant to participate in the study
• Asthma exacerbation: any asthma exacerbation requiring OCS within 12 weeks of visit 1, or that
resulted in overnight hospitalisation requiring additional treatment for asthma within 6 months before visit 1
• Concurrent respiratory disease: Participant must not have current evidence of pneumonia,
pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis,
emphysema, COPD or respiratory abnormalities other than asthma
• Other concurrent diseases/abnormalities: Participant must not have any clinically significant,
uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the
patient at risk through study participation or would confound interpretation of efficacy results if the
condition/disease was exacerbated during the study
• Oropharyngeal examination: Participant will not be eligible for the run-in if he/she has clinical visual
evidence of candidiasis at visit 1
• Allergies: drug allergy: any adverse reaction including immediate or delayed hypersensitivity to any
beta2-agonist or sympathomimetic drug, or to any intranasal, inhaled or systemic corticosteroid therapy.
Known or suspected sensitivity to constituents of the new powder inhaler (i.e. lactose or magnesium
stearate). Milk protein allergy: history of severe milk protein allergy
• Concomitant medications: use of protocol-defined prohibited medications before visit 1 or during the
study, in accordance with the protocol
• Tobacco use: current smoker or participants with smoking history of 10 pack-years ( i.e. 20 cigarettes/d
for 10 years). Participant may not have used inhaled tobacco products within the past 3 months (i.e.
cigarettes, cigars, smokeless or pipe tobacco)
• Affiliation with investigator site: Participant will not be eligible for this study if he/she is an immediate
family member of the participating investigator, subinvestigator or study co-ordinator, or an employee of
the participating investigator
• Previous participation: Participant may not have previously been randomised to treatment in another
phase III FF/VI combination product study (i.e. HZA113714, HZA106827, HZA106829, HZA106837,
HZA106839, HZA106851, HZA113091)
• Compliance: Participant will not be eligible if he/she or his/her parent or legal guardian has an
infirmity, disability, disease or geographical location that seems likely (in the opinion of the Investigator) to
impair compliance with any aspect of this study protocol, including visit schedule and completion of daily
diaries
Interventions FF/VI ICS/LABA combination vs placebo
Outcomes Primary outcome measure
• Mean change from baseline in PM PEF averaged over 12-week treatment period
Secondary outcome measures
• Mean change from baseline in daily AM PEF averaged over 12-week treatment period
• Change from baseline in percentage of rescue-free 24-hour periods during 12-week treatment period
• Change from baseline in percentage of symptom-free 24-hour periods during 12-week treatment period
• Change from baseline in total AQLQ score at week 12
Starting date January 2012
Contact information GlaxoSmithKline Research and Development Limited
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Trial name or title A multi-centee, randomised, double-blind, dose-ranging study to evaluate GSK573719 in combination with
fluticasone furoate, fluticasone furoate alone and an active control of fluticasone furoate/vilanterol combina-
tion in participants with asthma
Methods Randomised double-blind cross-over study
Participants Participants with asthma. 18 years of age or older
Inclusion criteria
• Outpatient
• 18 years of age or older at visit 1
• Diagnosis of asthma
• Male or eligible female
• Pre-bronchodilator FEV1 40% to 80% of predicted normal value at visit 1
• Demonstrated reversibility by ≥ 12% and ≥ 200 mL of FEV1 within 40 minutes following albuterol
at visit 1
• Need for regular controller therapy (i.e. ICSs alone or in combination with a LABA, or leukotriene
modifier, etc.) for a minimum of 8 weeks before visit 1
Exclusion criteria
• History of life-threatening asthma
• Respiratory infection not resolved
• Asthma exacerbation
• Concurrent respiratory disease
• Current smokers
• Other uncontrolled disease or disease state that, in the opinion of the investigator, would put the safety
of the patient at risk through study participation, or would confound interpretation of efficacy results if the
condition/disease was exacerbated during the study
• Positive hepatitis B surface antigen or positive hepatitis C antibody and/or HIV
• Visual clinical evidence of oropharyngeal candidiasis
• Drug or milk protein allergies
• Concomitant medications affecting course of asthma
• Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)
• Previous use of GSK573719
• Any disease preventing use of anticholinergics
• Any condition that impairs compliance with study protocol including visit schedule and completion of
daily diaries
• Any participant with a history of alcohol or substance abuse
• Any affiliation with investigator’s site
Interventions FF 100 mcg vs FF/VI 100/25 mcg vs FF/GSK573719 100/15.6 to 250 mcg
Outcomes Primary outcome measures
• Change from baseline in trough FEV1
• FEV1 value obtained 24 hours after morning dosing on day 14 of each treatment period
Secondary outcome measures
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• Mean change from baseline in daily AM/PM PEF
• Mean change from baseline in rescue albuterol use
Starting date April 2012
Contact information GlaxoSmithKline Research and Development Limited; GSKClinicalSupportHD@gsk.com
Notes
NCT01706198
Trial name or title A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (GW685698)/vi-
lanterol (GW642444) inhalation powder delivered once-daily via a novel dry powder inhaler compared with
usual maintenance therapy in participants with asthma
Methods Randomised parallel-group study
Participants Participants with asthma. 18 years of age or older
Inclusion criteria
Participants eligible for enrolment in the study must meet all of the following criteria
• Informed consent: Participants must be able to provide informed consent and have their consent
signed and dated
• Type of participants: participants with documented GP diagnosis of asthma as their primary
respiratory disease
• Current antiasthma therapy: All participants must be prescribed maintenance therapy and must be
receiving ICS with or without LABA (fixed combination or via separate inhalers) for ≥ 4 weeks before visit
2. Other background asthma medication such as antileukotrienes are permitted
• All participants receiving ICS monotherapy or ICS/LABA combination (this can be a fixed-dose
combination or an ICS alone or LABA alone in separate inhalers) must have had symptoms in the past week
before visit 2. Symptoms are defined by daytime symptoms more than twice per week, use of SABA
bronchodilator more than twice per week, any limitation of activities or any nocturnal symptoms/
awakening (Symptoms are based on participant’s recall and are consistent with GINA and agree in principle
with BTS/SIGN guidelines)
• Participant questionnaires: Participants must be able to complete electronic participant questionnaires
as well as questionnaires to be completed by phone or must provide a proxy (e.g. partner/relative/friend)
who can do so on their behalf
• Gender and age: male or female participants ≥ 18 years of age at visit 1. A female is eligible to enter
and participate in the study if she is of: non-childbearing potential (i.e. physiologically incapable of
becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile
females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal
ligation. Post-menopausal females are defined as amenorrhoeic for > 1 year with an appropriate clinical
profile (e.g. age appropriate, history of vasomotor symptoms). However. in questionable cases, a blood
sample with FSH > 40 MIU/mL and estradiol < 40 pg/mL (< 147 pmol/L) is confirmatory OR childbearing
potential has a negative urine pregnancy test at visit 2, and participant agrees to one of the highly effective
and acceptable contraceptive methods used consistently and correctly (i.e. in accordance with approved
product label and instructions of the physician for the duration of the study - visit 2 to end of study)
Exclusion criteria
Participants meeting any of the following criteria must not be enrolled in the study
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• Recent history of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 6
months
• COPD: Participant must not have current evidence or GP diagnosis of COPD
• Other diseases/abnormalities: participants with historical or current evidence of uncontrolled or
clinically significant disease. Significant is defined as any disease that, in the opinion of the GP/investigator,
would put the safety of the patient at risk through study participation, or that would affect the efficacy or
safety analysis if the disease/condition was exacerbated during the study
• Drug/food allergy: participants with a history of hypersensitivity to any of the study medications (e.g.
beta2-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate).
In addition, participants with a history of severe milk protein allergy that, in the opinion of the GP/
investigator, contraindicates the participant’s participation will also be excluded
• Investigational medications: Participant must not have used any investigational drug within 30 days
before visit 2 or within 5 half-lives (t½) of prior investigational study (whichever is the longer of the 2) (if
unsure, discuss with medical monitor before screening)
• Long-term user of systemic corticosteroids: participant who, in the opinion of the GP/investigator, is
considered to be a long-term user of systemic corticosteroids for respiratory or other indications (if unsure,
discuss with the medical monitor before screening)
• Participants who are using LABA without an ICS as asthma maintenance therapy
• Participants who plan to move away from the geographical area where the study is being conducted
during the study period and/or if participants have not consented to inclusion of their medical records in
the electronic medical records database that is operational in the Salford area
Interventions GW685698+GW642444 once-daily via a novel dry powder inhaler vs existing maintenance therapy (ICS
alone or in combination with a LABA)
Outcomes Primary outcome measure
• Percentage of participants who have an ACT total score ≥ 20 at week 24 (6th month) assessment
Secondary outcome measures
• Percentage of participants with asthma control (ACT total score ≥ 20)
• Mean change from baseline in ACT total score
• Percentage of participants who have an increase from baseline of ≥ 3 in ACT total score
• Asthma-related secondary care contacts
• Asthma-related primary care contacts
• All secondary care contacts
• All primary care contacts
• Mean annual rate of severe asthma exacerbations
• Number of salbutamol inhalers (adjusted to equivalence of 200 actuations) collected by participants
from study-enrolled community pharmacies over the entire treatment period
• Time to discontinuation or modification of initial therapy
• Percentage of participants who have an increase from baseline ≥ 0.5 in AQLQ(S) total score at week 52
• Percentage of participants who have an increase from baseline ≥ 0.5 in AQLQ(S) environmental
stimuli domain score at week 52
Starting date November 2012
Contact information GlaxoSmithKline Research and Development Limited; GSKClinicalSupportHD@gsk.com
Notes
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Trial name or title A study to assess the bronchodilator effect of a single dose of fluticasone furoate (FF)/vilanterol (VI) 100/25
micrograms (mcg) combination when administered in adult participants with asthma
Methods Randomised double-blind placebo-controlled cross-over study
Participants 32 adult participants with moderately severe asthma
Inclusion criteria
• Asthma: a doctor diagnosis of asthma
• Age of participant: 18 to 65 years of age inclusive, at the time of signing the informed consent
• Severity of disease: screening pre-bronchodilator FEV1 ≥ 60% of predicted
• Reversibility of disease: demonstrated presence of reversible airway disease at screening
• Current therapy: on ICS with or without a SABA for ≥ 12 weeks before screening. Able to stop
current short-acting beta2-agonists (SABAs) and replace with albuterol/salbutamol inhaler
• Body weight and BMI: body weight ≥ 50 kg and BMI within the range 19.0 to 29.9 kg/m2 (inclusive)
• Gender: male or female. A female participant is eligible to participate if she is of:
Non-childbearing potential. Females on HRT and whose menopausal status is in doubt will be required to
use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they
must discontinue HRT to allow confirmation of post-menopausal status before study enrolment
Childbearing potential and agrees to use one of the contraception methods for an appropriate period of time
(as determined by product label or investigator) before the start of dosing to sufficiently minimise risk of
pregnancy at that point. Female participants must agree to use contraception until completion of the follow-
up visit
• Liver criteria: AST and ALT < 2 × ULN; alkaline phosphatase and bilirubin ≤ 1.5 × ULN (isolated
bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
• Consent: capable of giving written informed consent, which includes compliance with requirements
and restrictions listed in the consent form
Exclusion criteria
• History of life-threatening asthma
• Other significant pulmonary disease: pneumonia, pneumothorax, atelectasis, pulmonary fibrotic
disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, COPD, respiratory abnormalities
other than asthma
• Respiratory infection: culture-documented or suspected bacterial or viral infection of the upper or
lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that; led to a
change in asthma management OR, in the opinion of the Investigator, is expected to affect the participant’s
asthma status, OR the participant’s ability to participate in the study
• Asthma exacerbation: any asthma exacerbation requiring OCS within 12 weeks of screening or that
resulted in overnight hospitalisation requiring additional treatment for asthma within 6 months before
screening
• Concomitant medications: use of medications, ICS prohibited for each study period from 24 hours
before dosing to 72 hours after dosing; LABA, LTRA or LAMA prohibited for 12 weeks before screening;
high doses of an ICS prohibited for 8 weeks before screening; OCS prohibited for 12 weeks before
screening; potent CYP3A4 inhibitors prohibited within 4 weeks before dosing. The following medications
may not be used during the study from first dosing to the end of period 2 inclusive: anticonvulsants,
polycyclic antidepressants, beta-adrenergic blocking agents, phenothiazines and MAO inhibitors
• Other concurrent diseases/abnormalities: Participant has any clinically significant, uncontrolled
condition or disease state that, in the opinion of the investigator, would put the safety of the patient at risk
through study participation or would confound interpretation of study results if the condition/disease was
exacerbated during the study
• Oropharyngeal examination: Participant will not be eligible if he/she has clinical visual evidence of oral
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candidiasis at screening
• Pregnant and lactating females: pregnant females as determined by positive serum human chorionic
gonadotropin (hCG) test at screening or by positive urine hCG test before dosing. Lactating females
• Allergies: milk protein allergy: history of severe milk protein allergy. Drug allergy: any adverse reaction
including immediate or delayed hypersensitivity to any beta2-agonist or sympathomimetic drug, or to any
intranasal, inhaled or systemic corticosteroid therapy. Known or suspected sensitivity to constituents of the
DPI (i.e. lactose or magnesium stearate). Historical allergy: history of drug or other allergy that, in the
opinion of the investigator or the GSK medical monitor, contraindicates participation
• 12-Lead ECG abnormality: significant abnormality in the 12-lead ECG performed at screening
• Tobacco use: current smokers or smoking history ≥ 10 pack-years. Participant may not have used any
inhaled tobacco products in the 12-month period preceding the screening visit
• Previous participation: exposure to more than 4 new chemical entities within 12 months before first
dosing day
Interventions After screening, participant will be randomised and will be assigned to 1 of 2 treatment sequences (AB or BA,
where A is placebo and B is FF/VI 100/25 mcg). Between the 2 treatment periods, a washout period of 7 to
14 days will occur
Outcomes Serial FEV1 measurements will be taken at 15 and 30 minutes, and at 1, 2, 4, 12, 24, 36, 48, 60 and 72
hours post dose. Safety assessments will include vital signs, ECGs, AE monitoring and laboratory safety tests;
however, these will not constitute study endpoints. Results of the study will provide supporting information
to prescribers on the bronchodilator effect of FF/VI over 72 hours
Starting date Information on http://clinicaltrials.gov/ in October 2013 indicated that study was not yet recruiting. Esti-
mated primary completion date: December 2013
Contact information GlaxoSmithKline Research and Development Limited; GSKClinicalSupportHD@gsk.com
Notes
NCT02094937
Trial name or title A study to compare the efficacy and safety of fluticasone furoate (FF) 100 mcg once-daily with fluticasone
propionate (FP) 250 mcg twice-daily and FP 100 mcg twice-daily in well-controlled asthmatic Japanese
participants
Methods Randomised double-blind multi-centre parallel-group study
Participants Exclusion criteria
• History of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within past 10 years
• Respiratory infection: culture-documented or suspected bacterial or viral infection of the upper or
lower respiratory tract, sinus or middle ear that was not resolved within 8 weeks of visit 1 and led to a
change in asthma management or, in the opinion of the investigator, is expected to affect the participant’s
asthma status or ability to participate in the study
• Asthma exacerbation: any asthma exacerbation requiring systemic corticosteroids or injection within
12 weeks of visit 1, or that resulted in overnight hospitalisation requiring additional treatment for asthma
within 6 months before visit 1
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• Concurrent respiratory disease: Participant must not have current evidence of pneumonia,
pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis,
emphysema, COPD or any respiratory abnormalities other than asthma
• Other concurrent diseases/abnormalities: Participant must not have a clinically significant,
uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the
patient at risk through study participation or would confound interpretation of efficacy results if the
condition/disease was exacerbated during the study. The list of additional excluded conditions/diseases
includes, but is not limited to, the following: congestive heart failure, known aortic aneurysm, clinically
significant coronary heart disease, clinically significant cardiac arrhythmia, stroke within 3 months of visit 1,
uncontrolled hypertension (≥ 2 measurements with systolic BP > 160 mmHg, or DBP > 100 mmHg),
recent or poorly controlled peptic ulcer, haematologic, hepatic or renal disease, immunologic compromise,
current malignancy (history of malignancy is acceptable only if participant has been in remission for 1 year
before visit 1 (remission = no current evidence of malignancy and no treatment for malignancy in the 12
months before visit 1), tuberculosis (current or untreated) (participants with a history of tuberculosis
infection who have completed an appropriate course of antituberculous treatment may be suitable for study
entry provided there is no clinical suspicion of active or recurrent disease), Cushing’s disease, Addison’s
disease, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, recent history of drug or alcohol abuse
• Oropharyngeal examination: Participant will not be eligible for the run-in if he/she has clinical visual
evidence of candidiasis at visit 1
• Investigational medications: Participant must not have used any investigational drug within 30 days
before visit 1 or within 5 half-lives (t1/2) of the prior investigational study (whichever is longer of the 2)
• Allergies: drug allergy: any adverse reaction including immediate or delayed hypersensitivity to any
beta2-agonist or sympathomimetic drug, or to any intranasal, inhaled or systemic corticosteroid therapy.
Known or suspected sensitivity to constituents of the investigational product (i.e. lactose or magnesium
stearate); milk protein allergy: history of severe milk protein allergy
• Concomitant medication: administration of prescription or over-the-counter medication that would
significantly affect the course of asthma, or interact with study drug, such as anticonvulsants (barbiturates,
hydantoins, carbamazepine); polycyclic antidepressants; beta-adrenergic blocking agents; phenothiazines
and MAO inhibitors. Immunosuppressive medications: Participant must not be using or require use of
immunosuppressive medications during the study.
Note: Immunotherapy is permitted for treatment of allergies during the study, provided it was initiated
≥ 4 weeks before visit 1 and participants remain in the maintenance phase for the duration of the study;
cytochrome P450 3A4 (CYP3A4) inhibitors: participants who have received a potent CYP3A4 inhibitor
within 4 weeks of visit 1 (e.g. clarithromycin, atazanavir, indinavir, itraconazole, ketoconazole, nefazodone,
nelfinavir; ritonavir; saquinavir; telithromycin, troleandomycin, voriconazole, mibefradil, cyclosporine)
• Compliance: Participant will not be eligible if he/she or his/her parent or legal guardian has any
infirmity, disability, disease or geographical location that seems likely (in the opinion of the investigator) to
impair compliance with any aspect of this study protocol, including visit schedule and completion of
eDiaries and a paper medical conditions diary
• Tobacco use: current smoker or smoking history of 10 pack-years (e.g. 20 cigarettes/d for 10 years).
Participant may not have used inhaled tobacco products within the past 3 months (i.e. cigarettes, cigars or
pipe tobacco)
• Affiliation with investigator’s site: Participant will not be eligible for this study if he/she is an
immediate family member of the participating investigator, subinvestigator or study co-ordinator, or an
employee of the participating investigator
Other exclusion criteria at visit 2 and visit 5
• Evidence of clinically significant abnormal laboratory tests during visit 1 that are still abnormal upon
repeat analysis and are not believed to be due to disease(s) present. Each investigator will use his/her own
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discretion in determining the clinical significance of the abnormality
• Changes in asthma medication (excluding salbutamol inhalation aerosol provided at visit 1)
• Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower
respiratory tract, sinus or middle ear during run-in and open-label treatment periods that led to a change in
asthma management or, in the opinion of the investigator, is expected to affect participant’s asthma status or
ability of the participant to participate in the study
• Any asthma exacerbation requiring systemic corticosteroids or injection or that resulted in overnight
hospitalisation requiring additional treatment for asthma. Clinical visual evidence of oral candidiasis at visit
2 and visit 5
• Positive urine pregnancy test for all females of childbearing potential at visit 2 and visit 5
• Participants for whom the investigator decides that it is impossible for participant to do “switch (visit
2)” and “step-down (visit 5)”
Interventions • Arm 1: FF/VI 100/25 mcg participants will receive FF/VI 100/25 mcg once-daily via DPI for 8 weeks
in the open-label treatment period
• Arm 2: FF 100 mcg participants will receive FP matching placebo twice-daily (morning and evening)
and FF 100 mcg once-daily in the evening, via DPI for 12 weeks in the double-blind treatment period
• Arm 3: FP 250 mcg participants will receive FP 250 mcg twice-daily (morning and evening) and FF
matching placebo once-daily in the evening, via DPI for 12 weeks in the double-blind treatment period
• Arm 4: FP 100 mcg participants will receive FP 100 mcg twice-daily (morning and evening) and FF
matching placebo once-daily in the evening, via DPI for 12 weeks in the double-blind treatment period
Outcomes Primary outcome measures
• Time to withdrawal due to poorly controlled (requires step-up) asthma during period 2
• Proportion of participants with well-controlled asthma at the end of period 2
Secondary outcome measures
• Mean change from baseline in clinic visit trough FEV1 at the end of period 2
• Mean change from baseline in daily AM and PM PEF averaged during period 2
• Mean change from baseline in percentage of symptom-free 24-hour periods during period 2
• Mean change from baseline in percentage of rescue-free 24-hour periods during period 2
• Mean change from baseline in ACT score during period 2
• Proportion of participants with ACT score ≥ 20 at the end of period 2
Starting date March 2014
Contact information GlaxoSmithKline Research and Development Limited; GSKClinicalSupportHD@gsk.com
Notes
NCT02301975
Trial name or title An efficacy and safety study of fluticasone furoate/vilanterol 100/25 microgram (mcg) inhalation powder,
fluticasone propionate/salmeterol 250/50 mcg inhalation powder and fluticasone propionate 250 mcg in-
halation powder in adults and adolescents with persistent asthma
Methods Randomised double-blind double-dummy parallel-group multi-centre non-inferiority study
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Participants Inclusion criteria
• Participants must give their signed and dated written informed consent to participate before
commencing any study-related activities
• Participants must be outpatients ≥ 12 years of age at visit 1 who have had a diagnosis of asthma, as
defined by the National Institutes of Health, for ≥ 12 weeks before visit 1 (Note: Countries with local
restrictions prohibiting enrolment of adolescents will enrol only participants ≥ 18 years of age)
• Participants may be male or an eligible female. An eligible female is defined as having non-childbearing
potential or having childbearing potential and a negative urine pregnancy test at screening and agrees to use
an acceptable method of birth control consistently and correctly
• Participants must have a best pre-bronchodilator FEV1 ≥ 80% of predicted normal value
• Participants are eligible if they have received mid-dose ICS plus LABA (equivalent to FP/SAL 250/50
twice-daily or an equivalent combination via separate inhalers) for at least the 12 weeks immediately
preceding visit 1
• All participants must be able to replace their current SABA treatment with albuterol/salbutamol
aerosol inhaler at visit 1 for use, as needed, for the duration of the study. Participants must be able to
withhold albuterol/salbutamol for ≥ 6 hours before study visits
• If in the opinion of the investigator the participant’s asthma is well controlled
Exclusion criteria
• History of life-threatening asthma, defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 5
years
• Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract,
sinus or middle ear that is not resolved within 4 weeks of visit 1 and led to a change in asthma management
or, in the opinion of the investigator, was expected to affect the participant’s asthma status or the ability of
the participant to participate in the study
• Any asthma exacerbation requiring OCS within 12 weeks of visit 1 or resulting in an overnight
hospitalisation requiring additional treatment for asthma within 6 months before visit 1
• Participant must not have current evidence of atelectasis, bronchopulmonary dysplasia, chronic
bronchitis, chronic obstructive pulmonary disease, pneumonia, pneumothorax, interstitial lung disease or
any evidence of concurrent respiratory disease other than asthma
• Participant must not have any clinically significant, uncontrolled condition or disease state that, in the
opinion of the investigator, would put the safety of the patient at risk through study participation or would
confound interpretation of results if the condition/disease was exacerbated during the study
• Participant must not have used any investigational drug within 30 days before visit 1 or within 5 half-
lives (t½) of the prior investigational study, whichever is longer of the 2
• Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist or
sympathomimetic drug, or to any intranasal, inhaled or systemic corticosteroid therapy. Known or
suspected sensitivity to the constituents of RELVAR ELLIPTA inhaler, SERETIDE ACCUHALER/
DISKUS inhaler or FP 250
• History of severe milk protein allergy
• Administration of prescription or non-prescription medication that would significantly affect the
course of asthma, or interact with study drug
• Participant must not be using or require the use of immunosuppressive medications during the study
• Participant will not be eligible if he/she or his/her parent or legal guardian has an infirmity, disability,
disease or geographical location that seems likely (in the opinion of the investigator) to impair compliance
with any aspect of this study protocol, including visit schedule and completion of daily diaries
• Current tobacco smoker or smoking history of 10 pack-years (20 cigarettes/d for 10 years). Participant
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may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g. cigarettes,
cigars, electronic cigarettes, pipe tobacco)
• Participant will not be eligible for this study if he/she is an immediate family member of the
participating investigator, subinvestigator or study co-ordinator, or is an employee of the participating
investigator
Interventions • Experimental 1: FF/VI 100/25 mcg by inhalation once-daily (PM) via ELLIPTA plus placebo by
inhalation twice-daily (AM and PM) via ACCUHALER/DISKUS for 24 weeks. Interventions: drug: FF/VI
100/25 mcg via ELLIPTA inhaler; drug: placebo inhalation powder via ACCUHALER/DISKUS inhaler
• Experimental 2: FP/SAL 250/50 mcg by inhalation twice-daily (AM and PM) via ACCUHALER/
DISKUS plus placebo by inhalation once-daily (PM) via ELLIPTA for 24 weeks. Interventions: drug:
placebo inhalation powders via ELLIPTA inhaler; drug: FP/SAL 250/50 mcg via ACCUHALER/DISKUS
inhaler
• Experimental 3: FP 250 mcg by inhalation twice-daily (AM and PM) via ACCUHALER/DISKUS
plus placebo by inhalation once-daily (PM) via ELLIPTA for 24 weeks
Outcomes Primary outcome measures
• Change from baseline in clinic visit PM FEV1 (pre-bronchodilator and pre-dose) at the end of the 24-
week treatment period
Secondary outcome measures
• Change from baseline in percentage of rescue-free 24-hour periods during 24-week treatment period
• Change from baseline in percentage of symptom-free 24-hour periods during 24-week treatment period
• Change from baseline in AM PEF averaged over 24-week treatment period
• Percentage of participants controlled at the end of the 24-week treatment period
• Change from baseline in PM PEF averaged over 24-week treatment period
Starting date February 2015
Contact information GlaxoSmithKline Research and Development Limited; GSKClinicalSupportHD@gsk.com
Notes
NCT02301975 2015
Trial name or title An efficacy and safety study of fluticasone furoate/vilanterol 100/25 microgram (mcg) inhalation powder,
FP/SAL 250/50 mcg inhalation powder and fluticasone propionate 250 mcg inhalation powder in adults and
adolescents with persistent asthma
Methods This study is a randomised double-blind double-dummy parallel-group multi-centre non-inferiority study
Participants Inclusion criteria
• Participants must give their signed and dated written informed consent to participate before
commencing any study-related activities
• Participants must be outpatients ≥ 12 years of age at visit 1 who have had a diagnosis of asthma, as
defined by the National Institutes of Health, for ≥ 12 weeks before visit 1 (Note: Countries with local
restrictions prohibiting enrolment of adolescents will enrol only participants ≥ 18 years of age)
• Participants may be male or an eligible female. An eligible female is defined as having non-childbearing
potential or having childbearing potential and a negative urine pregnancy test at screening and agrees to use
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an acceptable method of birth control consistently and correctly
• Participants must have FEV1 ≥ 80% of predicted normal value
• Participants are eligible if they have received mid-dose ICS plus LABA (equivalent to FP/SAL 250/50
twice-daily or an equivalent combination via separate inhalers) for at least the 12 weeks immediately
preceding visit 1
• All participants must be able to replace their current SABA treatment with albuterol/salbutamol
aerosol inhaler at visit 1 for use, as needed, for the duration of the study. Participants must be able to
withhold albuterol/salbutamol for ≥ 6 hours before study visits
• If in the opinion of the investigator, the participant’s asthma is well controlled
Exclusion criteria
• History of life-threatening asthma, defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 5
years
• Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract,
sinus or middle ear that is not resolved within 4 weeks of visit 1 and led to a change in asthma management
or, in the opinion of the investigator, was expected to affect the participant’s asthma status or the
participant’s ability to participate in the study
• Any asthma exacerbation requiring oral corticosteroids within 12 weeks of visit 1 or resulting in an
overnight hospitalisation requiring additional treatment for asthma within 6 months before visit 1
• Participant must not have current evidence of atelectasis, bronchopulmonary dysplasia, chronic
bronchitis, chronic obstructive pulmonary disease, pneumonia, pneumothorax, interstitial lung disease, or
any evidence of concurrent respiratory disease other than asthma
• Participant must not have any clinically significant, uncontrolled condition or disease state that, in the
opinion of the investigator, would put the safety of the patient at risk through study participation or would
confound interpretation of results if the condition/disease was exacerbated during the study
• Participant must not have used any investigational drug within 30 days before visit 1 or within 5 half-
lives (t½) of the prior investigational study, whichever is longer of the 2
• Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist or
sympathomimetic drug, or any intranasal, inhaled or systemic corticosteroid therapy. Known or suspected
sensitivity to the constituents of RELVAR ELLIPTA inhaler, SERETIDE ACCUHALER/DISKUS inhaler
or FP 250
• History of severe milk protein allergy
• Administration of prescription or non-prescription medication that would significantly affect the
course of asthma, or interact with study drug
• Participant must not be using or require the use of immunosuppressive medications during the study
• Participant will not be eligible if he/she or his/her parent or legal guardian has an infirmity, disability,
disease or geographical location that seems likely (in the opinion of the investigator) to impair compliance
with any aspect of this study protocol, including visit schedule and completion of daily diaries
• Current tobacco smoker or has a smoking history of 10 pack-years (20 cigarettes/d for 10 years).
Participant may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g.
cigarettes, cigars, electronic cigarettes, pipe tobacco)
• Participant will not be eligible for this study if he/she is an immediate family member of the
participating investigator, subinvestigator or study co-ordinator, or an employee of the participating
investigator
Interventions The study will enrol adult and adolescent asthmatic participants who are currently receiving mid-dose inhaled
corticosteroids (ICSs) plus a long-acting beta2-agonist (LABA) (equivalent to FP/SAL 250/50 microgram
(mcg) twice-daily (BD)), via a fixed-dose combination product or through separate inhalers. The study consists
of a LABA washout period of 5 days and a run-in period of 4 weeks, followed by a treatment period of 24
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weeks and a follow-up contact period of 1 week. The total duration of the study is 30 weeks. Approximately
1461 participants will be randomised to 1 of the following 3 treatments (487 per treatment): FF/VI 100/
25 mcg once-daily (OD) in the evening (PM) via ELLIPTA inhaler plus placebo BD via ACCUHALER/
DISKUS; FP/SAL250/50mcgBDvia ACCUHALER/DISKUS inhaler plus placeboOD(PM) via ELLIPTA
inhaler; FP 250 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler.
In addition, all participants will be supplied with albuterol/salbutamol inhalation aerosol for use as needed
to treat acute asthma symptoms
Outcomes Primary outcome measures
• Change from baseline in clinic visit evening (PM) forced expiratory volume in 1 second (FEV1) (pre-
bronchodilator and pre-dose) at the end of the 24-week treatment period (time frame: baseline and week
24) (designated as safety issue: no) FEV1 is a measure of lung function and is defined as the maximal
amount of air that can be forcefully exhaled in 1 second. Baseline will be the pre-dose value obtained at the
visit 3 clinic visit. Change from baseline will be calculated as the week 24 value minus the baseline value
Secondary outcome measures
• Change from baseline in percentage of rescue-free 24-hour periods during 24-week treatment period
(time frame: baseline and weeks 1 to 24) (designated as safety issue: no). Participants will record the number
of inhalations of rescue medication used during the day and night in a daily electronic diary (eDiary). A 24-
hour period in which a participant’s responses to both morning and evening assessments indicated no rescue
medication use will be considered to be a rescue-free 24-hour period. Baseline value will be derived from the
last 7 days of the daily eDiary before randomisation of participant. Change from baseline will be calculated
as the value during the 24-week treatment period minus the baseline value
• Change from baseline in percentage of symptom-free 24-hour periods during 24-week treatment
period (time frame: baseline and weeks 1 to 24) (designated as safety issue: no). Asthma symptoms will be
recorded in a daily eDairy by participants every day morning and evening. A 24-hour period in which a
participant’s responses to both morning and evening assessments indicated no symptoms will be considered
to be a symptom-free 24-hour period. Baseline value will be derived from the last 7 days before
randomisation of the participant. Change from baseline will be calculated as the value during the 24-week
treatment period minus the baseline value
• Change from baseline in morning (AM) peak expiratory flow (PEF) averaged over 24-week treatment
period (time frame: baseline and weeks 1 to 24) (designated as safety issue: no). PEF is defined as maximum
airflow during a forced expiration beginning with the lungs fully inflated. PEF will be measured by
participants using a hand-held electronic peak flow meter each morning before the dose of study medication
and any rescue albuterol/salbutamol inhalation aerosol use. The best of 3 measurements will be recorded.
Change from baseline (defined from the last 7 days before randomisation of the participant) will be
calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the baseline
value
• Percentage of participants controlled at the end of the 24-week treatment period (time frame: week 24)
(designated as safety issue: no). Percentage of participants controlled will be defined using an Asthma
Control Test (ACT) score ≥ 20 at the end of the 24-week treatment period. The ACT is a 5-item
questionnaire developed as a measure of a participant’s asthma control that can be quickly and easily
completed in clinical practice. The questionnaire will be self completed by participants
• Change from baseline in PM PEF averaged over 24-week treatment period (time frame: baseline and
weeks 1 to 24) (designated as safety issue: no). PEF is defined as maximum airflow during a forced
expiration beginning with the lungs fully inflated. PEF will be measured by participants using a hand-held
electronic peak flow meter each evening before the dose of study medication and any rescue albuterol/
salbutamol inhalation aerosol use. Change from baseline (defined as the last 7 days before randomisation of
participants) will be calculated as the value of the averaged daily PM PEF over the 24-week treatment period
minus the baseline value
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Starting date March 2015
Contact information US GSK Clinical Trials Call Center
Notes
NCT02446418 2015
Trial name or title A study to compare the efficacy of fluticasone furoate/vilanterol inhalation powder with usual inhaled corti-
costeroids (ICS)/long-acting beta-agonists (LABA) in persistent asthma
Methods Multi-centre open-label randomised parallel-group study
Participants Inclusion criteria
• Informed consent: capable of giving signed informed consent, which includes compliance with
requirements and restrictions listed in the consent form and in this protocol
• Gender and age: male or female participants ≥ 18 and ≤ 75 years of age at screening visit
Female participant is eligible to participate if she is not pregnant (as confirmed by a negative urine human
chorionic gonadotrophin (hCG) test), is not lactating and at least one of the following conditions applies:
• Non-reproductive potential defined as pre-menopausal females with 1 of the following: documented
tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of
bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy. Postmenopausal defined as 12
months of spontaneous amenorrhoea (in questionable cases, a blood sample with simultaneous follicle-
stimulating hormone (FSH) and oestradiol levels consistent with menopause (refer to laboratory reference
ranges for confirmatory levels)); females on hormone replacement therapy (HRT) and whose menopausal
status is in doubt will be required to use one of the highly effective contraception methods if they wish to
continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of
post-menopausal status before study enrolment
• Reproductive potential and agrees to follow 1 of the options listed below in the GSK Modified List of
Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements
from 30 days before the first dose of study medication and until week 24
GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP
This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle,
or for participants who are and will continue to be abstinent from penile-vaginal intercourse on a long-
term and persistent basis: contraceptive subdermal implant that meets standard operating procedure (SOP)
effectiveness criteria, including a < 1% rate of failure per year, as stated in the product label; intrauterine
device or intrauterine system that meets SOP effectiveness criteria, including a < 1% rate of failure per year, as
stated in the product label; oral contraceptive, either combined or progestogen alone; injectable progestogen;
contraceptive vaginal ring; percutaneous contraceptive patches; male partner sterilisation with documentation
of azoospermia before entry of female participant into the study, and this male is the sole partner for that
participant; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository). These
allowed methods of contraception are effective only when used consistently, correctly and in accordance with
the product label. The investigator is responsible for ensuring that participants understand how to properly
use these methods of contraception
• Types of participants: participants with documented physician’s diagnosis of asthma ≥ 1 year,
unsatisfactorily controlled asthma (ACT < 20 at screening and randomisation visit) treated by ICS alone
and intended to be treated by ICS/LABA maintenance therapy; participant will be eligible for inclusion in
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this study only if affiliated with or a beneficiary of a Social Security category
• Current asthma therapy: All participants must be prescribed maintenance therapy and receiving ICS
alone without LABA for ≥ 4 weeks before randomisation visit; other background asthma medication such
as anti-leukotrienes or theophylline is permitted as an alternative to ICS alone, if initiated ≥ 4 weeks before
screening visit
• Participant questionnaires: Participants must be able to complete the questionnaires themselves
Exclusion criteria:
• History of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 6
months before screening and randomisation visit
• Participants having a severe and unstable asthma, with ACT score < 15 at screening and randomisation
visit, history of repeated severe exacerbations (3/y) and/or a severe exacerbation in the previous 6 weeks
before screening and randomisation visit
• Chronic obstructive pulmonary disease (COPD): respiratory disease: A participant must not have
current evidence or diagnosis of chronic obstructive pulmonary disease at screening visit
• Current or former cigarette smokers with a history of cigarette smoking ≥ 10 pack-years at screening
(number of pack-years = (number of cigarettes per day/20) × number of years smoked (e.g. 20 cigarettes per
day for 10 years, 10 cigarettes per day for 20 years))
• Other diseases/abnormalities: participants with historical or current evidence of uncontrolled or
clinically significant disease at screening and randomisation visit. Significant is defined as any disease that, in
the opinion of the investigator, would put the safety of the patient at risk through study participation or
would affect the efficacy or safety analysis if the disease/condition was exacerbated during the study
• Participants with a history of adverse reaction, including immediate or delayed hypersensitivity to any
intranasal, inhaled or systemic corticosteroid and LABA therapy and to components of the inhalation
powder (e.g. lactose, magnesium stearate) at screening and randomisation visit. In addition, participants
with a history of severe milk protein allergy that, in the opinion of the Investigator, contraindicates the
participant’s participation
• Investigational medications: A participant must not have used any investigational drug within 30 days
before randomisation visit or within 5 half-lives (t½) of the prior investigational study (whichever is longer
of the 2) (if unsure, discuss with the medical monitor before screening)
• Long-term user of systemic corticosteroids: participant who, in the opinion of the Investigator, is
considered to be a long-term user of systemic corticosteroids for respiratory or other indications (if unsure,
discuss with the medical monitor before screening) at screening visit
• Participants treated by the monoclonal antibody omalizumab at screening visit. Treatment with
omalizumab is not allowed during the study
• Participants involved in other clinical trials at screening visit
• Affiliation with investigator site: is an investigator, sub-investigator, study co-ordinator or employee of
a participating investigator or study site, or immediate family member of the aforementioned who is
involved in this study
• Participants who plan to move away during the study from the geographical area where the study is
being conducted
Interventions To evaluate the efficacy and safety of FF/VI compared with 2 usual ICS/LABA fixed combinations (FP/SAL
or budesonide/formoterol (BUD/F)) in participants with persistent asthma, in “close to real life” settings.
FF/VI will be administered once-daily (QD) via ELLIPTA dry powder inhaler (DPI), and FP/SAL or BUD/
F will be administered twice-daily (BID) via DISKUS and TURBUHALER DPI, respectively. ELLIPTA
is a new powder inhaler designed to be easy to use. The total duration of individual participation will be
approximately 6 months (24 weeks)
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Outcomes Primary outcome measures
• Change from baseline in Asthma Control Test (ACT) total score at week 12 (time frame: baseline and
week 12) (designated as safety issue: no). ACT is a validated self administered questionnaire utilising 5
questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). The total
score is calculated as the sum of the scores from all 5 questions. By answering all 5 questions, a participant
with asthma can obtain a score that may range between 5 and 25, with higher scores indicating better
control. Change from baseline was calculated as total ACT score at week 12 minus total ACT score at
baseline
Secondary outcome measures
• Change from baseline in ACT score at week 24 (time frame: baseline and week 24) (designated as
safety issue: no). ACT is a validated self administered questionnaire utilising 5 questions to assess asthma
control during the past 4 weeks on a 5-point categorical scale (1 to 5). The total score is calculated as the
sum of the scores from all 5 questions. By answering all 5 questions, a participant with asthma can obtain a
score that may range between 5 and 25, with higher scores indicating better control. Change from baseline
was calculated as total ACT score at week 24 minus total ACT score at baseline
• Percentage of participants making at least 1 Type A error (likely to be critical) and overall errors at
week 12 and at week 24 independent of use at week 12 (time frame: week 12 and week 24) (designated as
safety issue: no). Participants will be asked to read the instruction leaflet of the assigned device and will be
instructed by the investigator on the proper use of inhalers. Then, participant will be asked to self
administer dose of assigned study drug. Any errors (critical or non-critical) made by the participant will be
recorded by the healthcare professional (HCP). A critical error is defined as an error that may impact the
ability of the drug to reach the lung and hence impact efficacy. Overall errors includes non-critical errors
Starting date July 2015
Contact information US GSK Clinical Trials Call Center
Notes
NCT02730351 2016
Trial name or title Crossover study comparing fluticasone furoate (FF)/vilanterol (VI) once-daily versus fluticasone propionate
(FP) twice-daily in participants with asthma and exercise-induced bronchoconstriction (EIB)
Methods Multi-centre randomised double-blind double-dummy cross-over study with two 2-week treatment periods
separated by a 2-week washout period
Participants Participants with asthma and exercise-induced bronchoconstriction (EIB) between 12 and 50 years of age
Inclusion criteria
Participants eligible for enrolment in the study must meet the following criteria
• Informed consent: Participants must give their signed and dated written informed consent to
participate before commencing any study-related activities
• Age range: 12 to 50 years of age, inclusive, at visit 1 (screening)
• Diagnosis: diagnosis of asthma, as defined by the National Institutes of Health for ≥ 12 weeks before
visit 1
• Asthma severity: Participants must have a pre-bronchodilator FEV1 ≥ 70% of predicted normal value.
Predicted values will be based upon Global Lung Function Initiative equations for spirometry reference
values
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• Evidence of EIB: Participants must answer “Yes” to at least 2 of the following 3 questions reflecting on
the previous 12 months: Are you short of breath during exercise or other physical exertion? Do you wheeze
after exercise or other physical exertion? Do you cough after exercise or other physical exertion?
• Concurrent antiasthma therapy: Participants must be taking low- to moderate-dose inhaled steroids for
12 weeks before visit 1 to participate, with no change in dose for the 4 weeks before visit 1
• Gender: Participants may be male or an eligible female. A female is eligible to enter and participate in
the study if she is of non-childbearing potential (i.e. physiologically incapable of becoming pregnant,
including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as
those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal
females are defined as amenorrhoeic for longer than 1 year, with an appropriate clinical profile (e.g. age
appropriate, > 45 years), in the absence of hormone replacement therapy
OR
• Childbearing potential: has a negative pregnancy test at screening, and agrees to acceptable
contraceptive methods approved in local country, when used consistently and correctly (i.e. in accordance
with the approved product label and instructions of the physician for the duration of the study - screening
to follow-up contact)
• Albuterol/salbutamol use: All participants must be able to replace their current short-acting beta2-
agonist with albuterol/salbutamol, to be used only on an as-needed basis for the duration of the study. Each
participant must be judged capable of withholding albuterol/salbutamol for ≥ 6 hours before performing
spirometric evaluations
• Physical capacity: Each participant must be physically able to perform exercise challenges on a
treadmill when bronchodilators have been withheld
Exclusion criteria
Participants are not eligible for enrolment in the study if they meet the following criteria
• Intermittent asthma, seasonal asthma or exercise-induced bronchoconstriction only: Participants with
only intermittent or seasonal asthma or only exercise-induced asthma are excluded from participation in this
study
• History of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 10
years
• Asthma exacerbation: any asthma exacerbation requiring oral corticosteroids within 12 weeks of visit 1,
or that resulted in an overnight hospitalisation requiring additional treatment for asthma within 6 months
before visit 1
• Symptomatic allergic rhinitis: Participants with symptomatic allergic rhinitis at visit 1 may be treated
for up to 4 weeks with intranasal corticosteroids, followed by a repeat screening visit to determine eligibility
before entry into the study. Participants who continue to be symptomatic after up to 4 weeks of treatment
will be excluded
• 12-Lead electrocardiogram (ECG): A participant is not eligible if he/she has an abnormal, clinically
significant ECG as determined by investigator at the screening visit.
• Pregnancy: women who are pregnant or lactating or are planning on becoming pregnant during the
study
• Respiratory infection: culture-documented or suspected bacterial or viral infection of the upper or
lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of visit 1 and led to a change
in asthma management or, in the opinion of the investigator, is expected to affect participant’s asthma status
or ability of participant to participate in the study
• Concurrent respiratory disease: A participant must not have current evidence of atelectasis,
bronchopulmonary dysplasia, chronic bronchitis, chronic obstructive pulmonary disease (COPD) (current
or past diagnosis including asthma/COPD overlap), pneumonia, pneumothorax, interstitial lung disease or
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any evidence of concurrent respiratory disease other than asthma
• Other concurrent diseases/abnormalities: A participant must not have any clinically significant,
uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the
patient at risk through study participation or would confound interpretation of efficacy results if the
condition/disease was exacerbated during the study
• Investigational medications: A participant must not have used any investigational drug within 30 days
before visit 1 or within 5 half-lives (t1/2) of the prior investigational study, whichever is longer of the 2
periods
• Allergies: drug allergy: any adverse reaction including immediate or delayed hypersensitivity to any
beta2-agonist or sympathomimetic drug, or to any intranasal, inhaled or systemic corticosteroid therapy, or
excipients used with FF/VI 100/25 or FP 250 (i.e. drug, lactose or magnesium stearate); milk protein
allergy: history of severe milk protein allergyl latex allergy: history of allergy or sensitivity to latex that, in the
opinion of the investigator, contraindicates participation of the patient in the study
• Concomitant medication: administration of prescription or non-prescription medication that would
significantly affect the course of asthma, or interact with study drug
• Immunosuppressive medication: A participant must not be using or require the use of
immunosuppressive medications during the study
• Compliance: A participant will not be eligible if he/she or his/her parent or legal guardian has an
infirmity, disability, disease or geographical location that seems likely (in the opinion of the investigator) to
impair compliance with any aspect of this study protocol
• Tobacco/Marijuana use: current tobacco smoker or has a smoking history of ≥ 10 pack-years (20
cigarettes/d for 10 years). Participant may not have used inhaled tobacco products or inhaled marijuana
within the past 3 months (e.g. cigarettes, cigars, electronic cigarettes, pipe tobacco)
• Affiliation with investigator’s site: Participant will not be eligible for this study if he/she is an
immediate family member of the participating investigator, subinvestigator or study co-ordinator, or an
employee of the participating investigator
Interventions This study is designed to compare fluticasone furoate (FF)/vilanterol (VI) once-daily vs fluticasone propionate
(FP) twice-daily in participants with asthma and exercise-induced bronchoconstriction (EIB)
Outcomes Primary outcome measures
• Maximal percent decrease from pre-exercise forced expiratory volume in 1 second (FEV1) following
exercise challenge at 12 hours post evening dose at the end of 2-week treatment period
• Maximal percent decrease will be defined as percent change from pre-exercise FEV1 to minimum
FEV1 collected within 1 hour following exercise challenge at 12 hours post dose
Secondary outcome measures
• Maximal percent decrease from pre- exercise FEV1 following exercise challenge at 23 hours post
evening dose at the end of 2-week treatment period
• Maximal percent decrease will be defined as percent change from pre-exercise FEV1 to minimum
FEV1 collected within 1 hour following exercise challenge at 23 hours post dose. Pre-exercise FEV1 will be
defined as FEV1 value collected before the exercise challenge test at 23 hours post dose. Serial spirometry
will be performed at time points 5, 10, 15, 30, 45 and 60 minutes post exercise challenges
• Proportion of participants with a 30-minute post-challenge FEV1 that was no more than 5% lower
than their pre-exercise FEV1 following the exercise challenge at 12 hours and 23 hours post evening dose at
the end of 2-week treatment period
• Serial spirometry will be performed at time points 5, 10, 15, 30, 45 and 60 minutes post exercise
challenges
• Weighted mean for percent decrease from pre-exercise FEV1 following exercise challenge at 12 hours
and 23 hours post evening dose at the end of 2-week treatment period
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• Serial spirometry will be performed at time points 5, 10, 15, 30, 45 and 60 minutes post exercise
challenges




Trial name or title A study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) or Relvar Ellipta DPI
on ventilation heterogeneity in asthma
Methods A randomised assessor-blinded parallel-group trial
Participants Inclusion criteria for participants on Seretide Accuhaler 250/50 µg at screening
• Male and female participants ≥ 18 years old
• Adequate contraception
• Documented clinical history of asthma for ≥ 6 months before screening visit
• Using Seretide Accuhaler at a stable dose of 250/50 µg twice-daily at screening for ≥ 8 weeks
• Uncontrolled asthma as defined by Asthma Control Questionnaire (ACQ-6) score ≥ 1.0
• R5-R20 ≥ 0.10 kPa/L/s as measured on impulse oscillometry during screening visit
• Historical evidence (within 24 months) of eosinophilic airways disease evidenced by sputum
eosinophil count ≥ 3% and/or FeNO 35 ppb
Inclusion criteria for participants on equivalent /higher dose or other ICS-LABAs or higher dose of Seretide
at screening
• Male and female participants ≥ 18 years old
• Adequate contraception
• Documented clinical history of asthma for ≥ 6 months before screening visit
• R5-R20 ≥ 0.07 kPa/L/s as measured on impulse oscillometry during screening visit 5. Historical
evidence (within past 24 months) of eosinophilic airways disease, evidenced by sputum eosinophil count ≥
3% and/or FeNo ≥ 35 ppb
Exclusion criteria for all participants
• Any severe chronic respiratory disease other than asthma
• Participant has a smoking history ≥ 10 “pack-years” (i.e. ≥ 1 pack of 20 cigarettes/d for 10 years or 10
packs/d for 1 year, etc)
• Current smoking history within 12 months before screening visit
• Near fatal or life-threatening (including intubation) asthma within the past year
• Known history of systemic (injectable or oral) corticosteroid medication within 1 month of visit 1
• Evidence of clinically unstable disease as determined by medical history or physical examination that,
in the investigator’s opinion, precludes entry into the study. ’Clinically unstable’ is defined as any disease
that, in the opinion of the Investigator, would put the patient at risk through study participation, or would
affect the outcome of the study
• In the investigator’s opinion, a clinically significant upper or lower respiratory infection within 4 weeks
before visit 1
• Current evidence or known history of alcohol and/or substance abuse within 12 months pbefore
screening visit
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• Participant has taken β-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors,
astemizole, quinidine type antiarrhythmics or potent CYP 3A4 inhibitors such as ketoconazole within 1
week before screening visit
• Current use of bronchodilators/anti-inflammatory agents other than those specified in the protocol
• Known or suspected sensitivity to study drug or excipients
• Participation in a clinical drug study within 30 days of screening visit
• Current participation in a clinical study
Exclusion criteria for participant or participants undergoing OR-MRI and HD-CT
• Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but
is not limited to presence of non-MRI compatible artificial heart valves, hydrocephalus shunts, intracranial
aneurysm clips, joint replacements or metal implants, pacemakers or other cardiac rhythm management
devices, claustrophobia, history of metal in the eye, presence of shrapnel from a war injury, callipers or
braces, dentures, dental plates or hearing aids that include metal and cannot be removed, history of epilepsy
or blackouts, ear implants, piercings that cannot be removed, intrauterine contraceptive device or coil
• Inability to stay in the supine position for the duration of the scanning procedure
• Obesity (body weight > 140 kg)
Interventions Comparison between fluticasone/formoterol BAI vs fluticasone/vilanterol DPI (Relvar Ellipta DPI)
Outcomes Primary outcome measures
• Measurement of peripheral airway resistance (R5-R20)
• Measurement of peripheral airway resistance (R5-R20)
Secondary outcome measures
• Ventilation heterogeneity (using functional respiratory imaging)
• Distal airway volume and resistance (using impulse oscillometry)
• Evaluation of asthma control (using ACQ-6)
• Evaluation of health status (using AQLQ
Starting date April 2016
Contact information Mundipharma Research Limited
Notes
New 2014 (NCT01551758)
Trial name or title A randomised effectiveness study comparingfluticasone furoate (FF,GW685698)/vilanterol (VI,GW642444)
with standard treatment in chronic obstructive pulmonary disease (COPD)
Methods This is a phase III multi-centre randomised open-label study
Participants Inclusion criteria
Participants eligible for enrolment in the study must meet all of the following criteria
• Types of participants: participants with documented GP diagnosis of COPD, and currently receiving
maintenance therapy
• Informed consent: Participants must be able to provide informed consent, have their consent signed
and dated. Participants must be able to complete the electronic participant questionnaires or allow a proxy
to do so on their behalf
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• Gender and age: male or female participants ≥ 40 years of age at visit 1. A female is eligible to enter
and participate in the study if she is of non-childbearing potential (i.e. physiologically incapable of
becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile
females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal
ligation. Post-menopausal females are defined as amenorrhoeic for longer than 1 year with an appropriate
clinical profile (e.g. age appropriate, history of vasomotor symptoms). However, in questionable cases, a
blood sample with FSH > 40 MIU/mL and oestradiol < 40 pg/mL (< 140 pmol/L) is confirmatory. Or with
childbearing potential has a negative urine pregnancy test at visit 2, and agrees to 1 of the highly effective
and acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved
product label and instructions of the physician for the duration of the study - visit 2 to the end of the study)
• Participants with exacerbation history
• Current COPD maintenance therapy
Exclusion criteria
Participants meeting any of the following criteria must not be enrolled in the study
• Participants with any life-threatening condition (e.g. low probability (in the opinion of the GP/
Investigator) of 12-month survival due to severity of COPD or co-morbid condition) at point of entry into
the study
• Other diseases/abnormalities: participants with historical or current evidence of uncontrolled or
clinically significant disease. Significant is defined as any disease that, in the opinion of the GP/ Investigator,
would put the safety of the patient at risk through participation or would affect the efficacy or safety analysis
if the disease/condition was exacerbated during the study
• Participants with unstable COPD, defined as the occurrence of the following in the 2 weeks before
visit 2: acute worsening of COPD that is managed by the participant with corticosteroids or antibiotics or
that requires treatment prescribed by a physician
• Long-term user of oral corticosteroids: participants who, in the opinion of the GP/Investigator, are
considered to be long-term users of oral corticosteroids for respiratory or other indications (if unsure,
discuss with the medical monitor before screening)
• Drug/food allergy: participants with a history of hypersensitivity to any of the study medications (e.g.
beta-agonists, corticosteroids) or components of the inhalation powder (e.g. lactose, magnesium stearate). In
addition, participants with a history of severe milk protein allergy that, in the opinion of the GP/
investigator, contraindicates the patient’s participation
• Investigational medications: A participant must not have used any investigational drug treatment
within 30 days before visit 2 or within 5 half-lives (t½) of the prior investigational study (whichever is the
longer of the 2)
• Participants who plan to move away during the study period from the geographical area where the
study is being conducted and/or participants who have not consented to inclusio of their medical records in
the electronic medical records database that is operational in the Salford area
Interventions This study is designed to compare the effectiveness and safety of FF/VI. Inhalation powder (100 mcg FF,
GW685698)/25 mcgVI, GW642444)) delivered once-daily via a novel dry powder inhaler (NDPI) compared
with existingCOPDmaintenance therapy over 12months in participants diagnosedwithCOPD. Participants
who meet eligibility criteria are randomised and will enter a 12-month treatment period
Outcomes Primary outcome measures
• Mean annual rate of moderate and severe exacerbations (time frame: 12 months) (designated as safety
issue: no). A moderate exacerbation is defined by the participant receiving an exacerbation-related
prescription of oral corticosteroids and/or antibiotic (with NHS contact) not requiring hospitalisation. A
severe exacerbation is defined as an exacerbation-related hospitalisation
Secondary outcome measures
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• Variety of healthcare utilisation endpoints (time frame: 12 months). (designated as safety issue: no).
Healthcare utilisation
• Serious adverse events and non-serious adverse drug reactions (time frame: 12 months). (designated as
safety issue: no). Frequency and types of serious adverse events and non-serious adverse drug reactions
• Patient-reported outcomes (time frame: 12 months). (designated as safety issue: no). Patient-reported
outcomes




Trial name or title An effectiveness study comparing fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) with
standard treatment in asthma
Methods Multi-centre randomised open-label study
Participants Inclusion criteria
Participants eligible for enrolment in the study must meet all of the following criteria
• Informed consent: Participants must be able to provide informed consent, have their consent signed
and dated
• Types of participants: participants with documented GP diagnosis of asthma as their primary
respiratory disease
• Current antiasthma therapy: All participants must be prescribed maintenance therapy and must be
receiving ICS with or without LABA (fixed combination or via separate inhalers) and for at least 4 weeks
before visit 2. Other background asthma medications such as anti-leukotrienes are permitted
• All participants receiving ICS monotherapy or ICS/LABA combination (this can be a fixed-dose
combination or an ICS alone or LABA alone in separate inhalers) must have had symptoms in the past week
before visit 2. Symptoms are defined by daytime symptoms more than twice per week, use of a short-acting
beta2-agonist bronchodilator more than twice per week, any limitation of activities or any nocturnal
symptoms/awakening (Symptoms are based on participant’s recall and are consistent with the GINA and in
principle with BTS/SIGN guidelines)
• Participant questionnaires: Participants must be able to complete the electronic participant
questionnaires as well as those questionnaires completed by phone or provide a proxy (e.g. partner/relative/
friend who can do so on their behalf )
• Gender and age: male or female participants ≥ 18 years of age at visit 1. A female is eligible to enter
and participate in the study if she is of:non-childbearing potential (i.e. physiologically incapable of
becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile
females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal
ligation. Post-menopausal females are defined as amenorrhoeic for longer than 1 year with an appropriate
clinical profile (e.g. age appropriate, history of vasomotor symptoms). However, in questionable cases, a
blood sample with FSH > 40 MIU/mL and oestradiol < 40 pg/mL (< 147 pmol/L) is confirmatory
OR
Childbearing potential with a negative urine pregnancy test at visit 2, and agrees to one of the highly effective
and acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved
83Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Woodcock 2014 (NCT01706198) (Continued)
product label and instructions of the physician for the duration of the study - visit 2 to the end of the study)
Exclusion criteria
Participants meeting any of the following criteria must not be enrolled in the study
• Recent history of life-threatening asthma: defined for this protocol as an asthma episode that required
intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the past 6
months
• COPD: respiratory disease: Participant must not have current evidence or GP diagnosis of chronic
obstructive pulmonary disease
• Other diseases/abnormalities: participants with historical or current evidence of uncontrolled or
clinically significant disease. Significant is defined as any disease that, in the opinion of the GP/investigator,
would put the safety of the patient at risk through study participation or would affect the efficacy or safety
analysis if the disease/condition was exacerbated during the study
• Drug/food allergy: participants with a history of hypersensitivity to any of the study medications (e.g.
beta2-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate).
In addition, participants with a history of severe milk protein allergy that, in the opinion of the GP/
Investigator, contraindicates the patient’s participation
• Investigational medications: Participant must not have used any investigational drug within 30 days
before visit 2 or within 5 half-lives (t½) of the prior investigational study (whichever is longer of the 2) (if
unsure, discuss with the medical monitor before screening)
• Long-term user of systemic corticosteroids: participant who, in the opinion of the GP/investigator, is
considered to be a long-term user of systemic corticosteroids for respiratory or other indications (if unsure,
discuss with the medical monitor before screening)
• Participants who are using LABA without an ICS as asthma maintenance therapy
• Participants who plan to move away during the study period from the geographical area where the
study is being conducted and/or participants who have not consented to inclusion of their medical records
in the electronic medical records database that is operational in the Salford area
Interventions This study is designed to compare the effectiveness and safety of FF/VI inhalation powder ((100 mcg FF)
, GW685698)/25 mcg VI, GW642444) or 200 mcg FF, GW685698)/25 mcg VI, GW642444)) delivered
once-daily via a novel dry powder inhaler (NDPI) compared with the existing asthma maintenance therapy
over 12 months in participants diagnosed with asthma. Participants who meet the eligibility criteria are
randomised and will enter a 12-month treatment period
Outcomes Primary outcome measures
• Percentage of participants who have an ACT total score ≥ 20 at week 24 (6th month) assessment (time
frame: week 24) (designated as safety issue: no]
• Percentage of participants who have an ACT total score ≥ 20 at week 24 (6th month) assessment
Secondary outcome measures
• Percentage of participants with asthma control (ACT total score ≥ 20) (time frame: weeks 12, 40 and
52) (designated as safety issue: no). Percentage of participants with asthma control (ACT total score ≥ 20)
• Mean change from baseline in ACT total score (time frame: weeks 12, 24, 40 and 52) (designated as
safety issue: no). Mean change from baseline in ACT total score
• Percentage of participants who have an increase from baseline ≥ 3 in ACT total score (time frame:
weeks 12, 24, 40 and 52) (designated as safety issue: no). Percentage of participants who have an increase
from baseline ≥ 3 in ACT total score
• Asthma-related secondary care contacts (time frame: 12 months) (designated as safety issue: no).
Asthma-related secondary care contacts
• Asthma-related primary care contacts (time frame: 12 months) (designated as safety issue: no).
Asthma-related primary care contacts
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• All secondary care contacts (time frame: 12 months) (designated as safety issue: no). All secondary care
contacts
• All primary care contacts (time frame: 12 months) (designated as safety issue: no). All primary care
contacts
• Mean annual rate of severe asthma exacerbations (time frame: 12 months) (designated as safety issue:
no). Mean annual rate of severe asthma exacerbations
• Number of salbutamol inhalers (adjusted to equivalence of 200 actuations) collected by participants
from study-enrolled community pharmacies over the entire treatment period (time frame: 12 months)
(designated as safety issue: no). Number of salbutamol inhalers (adjusted to equivalence of 200 actuations)
collected by participants from study-enrolled community pharmacies over the entire treatment period
• Time to discontinuation or modification of initial therapy (time frame: 12 months) (designated as
safety issue: no). Time to discontinuation or modification of initial therapy
• Percentage of participants who have an increase from baseline ≥ 0.5 in AQLQ(S) total score at week
52 (time frame: week 52) (designated as safety issue: no). Percentage of participants who have an increase
from baseline ≥ 0.5 in AQLQ(S) total score at week 52
• Percentage of participants who have an increase from baseline ≥ 0.5 in AQLQ(S) environmental
stimuli domain score at week 52 (time frame: week 52) (designated as safety issue: no). Percentage of
participants who have an increase from baseline ≥ 0.5 in AQLQ(S) environmental stimuli domain score at
week 52
Starting date November 2012
Contact information US GSK Clinical Trials Call Center
Notes
ACT: Asthma Control Test
AE: adverse event
AM: morning
AQLQ: Asthma Quality of Life Questionnaire
BTS: British Thoracic Society
COPD: chronic obstructive pulmonary disease
DPI: dry powder inhaler
ECG: electrocardiogram
FEV1: forced expiratory volume in one second
FF: fluticasone furoate
FP: fluticasone propionate
FRP: female reproductive potential
FSH: follicle-stimulating hormone
GINA: Global Initiative for Asthma
GP: general practitioner
HCP: healthcare practitioner
HRT: hormone replacement therapy
ICS: inhaled corticosteroid
LABA: long-acting beta2-agonist
LAMA: long-acting muscarinic agonist
LTRA: leukotriene receptor antagonist
MAO: monoamine oxidase
NHANES: National Health and Nutrition Examination Survey
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SIGN: Scottish Intercollegiate Guidelines Network
SOP: standard operating procedure
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D A T A A N D A N A L Y S E S
Comparison 1. FF/VI 100/25 versus placebo




participants Statistical method Effect size
1 Change in quality of life
(measured by AQLQ at 12 wk)
1 329 Mean Difference (Fixed, 95% CI) 0.3 [0.14, 0.46]
2 Exacerbations 2 161 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events 5 721 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEV1 Litres 1 Mean Difference (Fixed, 95% CI) 0.17 [0.09, 0.26]
5 PEFR AM L/min (change from
baseline at 12 wk)
1 Mean Difference (Fixed, 95% CI) 33.3 [26.59, 40.01]
6 PEFR PM L/min (change from
baseline at 12 wk)
1 Mean Difference (Fixed, 95% CI) 28.2 [21.67, 34.73]
7 Change in asthma symptoms
(measured by ACT)
1 339 Mean Difference (Fixed, 95% CI) 1.9 [1.22, 2.58]
Comparison 2. FF/VI 100/25 versus same dose of FF




participants Statistical method Effect size
1 Change in quality of life
(measured by AQLQ at 12 wk)
1 Mean Difference (Fixed, 95% CI) 0.15 [-0.00, 0.30]
2 Exacerbations 2 2425 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [0.86, 2.22]
3 Serious adverse events 5 1258 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.42, 6.17]
4 Trough FEV1 (L) 1 Mean Difference (Fixed, 95% CI) 0.08 [0.02, 0.14]
5 PEFR AM (change from baseline
at 12 wk)
2 Mean Difference (Fixed, 95% CI) 20.29 [15.72, 24.85]
6 PEFR PM (change from baseline
at 12 wk)
2 Mean Difference (Fixed, 95% CI) 18.52 [14.03, 23.01]
7 Change in asthma symptoms
(measured by ACT)
1 Mean Difference (Fixed, 95% CI) 0.6 [-0.04, 1.24]
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Comparison 3. FF/VI 100/25 versus same dose VI




participants Statistical method Effect size
1 Serious adverse events 1 53 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. FF/VI 100/25 versus FP 500 µg




participants Statistical method Effect size
1 Exacerbations 1 301 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.10, 2.47]
2 Serious adverse events 1 301 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.05, 0.80]
Comparison 5. FF/VI 100/25 versus FPS 250/50 bd




participants Statistical method Effect size
1 Change in quality of life
(measured by AQLQ at 24 wk)
1 677 Mean Difference (Fixed, 95% CI) 0.09 [-0.03, 0.21]
2 Exacerbations 1 806 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.52]
3 Serious adverse events 1 806 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.21, 2.99]
4 FEV1 1 Mean Difference (Fixed, 95% CI) -0.02 [-0.07, 0.03]
5 Change in asthma symptoms
(measured by ACT)
1 Mean Difference (Fixed, 95% CI) 0.24 [-0.20, 0.68]
Comparison 6. FF/VI 100/25 µg versus FF/VI 200/25 µg




participants Statistical method Effect size
1 Exacerbations 2 515 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [0.50, 8.19]
2 Serious adverse events 2 515 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.18]
88Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 7. FF/VI 200/25 versus placebo




participants Statistical method Effect size
1 Exacerbations 1 114 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events 1 114 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 FEV1 Litres 1 Mean Difference (Fixed, 95% CI) 0.21 [0.13, 0.29]
4 Change in asthma symptoms
(measured by ACT)
1 Mean Difference (Fixed, 95% CI) 0.9 [0.12, 1.68]
Comparison 8. FF/VI 200/25 µg versus FP 500 µg




participants Statistical method Effect size
1 Change in quality of life
(measured by AQLQ at 12 wk)
2 606 Mean Difference (Fixed, 95% CI) 0.05 [-0.08, 0.17]
2 Change in quality of life
(measured by AQLQ at 24 wk)
1 Mean Difference (Fixed, 95% CI) 0.03 [-0.15, 0.21]
3 OLD***Health-related quality
of life
2 606 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.08, 0.17]
4 Exacerbations 2 611 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.22, 2.20]
5 Serious adverse events 3 1003 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.25, 1.49]
6 PEFR 1 Mean Difference (Fixed, 95% CI) 28.6 [20.23, 36.97]
7 PEFR AM 1 Mean Difference (Fixed, 95% CI) 33.0 [24.84, 41.16]
8 PEFR PM 1 Mean Difference (Fixed, 95% CI) 26.2 [18.04, 34.36]
9 % symptom-free days 1 Mean Difference (Fixed, 95% CI) 4.8 [-2.84, 12.44]
10 Change in asthma symptoms
(measured by ACT)
1 332 Mean Difference (Fixed, 95% CI) 0.8 [0.01, 1.59]
Comparison 9. FF/VI 200/25 versus same dose of FF




participants Statistical method Effect size
1 Change in quality of life
(measured by AQLQ at 12 wk)
1 Mean Difference (Fixed, 95% CI) 0.08 [-0.08, 0.24]
2 Change in quality of life
(measured by AQLQ at 24 wk)
1 307 Mean Difference (Fixed, 95% CI) 0.05 [-0.14, 0.24]
3 Serious adverse events 1 391 Odds Ratio (M-H, Fixed, 95% CI) 6.06 [0.72, 50.84]
4 FEV1 Litres 1 Mean Difference (Fixed, 95% CI) 0.19 [0.10, 0.28]
5 PEFR AM 1 Mean Difference (Fixed, 95% CI) 33.6 [25.41, 41.79]
6 PEFR PM 1 Mean Difference (Fixed, 95% CI) 30.7 [22.51, 38.89]
7 Change in asthma symptoms
(measured by ACT)
1 317 Mean Difference (Fixed, 95% CI) 0.3 [-0.50, 1.10]
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Analysis 1.1. Comparison 1 FF/VI 100/25 versus placebo, Outcome 1 Change in quality of life (measured by
AQLQ at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 1 Change in quality of life (measured by AQLQ at 12 wk)





N N IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 180 149 0.3 (0.0821) 100.0 % 0.30 [ 0.14, 0.46 ]
Total (95% CI) 180 149 100.0 % 0.30 [ 0.14, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours FF/VI 100/25
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Analysis 1.2. Comparison 1 FF/VI 100/25 versus placebo, Outcome 2 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 2 Exacerbations
Study or subgroup FF/VI 100/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/58 Not estimable
Kempsford 2012 0/24 0/23 Not estimable
Total (95% CI) 80 81 Not estimable
Total events: 0 (FF/VI 100/25), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours FF/VI 100/25 g Favours placebo
Analysis 1.3. Comparison 1 FF/VI 100/25 versus placebo, Outcome 3 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 3 Serious adverse events
Study or subgroup FF/VI 100/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/58 Not estimable
Bleecker 2012 0/201 0/203 Not estimable
Kempsford 2012 0/24 0/23 Not estimable
Oliver 2012 0/51 0/51 Not estimable
Oliver 2013 0/27 0/27 Not estimable
Total (95% CI) 359 362 Not estimable
Total events: 0 (FF/VI 100/25), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours FF/VI 100/25 Favours placebo
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Analysis 1.4. Comparison 1 FF/VI 100/25 versus placebo, Outcome 4 FEV1 Litres.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 4 FEV1 Litres





IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 0.172 (0.0434) 100.0 % 0.17 [ 0.09, 0.26 ]
Total (95% CI) 100.0 % 0.17 [ 0.09, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.96 (P = 0.000074)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours FF/VI 100/25
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Analysis 1.5. Comparison 1 FF/VI 100/25 versus placebo, Outcome 5 PEFR AM L/min (change from baseline
at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 5 PEFR AM L/min (change from baseline at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 33.3 (3.4224) 100.0 % 33.30 [ 26.59, 40.01 ]
Total (95% CI) 100.0 % 33.30 [ 26.59, 40.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.73 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours FF/VI 100/25
Analysis 1.6. Comparison 1 FF/VI 100/25 versus placebo, Outcome 6 PEFR PM L/min (change from baseline
at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 6 PEFR PM L/min (change from baseline at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 28.2 (3.3317) 100.0 % 28.20 [ 21.67, 34.73 ]
Total (95% CI) 100.0 % 28.20 [ 21.67, 34.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.46 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours FF/VI 100/25
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Analysis 1.7. Comparison 1 FF/VI 100/25 versus placebo, Outcome 7 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 1 FF/VI 100/25 versus placebo
Outcome: 7 Change in asthma symptoms (measured by ACT)





N N IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 185 154 1.9 (0.3471) 100.0 % 1.90 [ 1.22, 2.58 ]
Total (95% CI) 185 154 100.0 % 1.90 [ 1.22, 2.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.47 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours FF/VI
Analysis 2.1. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 1 Change in quality of life
(measured by AQLQ at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 1 Change in quality of life (measured by AQLQ at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 0.15 (0.0778) 100.0 % 0.15 [ 0.00, 0.30 ]
Total (95% CI) 100.0 % 0.15 [ 0.00, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 2 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 2 Exacerbations
Study or subgroup FF/VI 100/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bateman 2014 41/1009 29/1010 94.9 % 1.43 [ 0.88, 2.32 ]
Bleecker 2012 0/201 1/205 5.1 % 0.34 [ 0.01, 8.35 ]
Total (95% CI) 1210 1215 100.0 % 1.38 [ 0.86, 2.22 ]
Total events: 41 (FF/VI 100/25), 30 (Placebo)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 3 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 3 Serious adverse events
Study or subgroup FF/VI 100/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bernstein 2014 4/346 3/347 86.2 % 1.34 [ 0.30, 6.04 ]
Lee 2014 1/172 0/187 13.8 % 3.28 [ 0.13, 81.05 ]
NCT01453023 0/25 0/25 Not estimable
Oliver 2012 0/51 0/51 Not estimable
Oliver 2013 0/27 0/27 Not estimable
Total (95% CI) 621 637 100.0 % 1.61 [ 0.42, 6.17 ]
Total events: 5 (FF/VI 100/25), 3 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 4 Trough FEV1 (L).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 4 Trough FEV1 (L)





IV,Fixed,95% CI IV,Fixed,95% CI
Bernstein 2014 0.076 (0.0311) 100.0 % 0.08 [ 0.02, 0.14 ]
Total (95% CI) 100.0 % 0.08 [ 0.02, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 5 PEFR AM (change from
baseline at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 5 PEFR AM (change from baseline at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
Bernstein 2014 (1) 25.2 (3.182) 53.6 % 25.20 [ 18.96, 31.44 ]
Bleecker 2012 14.6 (3.4224) 46.4 % 14.60 [ 7.89, 21.31 ]
Total (95% CI) 100.0 % 20.29 [ 15.72, 24.85 ]
Heterogeneity: Chi2 = 5.15, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 8.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Change from baseline averaged over 12 weeks
Analysis 2.6. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 6 PEFR PM (change from
baseline at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 6 PEFR PM (change from baseline at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
Bernstein 2014 (1) 24.2 (3.1678) 52.3 % 24.20 [ 17.99, 30.41 ]
Bleecker 2012 12.3 (3.3164) 47.7 % 12.30 [ 5.80, 18.80 ]
Total (95% CI) 100.0 % 18.52 [ 14.03, 23.01 ]
Heterogeneity: Chi2 = 6.73, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 8.09 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Change from baseline averaged over 12 weeks
Analysis 2.7. Comparison 2 FF/VI 100/25 versus same dose of FF, Outcome 7 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 2 FF/VI 100/25 versus same dose of FF
Outcome: 7 Change in asthma symptoms (measured by ACT)





IV,Fixed,95% CI IV,Fixed,95% CI
Bleecker 2012 0.6 (0.3253) 100.0 % 0.60 [ -0.04, 1.24 ]
Total (95% CI) 100.0 % 0.60 [ -0.04, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 FF/VI 100/25 versus same dose VI, Outcome 1 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 3 FF/VI 100/25 versus same dose VI
Outcome: 1 Serious adverse events
Study or subgroup FF/VI 100/25 VI 25 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oliver 2013 0/27 0/26 Not estimable
Total (95% CI) 27 26 Not estimable
Total events: 0 (FF/VI 100/25), 0 (VI 25)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 1 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 4 FF/VI 100/25 versus FP 500 g
Outcome: 1 Exacerbations
Study or subgroup FF/VI 100/25 FP 500 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Busse 2013 3/201 3/100 100.0 % 0.49 [ 0.10, 2.47 ]
Total (95% CI) 201 100 100.0 % 0.49 [ 0.10, 2.47 ]
Total events: 3 (FF/VI 100/25), 3 (FP 500 g)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 FF/VI 100/25 versus FP 500 µg, Outcome 2 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 4 FF/VI 100/25 versus FP 500 g
Outcome: 2 Serious adverse events
Study or subgroup FF/VI 100/25 FP 500 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Busse 2013 3/201 7/100 100.0 % 0.20 [ 0.05, 0.80 ]
Total (95% CI) 201 100 100.0 % 0.20 [ 0.05, 0.80 ]
Total events: 3 (FF/VI 100/25), 7 (FP 500)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 1 Change in quality of life
(measured by AQLQ at 24 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 5 FF/VI 100/25 versus FPS 250/50 bd
Outcome: 1 Change in quality of life (measured by AQLQ at 24 wk)





N N IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 2013 342 335 0.09 (0.0608) 100.0 % 0.09 [ -0.03, 0.21 ]
Total (95% CI) 342 335 100.0 % 0.09 [ -0.03, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 2 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 5 FF/VI 100/25 versus FPS 250/50 bd
Outcome: 2 Exacerbations
Study or subgroup FF/VI 100/25 FPS 200/50 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woodcock 2013 1/403 2/403 100.0 % 0.50 [ 0.05, 5.52 ]
Total (95% CI) 403 403 100.0 % 0.50 [ 0.05, 5.52 ]
Total events: 1 (FF/VI 100/25), 2 (FPS 200/50)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 3 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 5 FF/VI 100/25 versus FPS 250/50 bd
Outcome: 3 Serious adverse events
Study or subgroup FF/VI 100/25 FPS 200/50 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woodcock 2013 4/403 5/403 100.0 % 0.80 [ 0.21, 2.99 ]
Total (95% CI) 403 403 100.0 % 0.80 [ 0.21, 2.99 ]
Total events: 4 (FF/VI 100/25), 5 (FPS 200/50)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 4 FEV1.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 5 FF/VI 100/25 versus FPS 250/50 bd
Outcome: 4 FEV1





IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 2013 -0.019 (0.0272) 100.0 % -0.02 [ -0.07, 0.03 ]
Total (95% CI) 100.0 % -0.02 [ -0.07, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 FF/VI 100/25 versus FPS 250/50 bd, Outcome 5 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 5 FF/VI 100/25 versus FPS 250/50 bd
Outcome: 5 Change in asthma symptoms (measured by ACT)





IV,Fixed,95% CI IV,Fixed,95% CI
Woodcock 2013 0.24 (0.2245) 100.0 % 0.24 [ -0.20, 0.68 ]
Total (95% CI) 100.0 % 0.24 [ -0.20, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 1 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 6 FF/VI 100/25 g versus FF/VI 200/25 g
Outcome: 1 Exacerbations
Study or subgroup FF/VI 200/25 g FF/VI 100/25 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/56 Not estimable
Busse 2013 6/202 3/201 100.0 % 2.02 [ 0.50, 8.19 ]
Total (95% CI) 258 257 100.0 % 2.02 [ 0.50, 8.19 ]
Total events: 6 (FF/VI 200/25 g), 3 (FF/VI 100/25 g)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 FF/VI 100/25 µg versus FF/VI 200/25 µg, Outcome 2 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 6 FF/VI 100/25 g versus FF/VI 200/25 g
Outcome: 2 Serious adverse events
Study or subgroup FF/VI 200/25 g FF/VI 100/25 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/56 Not estimable
Busse 2013 1/202 3/201 100.0 % 0.33 [ 0.03, 3.18 ]
Total (95% CI) 258 257 100.0 % 0.33 [ 0.03, 3.18 ]
Total events: 1 (FF/VI 200/25 g), 3 (FF/VI 100/25 g)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 FF/VI 200/25 versus placebo, Outcome 1 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 7 FF/VI 200/25 versus placebo
Outcome: 1 Exacerbations
Study or subgroup FF/VI 200/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/58 Not estimable
Total (95% CI) 56 58 Not estimable
Total events: 0 (FF/VI 200/25), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 FF/VI 200/25 versus placebo, Outcome 2 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 7 FF/VI 200/25 versus placebo
Outcome: 2 Serious adverse events
Study or subgroup FF/VI 100/25 Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/56 0/58 Not estimable
Total (95% CI) 56 58 Not estimable
Total events: 0 (FF/VI 100/25), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 FF/VI 200/25 versus placebo, Outcome 3 FEV1 Litres.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 7 FF/VI 200/25 versus placebo
Outcome: 3 FEV1 Litres





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 0.21 (0.0408) 100.0 % 0.21 [ 0.13, 0.29 ]
Total (95% CI) 100.0 % 0.21 [ 0.13, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.15 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 FF/VI 200/25 versus placebo, Outcome 4 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 7 FF/VI 200/25 versus placebo
Outcome: 4 Change in asthma symptoms (measured by ACT)





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 0.9 (0.398) 100.0 % 0.90 [ 0.12, 1.68 ]
Total (95% CI) 100.0 % 0.90 [ 0.12, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 1 Change in quality of life
(measured by AQLQ at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 1 Change in quality of life (measured by AQLQ at 12 wk)





N N IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2013 140 123 0.12 (0.1012) 39.4 % 0.12 [ -0.08, 0.32 ]
NCT01134042 180 163 0 (0.0816) 60.6 % 0.0 [ -0.16, 0.16 ]
Total (95% CI) 320 286 100.0 % 0.05 [ -0.08, 0.17 ]
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 2 Change in quality of life
(measured by AQLQ at 24 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 2 Change in quality of life (measured by AQLQ at 24 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 0.03 (0.0941) 100.0 % 0.03 [ -0.15, 0.21 ]
Total (95% CI) 100.0 % 0.03 [ -0.15, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 3 OLD***Health-related quality of
life.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 3 OLD***Health-related quality of life





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 180 0.74 (0.75) 163 0.74 (0.75) 61.0 % 0.0 [ -0.16, 0.16 ]
Lin 2013 140 0.8 (0.82) 123 0.69 (0.82) 39.0 % 0.11 [ -0.09, 0.31 ]
Total (95% CI) 320 286 100.0 % 0.04 [ -0.08, 0.17 ]
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 4 Exacerbations.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 4 Exacerbations
Study or subgroup FF/VI 200/25 FP 500 g Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Busse 2013 6/202 3/100 56.6 % 0.99 [ 0.24, 4.04 ]
Lin 2013 1/155 3/154 43.4 % 0.33 [ 0.03, 3.18 ]
Total (95% CI) 357 254 100.0 % 0.70 [ 0.22, 2.20 ]
Total events: 7 (FF/VI 200/25), 6 (FP 500 g)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 5 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 5 Serious adverse events
Study or subgroup FF/VI 200/25 FP 500 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Busse 2013 1/202 7/100 75.8 % 0.07 [ 0.01, 0.55 ]
Lin 2013 1/155 2/154 16.2 % 0.49 [ 0.04, 5.50 ]
NCT01134042 6/197 1/195 7.9 % 6.09 [ 0.73, 51.10 ]
Total (95% CI) 554 449 100.0 % 0.61 [ 0.25, 1.49 ]
Total events: 8 (FF/VI 200/25), 10 (FP 500)
Heterogeneity: Chi2 = 8.79, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 6 PEFR.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 6 PEFR





IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2013 28.6 (4.2709) 100.0 % 28.60 [ 20.23, 36.97 ]
Total (95% CI) 100.0 % 28.60 [ 20.23, 36.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 7 PEFR AM.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 7 PEFR AM





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 33 (4.1649) 100.0 % 33.00 [ 24.84, 41.16 ]
Total (95% CI) 100.0 % 33.00 [ 24.84, 41.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 8 PEFR PM.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 8 PEFR PM





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 26.2 (4.1649) 100.0 % 26.20 [ 18.04, 34.36 ]
Total (95% CI) 100.0 % 26.20 [ 18.04, 34.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.29 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.9. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 9 % symptom-free days.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 9 % symptom-free days





IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2013 4.8 (3.8962) 100.0 % 4.80 [ -2.84, 12.44 ]
Total (95% CI) 100.0 % 4.80 [ -2.84, 12.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 8.10. Comparison 8 FF/VI 200/25 µg versus FP 500 µg, Outcome 10 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 8 FF/VI 200/25 g versus FP 500 g
Outcome: 10 Change in asthma symptoms (measured by ACT)





N N IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 170 162 0.8 (0.4031) 100.0 % 0.80 [ 0.01, 1.59 ]
Total (95% CI) 170 162 100.0 % 0.80 [ 0.01, 1.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 1 Change in quality of life
(measured by AQLQ at 12 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 1 Change in quality of life (measured by AQLQ at 12 wk)





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 0.08 (0.0828) 100.0 % 0.08 [ -0.08, 0.24 ]
Total (95% CI) 100.0 % 0.08 [ -0.08, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours same dose FF Favours FF/VI 200/50
Analysis 9.2. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 2 Change in quality of life
(measured by AQLQ at 24 wk).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 2 Change in quality of life (measured by AQLQ at 24 wk)





N N IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 167 140 0.05 (0.0963) 100.0 % 0.05 [ -0.14, 0.24 ]
Total (95% CI) 167 140 100.0 % 0.05 [ -0.14, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours same dose FF Favours FF/VI 200/50
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Analysis 9.3. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 3 Serious adverse events.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 3 Serious adverse events
Study or subgroup FF/VI 200/25 FF 200 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT01134042 6/197 1/194 100.0 % 6.06 [ 0.72, 50.84 ]
Total (95% CI) 197 194 100.0 % 6.06 [ 0.72, 50.84 ]
Total events: 6 (FF/VI 200/25), 1 (FF 200)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours FF/VI 200/25 Favours FF 200
Analysis 9.4. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 4 FEV1 Litres.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 4 FEV1 Litres





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 0.19 (0.0459) 100.0 % 0.19 [ 0.10, 0.28 ]
Total (95% CI) 100.0 % 0.19 [ 0.10, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.14 (P = 0.000035)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours FF200 Favours FF/VI 200/25
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Analysis 9.5. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 5 PEFR AM.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 5 PEFR AM





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 33.6 (4.1791) 100.0 % 33.60 [ 25.41, 41.79 ]
Total (95% CI) 100.0 % 33.60 [ 25.41, 41.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.04 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours FF 200 Favours FF/VI 200/25
Analysis 9.6. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 6 PEFR PM.
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 6 PEFR PM





IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 30.7 (4.1792) 100.0 % 30.70 [ 22.51, 38.89 ]
Total (95% CI) 100.0 % 30.70 [ 22.51, 38.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.35 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours FF 200 Favours FF/VI 200/25
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Analysis 9.7. Comparison 9 FF/VI 200/25 versus same dose of FF, Outcome 7 Change in asthma symptoms
(measured by ACT).
Review: Vilanterol and fluticasone furoate for asthma
Comparison: 9 FF/VI 200/25 versus same dose of FF
Outcome: 7 Change in asthma symptoms (measured by ACT)





N N IV,Fixed,95% CI IV,Fixed,95% CI
NCT01134042 170 147 0.3 (0.4104) 100.0 % 0.30 [ -0.50, 1.10 ]
Total (95% CI) 170 147 100.0 % 0.30 [ -0.50, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours FF/VI
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study Duration (weeks) Severity at baseline Inclusion criteria Adverse events
Allen 2013 6 Reversibility > 12%




asthma for ≥ 12 weeks
Cortisol urinary excretion,
serum AUC and trough
Bateman 2014 24 to 78 Reversibility > 12%




History of ≥ 1 exacerba-
tion requiring hospitalisa-
tion or steroids in the past
year
None
Bernstein 2014 12 Reversibility > 12%
FEV1 50% to 80% of pre-
dicted
ICS for > 12 weeks before
study
> 12 years of age
Yes, not clear
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Table 1. Summary of study characteristics (Continued)
Bleecker 2012 12 Pre-bronchodilator FEV1
40% to 90% of predicted
normal
Reversibility FEV1 ≥ 12%
ICS for 12 weeks before
study
> 12 years of age
Details not stated
Busse 2013 52 Pre-bronchodilator FEV1
40% to 90% of predicted
normal




ICS at high dose
Details not stated
Hojo 2015 4 ACT suggesting poor con-
trol and FEV1 mean 70%
(SD 11%)
Asthma ≥ 20 years of age No, conference abstract
only
Lee 2014 4 Pre-bronchodilator FEV1
40% to 80% of predicted
Demonstrated reversibility
by ≥ 12%
Need for regular controller
therapy for minimum of 8
weeks
Stable dose of ICS for ≥ 4
weeks
≥ 18 years of age
Diagnosis of asthma for ≥
6 months
No
Lin 2013 12 Reversibility of disease:
demonstrated ≥ 12% and
FEV1 40% to 90%
ICS, with or without
LABA, for ≥ 12 weeks
Clinical diagnosis of
asthma for 12 weeks
Adults
No
Kempsford 2012 6 to 8 Pre-bronchodilator FEV1
≥ 60% of predicted.
18 and 70 years of age in-
clusive
Using an ICS, with or
without a SABA, for ≥ 12
weeks before screening
Participants who are cur-
rent non-smokers, who
have not used inhaled to-
bacco products in the 12-
month period preceding
screening visit
Body weight ≥ 50 kg and
BMI within the range 19.
0 to 29.9 kg/m2
Yes, details not stated
116Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summary of study characteristics (Continued)
NCT01134042 24 Pre-bronchodilator FEV1
40% to 90% of predicted
Reversibility FEV1 ≥ 12%
Current asthma therapy
that includes an ICS for ≥
12 weeks before first visit
Adults
Cor-
tisol, ECG, mouth swabs,
various blood parameters
NCT01453023 14 Mild to moderate (GINA) Stable asthma therapy (FP,
total daily dose ≤ 400 mcg
or equivalent) and SABA
inhaler for ≥ 4 weeks be-
fore screening
5 to 12 years of age
Clinical diagnosis of
asthma 6 months before
Controlled asthma (Child-
hood ACT > 19)
Not stated
Oliver 2012 8 Pre-bronchodilator FEV1
> 70% of predicted at
screening
Methacholine chal-
lenge PC20 < 8 mg/mL at
screening
Adults
Stable asthma therapy (FP,
total daily dose ≤ 400 mcg
or equivalent) and SABA
inhaler for ≥ 4 weeks be-
fore screening
BMI within the range 18.
5 to 35.0 kg/m2
Not stated
Oliver 2013 3 with 3 weeks’ washout Pre-bronchodilator FEV1
> 70% of predicted at
screening
Methacholine chal-
lenge PC20 < 8 mg/mL at
screening
Stable asthma therapy (FP,
total daily dose ≤ 400 mcg
or equivalent) and SABA
inhaler for ≥ 4 weeks be-
fore screening
BMI within the range 18.
5 to 35.0 kg/m2
Adults
Not stated
Woodcock 2013 24 Reversibility ≥ 12% and
200 mL within 10 to 40
minutes following 2 to 4
inhalations of albuterol
FEV1 40% to 85% pre-
dicted normal






ACT: Asthma Control Test
AUC: area under the curve
BMI: body mass index
ECG: electrocardiogram
FEV1: forced expiratory volume in one second
FP: fluticasone propionate
GINA: Global Initiative for Asthma
117Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ICS: inhaled corticosteroid
LABA: long-acting beta2-agonist
PC20: provocative concentration of methacholine estimated to result in a 20% reduction in FEV1
SABA: short-acting beta2-agonist












































































































- - - 0.37
(0.043), n =
335







- - - 4.1 (0.60),
n = 349
- - 1.4 (-0.3 to
3.0)
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AQLQ: asthma quality of life questionnaire; CI: confidence interval; EQ-5D: EuroQuality of Life-5D questionnaire; FF: fluticasone
furoate; FP: fluticasone propionate; MD: mean difference; SAL: salmeterol; SE: standard error; VI: vilanterol
Table 3. Asthma exacerbation
Study FF/VI
100/25 mcg


















- - 0/56 (0.
00%)




















































- - - - - - 0/23 (0.
00%)
119Vilanterol and fluticasone furoate for asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
















- - - 2/403 (0.
50%)
- - -
a One participant in the FF/VI 100/25mcg group experienced a severe asthma exacerbation concurrent with sinusitis and waswithdrawn
owing to lack of efficacy. The participant did not require hospitalisation, and the event, which was not classified as an AE, resolved
following treatment with prednisone
bThe incidence of asthma exacerbations was low, and no difference was noted between groups (3% vs 2% on FP/SAL vs FF/VI,
respectively (on-treatment events)). Eight (2%) participants in the FF/VI group and seven (2%) in the FP/SAL group withdrew because
of exacerbation. One patient in the FF/VI group and two in the FP/SAL group were hospitalised because of exacerbation
AM: morning; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; HR: hazard ratio; PM: afternoon; SAL:
salmeterol; VI: vilanterol






























- - 0/56 (0.
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- - 1/202 (0.
50%)






















- - - 1/155 (0.
65%)
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- - 0/26 (0.
00%)








- - - - 5/403 (1.
24%)
- - -
aThe main paper reports that 1 of the 52 withdrew during the study owing to an SAE, which occurred 4 days after the last dose in
the FF 100 treatment period. This participant was provisionally diagnosed with moderate (grade 2) Still’s disease. Six weeks later,
the participant was hospitalised. A diagnosis of histiocytic necrotising lymphadenitis (Kikuchi’s disease) was made on the basis of
histology of an excised lymph node. Tapered prednisolone treatment, initiated at 60 mg per day, has been successful
FF: fluticasone furoate; FP: fluticasone propionate; SAE: serious adverse event; SAL: salmeterol; VI: vilanterol
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- - 0.183 L
(0.0300),
n = 190


























- - 0.258 L
(0.0483),
n = 86
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- - - - 0.300 L
(0.0193),
n = 389
- - -0.019 L (-
0.073 to 0.
034)
AM: morning; CI: confidence interval; FEV1: forced expiratory volume in one second; FF: fluticasone furoate; FP: fluticasone pro-
pionate; h: hour; LAR: late asthmatic response; MD: mean difference; PM: afternoon; SAL: salmeterol; SE: standard error; VI:
vilanterol
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Lin 2013 12 12 weeks’
duration.
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Table 6. Peak expiratory flow (Continued)
















































































AM: morning; CI: confidence interval; FF: fluticasone furoate; PEF: peak expiratory flow; PM: evening; SD: standard deviation; SE:
standard error; VI: vilanterol
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- - - 2.0 (0.16),
n = 348
- - 0.2 (-0.2
to 0.7)
ACT: asthma control test; CI: confidence interval; FF: fluticasone furoate; FP: fluticasone propionate; LS: least squares; MD: mean
difference; NR: not reported; OR: odds ratio; SAL: salmeterol; SE: standard error; VI: vilanterol






























- - 21/56 (38.
00%)


































- - - - - - 22/203
(10.84%)
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- - 22/26 (84.
62%)








- - - - 106/403
(26.30%)
- - -
Fractions shown in the table indicate the proportions of people who suffered one or more adverse events of any cause in each treatment
arm
AE: adverse event; F: fluticasone furoate; FP: fluticasone propionate; SAL: salmeterol; VI: vilanterol
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
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14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy for Cochrane Airways Group Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab








#12 #9 OR #10 OR #11
#13 #8 AND #12
#14 FF/VI:TI,AB
#15 #13 or #14
#16 #4 and #15
[In search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to writing of the protocol. NW and LB independently selected studies for inclusion in the review, CP
and SJM extracted data and KD entered the data into the RevMan file with cross-checking by SJM. KD wrote the Results section, and
NW, LB, CP, KD and SJM co-authored the Discussion and Conclusions sections.
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D E C L A R A T I O N S O F I N T E R E S T
The review authors have no declarations of interest to report.
S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no internal source funding was received for this systematic review, Other.
External sources
• The authors declare that no external source funding was received for this systematic review, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We conducted this review in accordance with the protocol. However, we removed content from the section detailing measures of
treatment effect: If two comparisons (e.g. drug A vs placebo and drug B vs placebo) were combined in the same meta-analysis, we
halved the control group to avoid double-counting. We changed the wording, but not the intent, of the objectives.
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